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ABSTRACT 
High-risk mucosal human papillomaviruses (HPVs) are major aetiological agents 
for the development of cervical cancer. Thus, the current goal of cervical cancer 
treatment is to develop vaccines against HPV s. Such vaccines would either 
prevent cervical cancer by eliminating HPV infection or be useful for treating 
established lesions by the destruction of cells displaying HPV proteins. 
The aim of this thesis was to characterise immune responses to the ES protein of 
HPV -16, one of several antigens with possible use in vaccination. To determine 
whether immune responses to HPV -16 ES existed and whether they could be 
correlated with disease severity or with the presence of HPV -16 DNA, both cell 
mediated (Chapter Two) and humoral (Chapter Three) immunity was investigated 
in women with and without cervical disease. Cellular responses in a minority of 
women were inversely correlated with disease severity. However, E5 specific 
antibodies were negatively correlated with the absence of HPV -16 DNA. Thus, 
although some immune responses were evident, these were generally limited to a 
small number of subjects and were not associated with the detection of HPV-16 
E5 mRNA or DNA sequence variants. 
Due to the immune responses in women, ES was further investigated to determine 
if the absence of HPV -16 E5 specific immune responses was due to the poor 
antigenicity of HPV -16. Mice were immunised with synthetic peptides 
corresponding to full length HPV -16 ES (Chapter Four). As with the human data, 
cellular responses and weak antibody responses were detected in mice. Some 
mice also exhibited cytotoxic T -lymphocyte responses and when ES/major 
histocompatibility class I (MHC-I) interactions were investigated, a number of 
peptides showed a high percentage of binding. 
The ES/MHC-I interactions were further investigated (Chapter Five). The surface 
expression of MHC-I on cells containing HPV-16 or -18 DNA was found to be 
lower than on HPV DNA negative cell lines even after stimulation with 
interferon-gamma. Stimulation with E5 synthetic peptides increased expression 
of cell surface MHC-I molecules on cell lines negative for HPV DNA. 
Furthem10re, the presence of the E5 gene reduced the expression of the ovalbumin 
gene in normal human keratinocytes. 
In conclusion, the data contained within this thesis indicate that HPV-16 E5 CMI 
is inversely correlated with disease status. It is possible to induce cell mediated 
responses to HPV -16 E5 and low-titre antibody responses. The presence of HPV­
16 ES DNA may impair nom1al cellular function. 
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Chapter One 
1.1 INTRODUCTION 
Cervical cancer is the most common female malignancy in the developing world 
where an estimated 80% of the 500,000 new cases occur annually (Munoz & Xavier­
Bosch, 1997). Worldwide it is the second leading cause of cancer related deaths 
among women (Parkin et ai., 1999). The most recent census reported 1,369 deaths 
due to cervical cancer in England and Wales, most of these occurred where women 
had not been screened for cervical abnormalities (World Health Organisation 
[W.H.O.], 1998). There has however, been a 24% decline in deaths due to cervical 
cancer since the introduction of large-scale screening in England and Wales (Office of 
popUlation census and survey; O.P .C.S., 1990). In comparison, of the 8,000,000 
women screened annually in the United States of America (U.S.A.), there are some 
13,000 new cases of cervical cancer resulting in about 4,500 deaths aImually (Boring 
et ai., 1991). When comparing death rates for the number of women screened, the 
U.S.A. has double the mortality (0.06%) of England and Wales (0.03%). This may 

reflect the benefits of a National Health Service (N.H.S.), where screening is freely 

available as opposed to the health insurance scheme operated in the U.S.A. 

Americans with the lowest standards of living have a two fold incidence of cervical 

cancer compared to Americans with a higher standard of living (Baquet et ai., 1991; 

Pappas et ai., 1993). 

The current treatment for cervical cancer is minor surgery if detection occurs before 

invasion of the subepithelial tissue. Cervical lesions are treated using cryotherapy, 

surgical loop excision, laser ablation, interferons or a variety of chemical regimes but 

no single treatment is completely effective and recurrences are common. 
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In addition to ineffective treatment, the cost of surgery on a day-care basis has been 
estimated around about £500 per out patient and this rises to approximately £1,000 
per in patient (London teaching hospitals, Jones, 1995). Of the 3.7 million women 
screened each year an estimated 206,200 abnormal smears are reported every year in 
England and Wales (Department of Health, 1997). The cost of surgery may be 
estimated to lie within the range of £ 125-250 million/year in the U.K. in addition to 
the £ 100 million spent on screening (Clear Communications, 1996). 
There is strong epidemiological and molecular biological evidence suggesting that the 
aetiology of cervical cancer is associated with genital infection by oncogenic human 
papillomaviruses (HPVs). The association of an infectious agent with cervical cancer 
provides a unique oppoliunity to target this disease by vaccination. The introduction 
of an effective vaccine against cancer associated HPVs would prove to be a highly 
cost effective public health policy. In addition to cost, a vaccine would relieve the 
emotional distress caused to patients with abnomlal smear results (Richardson et ul., 
1996). 
A prophylactic vaccine would supersede the need for population based scrccnll1g 
programs and a therapeutic vaccine would provide treatment for prc-malignant and 
malignant cervical lesions. Such vaccines would benefit all women, preventing 
and/or treating cervical lesions. Vaccines could also be modified to prevent and treat 
other HPY associated disease including cOI!£Zv/oma accumillata (CA), laryngeal 
papillomas and epidermo(Zvspiasia vernl.ciformis (BV, see section 1.3.4). 
The cost of mass inoculation can be estimated at around £ 17 per person and hence if 
the whole u.K. female population (27.5 x 106) were vaccinated the cost would be in 
the order of £467 million. Alternatively, assuming that there are approximately 0.5 x 
22 
Chapter One 
106 women in each year group and all women were vaccinated once at prepubescent 
the cost would be around £8.5 million/year, resulting in huge financial savings for the 
N.H.S. 
1.1.1 Pathological changes associated with cervical cancer 
Cervical cancer occurs at the transformation zone of the uterine cervix, where cells 
undergo rapid turnover. These cells appear to be particularly susceptible to 
carcinogens, as the incidence of cancer of the cervix is greater than cancers of other 
female genital sites (Singer, 1982). The uterine cervix comprises the ectocervix and 
the endocervix. The former is covered with squamous epithelium and the latter is 
lined by a single layer of mucinous columnar epithelium (Figure 1.1). The area where 
the two cell types meet is referred to as the squamocolumnar junction. In most young 
women the columnar epithelium extends from the endocervix onto the ectocervix, 
giving rise to an area termed the endocervical ectropion. As women age, the 
ectocervical columnar cells are increasingly replaced by squamous epithelial cells in a 
process known as squamous metaplasia, nie effect of which is the translocation of the 
squamocolumnar junction from the ectocervix to the internal Os, within the 
endocervix. The area between the original and the new squamocolumnar junction is 
referred to as the transformation zone. 
The pathology of cervical cancer consists of a range of progressive histological 
changes (Richart & Barron, 1969). Pre-invasive changes are termed squamous 
intraepitheliallesions (SIL; National Cancer Institute, N.C.l., 1988) and are classified 
histologically to denote severity (Figure 1.2). 
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Figure 1.1 Cross sectional view through the normal cervix showing the 
transformation zone. The chances of detecting SIL are diminished when the 
transformation zone withdraws into the endocervical cancal or when a small lesion is 
missed. Modified from Singer, (1982). 
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Asymtomatic L-SIL H-SIL Cancer ill situ 
Figure 1.2 The multistep progression of cervical cancer. A negative smear result may 
show some normal inflammatory changes or metaplasia, SIL is sub-divided into I, II or 
III depending on the severity of lesion. Cervical cancer is diagnosed once abnormal cells 
have breached the basement membrane. The median time for the progression of L-SIL 
to borderline H-SIL is approximately 5 years and progression of L-SIL to H-SIL takes 
about 7 years (Barron & Richart, 1971). In contrast, 62% of L-SIL and 52% of H-SIL 
regress to normal while 30% H-SIL and 16% L-SIL progressed to cancer (Nasiell et at., 
1986). Modified from Richart, (1976). 
Low grade SIL (L-SIL) show mild dysplasia, cells usually have a diploid or polyploid 
DNA content and display the cytopathic effects of HPV infection (koilocytosis). 
High grade SIL (H-SIL) show moderate to severe dysplasia consisting of proliferative 
basal type cells with a high nuclear to cytoplasmic ratio which are usually aneuploid 
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and monoclonal in nature. Neoplastic changes that are most often associated with 
cervical cancer are koilocytosis (characteristic vacoulated cells) dyskeratosis, basal 
cell hyperplasia and abnoffi1al mitotic figures (aneuploidy/polyploidy; Richart, 1987). 
1.1.2 The cervical smear test 
The cervical smear or the Papanicoloau test (Papanicoloau, 1955) involves 
examination of exfoliated cervical cells to detect the abnormalities. It is based on the 
fact that nuclear abnormalities of SIL are present throughout the whole thickness of 
the epithelium and can thus be detected in cells from the surface of the lesion. A 
spatula is inserted into the cervical Os and rotated through 3600 to harvest cells from 
the transformation zone (Ayer, 1949). Cervical mucus and cells adhering to the 
spatula are spread evenly across a glass slide, fixed in 95% ethanol in water (v/v) and 
stained with a trichrome mixture specifically developed for the investigation of 
cervical and vaginal cells (Papanicoloau, 1955). 
The chances of detecting underlying SIL are enhanced by the fact that there is poor 
cellular adhesion between neoplastic cells and these are readily removed during the 
scraping process. Smears are classified as Pap (from Papanicoloau) I and II, which 
correspond to no significant morphological changes; Pap IIIa with mild to moderate 
dysplasia; Pap IIIb with severe dysplasia; Pap IV with cancer ill situ; Pap V with 
invasive cancer. Women with abnormal Pap smears (IlIa, IlIb, IV or V) are referred 
for colposcopy and a biopsy may be taken for histological analysis to give a 
conclusive diagnosis of the cervical lesion. 
It is estimated that an average 5-30% of cervical abnormalities are missed, but 
because SIL progresses slowly, these lesions may be detected at a second 
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examination. The false negative rate for a cervical smear has been estimated to be 
about 10-20% with sampling errors accounting for the greatest number of misses. For 
example, pathologists tested on pre-screened smears, gave a false negative error rate 
of approximately 5% (Davey et al., 1993; Koss, 1993). There have also been isolated 
incidences of poor quality control within laboratories which have led to a number of 
preventable deaths. Even so, an estimated 3,900 cervical cancers are thought to be 
prevented each year in England and Wales. The cervical screening program may soon 
be improved by the introduction of automated screening as recommended by the 
W.H.O. in 1997. 
Cervical screening in England and Wales offers a three or five-yearly test to women 
aged 25 to 64 years. Potentially cervical cancer is avoidable through effective 
screening and early treatment of SIL. In practice however, despite a U.K. budget for 
promoting the cervical screening program of £100 million/year, many women at risk 
of developing cancer do not attend (Hakama et al., 1989; Clear Communications, 
1996). Reasons for this include ignorance, embarrassment or simply that many do not 
perceive they are at risk. Awareness of the value of screening is still largely restricted 
to women belonging to those social classes least likely to develop cervical cancer 
(O.P.C.S., .1990). 
A relationship between social status and the risk of cervical cancer exists historically, 
for example, during the years 1851 to 1971 the incidence and mortality from cervical 
cancer in England and Wales was twice as common in manual as in non-manual 
social classes, which long antedates cervical screening (Logon, 1982). Conversely, an 
improved social status, the education of women, later marriages and fewer 
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pregnancies resulted in a reduction in the incidence and mortality of cervical cancer in 
developed countries (Laara et ai., 1987). 
In countries that have introduced cervical screening tests which employ the cytology 
based Pap test, death rates and incidences of cervical cancer have fallen (W.H.O., 
1998). However, the number of positive smear results have been increasing, with 
19% developing into cancer within 2 years in the 1970s and, 30-40% progressing to 
cancer in the 1990s (Kinlen & Spriggs, 1978; Buckley, 1994). This may be due to 
changes in sexual practices following introduction of the contraceptive pill or may 
represent better diagnosis with more women, especially those at risk, attending for 
cervical screening tests. 
1.1.3 Historical infectious aetiological agents for cervical cancer 
Many reviews cite Rigoni-Stem, who, in 1842, published an article that implicated a 
sexually transmitted factor for cervical cancer and SIL, as lesions were frequently 
detected in married women but were rare in nuns. Much later, investigators found 
cervical cancer and SIL prevalent in women with a history of multiple sexual 
partners, early age of first coitus (Rotkin, 1973) and previous histories of venereal 
disease (Beral, 1974; Singer et at., 1982). 
Due to the sexually transmitted nature of cervical disease, a number of micro­
organisms have been investigated as a possible cause. These include, Herpes simplex 
virus-2 (HSV-2), Trichomona vaginalis, cytomegalovirus, Neisseria gonorrhoea, 
Treponema pallidum, protozoa and Chlamydia trachomatis. However, many of these 
associations proved to be casual rather than causal (Naib et ai., 1966; zur Hausen et 
at., 1974). The low incidence of cervical cancer amongst the Jewish community was 
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attributed to the absence of 'oncogenic' smegma under the prepuce of the penis but 
this is more likely due to circumcision and the reduction of HPV harbouring tissue 
(Singer, 1982; see 1.3.1). 
1.1.4 Evidence supporting association of human papillomaviruses with cervical 
disease 
HPV s were first investigated as potential causative agents of cervical cancer after 
anecdotal reports of the malignant conversion of warts. Other factors implicating 
HPVs in the aetiology of human anogenital cancer include: 
(i) HPV DNA is detected in at least 80% of patients with cervical cancer and 
progression of cervical lesions to cancer is more likely when they contain HPV -16 or 
-18, than HPV-6 or-ll (Durst et al., 1983; Syrjanenetal., 1985 Lorinczetal., 1987). 
(ii) Cell lines derived from patients with cervical cancer contain either HPV -16 or ­
18 DNA sequences integrated into host DNA, i.e. SiHa and CaSki cells contain HPV­
16 DNA sequences and the C4-1, HeLa and SW756 cell lines contain HPV-18 
sequences (Boshart et al., 1984; Yee et al., 1985; Schwarz et ai., 1985). 
(iii) The presence ofbiological analogues. Cottontail rabbit papillomavirus (CRPV) 
is associated with malignant papillomas in rabbits and bovine papillomavirus type-4 
(BPV-4) is associated with malignant conversion in highland cows (Shope et ai., 
1933; Jarrett et ai., 1978). 
(iv) Epidermodysplasia verruciformis (EV) is a rare inherited condition in which 
specific HPV types have been identified in squamous cell carcinoma developing 20­
30 years after the appearance of typical wart-like lesions.: HPV types -5 and -8 but 
also -9, -12, -14,15, -17, -19, -20, -21, -22, -23, -24, -25, -36, -37 and -38 have been 
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detected in EV (Pfister & Fuchs, 1987). In immunocompetent patients a high 
frequency of specific high risk HPV types have been found in cervical carcinomas 
and periungual squamous cell carcinoma. There is also accumulating evidence 
suggesting that squamous cell carcinoma occurring at other non-genital mucous 
membranes may be HPV related (Dehmezian et ai., 1987; McDonnell et at., 1989; 
Bradshaw et at., 1992). 
It is now established that HPV is the central aetiological factor of cervical cancer and 
SIL (International Agency for Research on Cancer, LA.R.C., 1995). Using 
polymerase chain reaction (PCR) assays HPV DNA is regularly demonstrated in 
invasive cancers from 72-100% of cancer positive samples (Gissmann, 1984; 
Schwarzt et at., 1985; zur Hausen, 1989; Resnick et at., 1990; Riou et al., 1990; van 
den Brule et at., 1991; Bergeron et al., 1992; Das et at., 1992; ter Meulen et al., 
1992). HPV types -16 and -18 predominate in invasive cancers with HPV-16 being 
the most frequently detected type (Durst et at., 1983; Kulski et at., 1987; Fuchs et ai., 
1988). In inner south-east London, where research for this thesis was performed, 
approximately 62% of invasive cancers are positive for HPV-16 DNA (Cavuslu et ai., 
1996). 
1.2 PAPILLOMAVIRUSES 
Papillomaviruses (PVs), from the Latin papilla, 'nipple or pustule' and the Greek 
suffix -oma 'tumour' are members of the Papovaviridae family (Murphy & 
Kingsbury, 1990). Polyomaviruses, which include Simian Vacuolating viruses 
(SV 40), JC polyomavirus and BK polyomavirus form the second half of the 
Papovaviridae sub-family. These are widespread in humans and animals causing 
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persistent, but silent, infections of the urinary tract, and are oncogenic when inj ected 
into newborn animals. This classification is based on the common capsid structure 
and similarities in biochemical composition of the two groups, although there is no 
similarity in genomic organisation. 
1.2.1 Human papillomavirus structure 
Virus particles are proteinaceous, non-enveloped with a diameter of 55-60 
nanometers (nm) and have an icosahedral structure of 72 capsomeres (Figure 1.3). 
The viral capsid is encoded by the L1 gene and consists of 72 capsomeres consisting 
of 60 hexomeric structures (adjacent to six cap somers) and 12 pentomeric structures 
(adjacent to five capsomers) arranged in a skew T=7 icosahedral surface lattice (Finch 
& Klug, 1965; Klug & Finch, 1965; Baker et ai., 1991). 
Cryoelectron microscopy has shown that cap somers consist of a trunk that broadens 
both distally and proximally. The capsomers project to a height of 5.8 run ending in a 
five pointed star shaped peak and meet at the base to form a 2 nm thick shell. A 
cylindrical channel of approximately 2.8 run extends centrally within each capsomer 
along its axis half way to the base (Baker et ai., 1991). Since capsomeres display a 
five fold symmetry they are probably pentamers composed of five molecules of the 
major capsid protein L1, which contributes to 80-90% of the protein content of the 
shell (Baker et al., 1991; Favre et al., 1975; Doorbar and Gallimore, 1987). 
Each virion contains a single copy of circular double-stranded DNA of 7,900 
basepairs (bp) in the f0D11 of chromatin like complex with cellular histones (Seedorf 
et ai., 1985; Pfister & Fuchs, 1987; Figure 1.4). All protein-encoding sequences are 
located on one DNA strand and the reading frames are designated early (E) or late (L) 
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to indicate their expression in the viral life cycle. The single coding strand of HPY­
16 DNA contains 6 E open reading frames (ORFs) and 2 L ORFs. The early region 
makes up approximately 45% of the viral genome, the late region makes up 40%. 
The rest is a non-coding region containing viral regulatory elements (NCR). 
Figure 1.3 HPV capsid structure. A computer enhanced electron micrograph of 
HPY-1. Capsomercs display a five-fold symmetry and are probably pentamers 
composed of five molecules of the major capsid protein L1. Reproduced by kind 
permission from Stannard, 1997. 
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Figure 1.4 HPV genomic structure. Reproduced with penmSSlOn Cambridge 
University Press (Man, 1998). 
Simplified organisation (linearised) of the human papillomavirus type-16 genome. Scale 
bar is in kilobase pairs. Rectangles represent the positions of open reading frames. The 
E genes encode proteins that are produced early in the infectious cycle (non-structural 
proteins); the L genes encode proteins that are produced late in infection (necessary for 
virus assembly). The actual protein products are complex owing to the production of 
multiple messenger RNA transcripts, (see section l.3.3). 
1.2.2 Genome organisation of human papillomavirus type-16 
1.2.2.1 Non coding region (NCR) 
The NCR (also known as the upstream regulatory region and the long control region) 
ofHPV-16 extends from the end of the late region to the beginning of the early region 
(Fig 1.4). The NCR spans approximately 1,000 bp and is a poorly conserved region 
present in the integrated regions of HPV in host DNA in cervical cancers. The NCR 
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is divided into three segments by four E2 binding sites, from the 5' end, the first and 
second E2 binding sites divide the NCR into three functionally distinct segments. 
The 5' segment is approximately 300 bp long and lies between the Ll termination 
codon and the first E2 binding site. The E2 binding site influences transcription from 
the E6/E7 promoter (Romanczuk et al., 1990). This segment contains transcription 
tennination and polyadenylation sites for late transcripts as well as negative 
regulatory elements (Kennedy et al., 1991). 
The central segment of the NCR is approximately 400 bp long and is flanked by two 
E2 binding sites (Gloss et al., 1987). This segment functions as an epithelial-specific 
transcription enhancer which may control the epithelial tropism of HPV s (Gloss et 0/., 
1987; Cripe et al., 1987). This enhancer is modulated by physiological factors 
including steroid hormones and intracellular signalling pathways downstream of 
membrane bound receptors. At least nine different cellular transcription factors have 
been reported to bind about twenty different sites on this segment. These factors 
include, activator protein (AP 1; Chan et of., 1990), papillomavirus enhancer binding 
factor (PEF 1; Cuthill et af., 1993), glucocorticoid and progesterone receptors; (Chan 
et al., 1989), nuclear factor (NFl), octamer binding factor 1 (Oct-I; Sibbet et al., 
1995), transcriptional enhancer factors (TEF-1 & TEF-2; Chong et al., 1991; Ishiji el 

al., 1992) and the transcription repressor (YY -1) yin yang-l (Gloss et al., 1987; 1989; 

Chong et al., 1990; Sibbet & Campo, 1990; Bauknecht et ai., 1992). 

The 3' segment is approximately 140 bp long and contains the E I binding site, which 

identifies the origin of replication. This segment also contains a Sp 1 transcription 

factor binding site, two E2 binding sites and a TAT A box. 
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1.2.2.2 The L1 protein 
The amino acid sequences of the Ll proteins are highly conserved amongst all 
papillomaviruses (PVs). They have an average molecular mass of 55,000 Daltons 
(Da) and are partially glycosylated which is unusual for proteins that are localised to 
the nucleus (Larsen et ai., 1987; Browne et ai., 1988; Zhou et al., 1990; Iftner et al., 
1990). By using vaccinia virus or baculovirus expression systems, Ll alone, forms 
virus like particles in mammalian cells (Hagensee et al., 1993; Kimbauer et al., 1992; 
Rose et al., 1993; Zhou et al., 1991; see 1.4.2). 
1.2.2.3 The L2 protein 
The L2 proteins have a molecular mass of 76,000 Da and are not as conserved as the 
L1 proteins (Doorbar & Gallimore, 1987; Komly et ai., 1986). Recombinant L1 
capsids expressed in mammalian cells via vaccinia virus appear to be identical to 
capsids of recombinant LlIL2 expressed the same way although capsid formation 
with L2 is more efficient (Hagensee et al., 1993). This suggests that L2 may playa 
role in virus assembly. As the amino terminus is able to bind DNA, it is thought that 
L2 has a role in attracting viral DNA during the assembly of viral particles or in the 
positioning of the mini chromosome within the capsid (Zhou et ai., 1994). 
1.2.2.4 The E1 protein 
Depending on HPV type, El proteins have a molecular weight of 68,000-85,000 Da 
and are between 600 and 650 amino acids long (ZhoLl et ai., 1994). The El protein 
accounts for the only enzymatic activities associated with PVs, namely the coupled 
NTPase and helicase activities. El may be described as a DNA-dependent ATPase or 
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an ATP-dependent helicase and is essential for episomal replication of the viral 
genome, interacting with DNA in a sequence independent manner, binding to the 
origin of replication and unwinding DNA at the replication fork (Seo et al., 1993; 
Yang et ai., 1993). It also engages in a variety of important interactions with E2, host 
replicative mechanisms and with itself undergoing multimerisation. 
1.2.2.5 The E2 protein 
As a result of mRNA splicing HPV -16, like other HPV s, encodes two E2 proteins. 
The full length E2 protein is approximately 43,000-48,000 Da and consists of three 
functional domains. These are a trans-acting domain in the amino terminus 
approximately 200 ammo acids long, a flexible hinge which vanes m size and 
sequence among PVs which overlaps the E4 gene in a different reading frame; and a 
DNA binding and protein dimerisation domain in the 90 carboxyl terminal residues 
(Giri & Yaniv, 1988; McBride et al., 1988). The E2 protein is involved in 
transcriptional regulation and viral replication by binding as a dimer to a palindromic 
consensus sequence ACCN6GGT known as the E2 binding site or the E2 responsive 
sequence (Androphy et ai., 1987; McBride et at., 1988; Hirochika et af., 1988; 
Chiang et al., 1991; Ustav & Stenlund, 1991; Winokur & McBride, 1992). There are 
multiple copies of E2 binding sites in all PVs and some of these are critical for the 
activity and regulation of the viral origin ofreplication. 
1.2.2.6 The E4 protein 
.HPV-16 E4 is a 10,000 Da protein and is detectable in the upper spinous and granular 
layers of epithelium only (Seedorf et ai., 1987; Stoler et al., 1989; Crum et al., 1990). 
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E4 is generally expressed at much lower levels in mucosal infections than in 

cutaneous infections and is usually cytoplasmic but can be found associated with 

cellular membranes or localised to the cell nucleus (Crum et at., 1990; Tomita et ai., 

1991; Palefsky et at., 1991; Doorbar et al., 1992). 

HPV -16 E4 is involved in disruption of keratin filaments in keratinised epithelium 

and expression of E4 in some cell lines results in disruption of the cytokeratin 

intennediate filament (Sterling et al., 1993; Doorbar et al., 1996; Roberts et al., 

1997). It is thought that one of its functions may be to prevent the comification of 
squamous epithelia facilitating the release of viruses once the cells are shed (Doorbar 
et at., 1996). 
1.2.2.7 The £5 protein 
Almost all HPV types, exceptions being the epiderrnotropic HPV types -5 and -8, 
encode the E5 protein. HPV E5 proteins are poorly conserved but all share an 
extremely hydrophobic structure with three transmembrane regions. HPV-16 E5 
interacts with the 16,000 Da proton pump protein and has been shown to interfere 
with the degradation of epidermal growth factor receptors (EGF-R; Straight et al., 
1993). It has also been shown to exhibit weak transforming activity in immortalised 
fibroblasts, inducing anchorage independence (Leechanachai et ai., 1992; Pim et al., 
1992). 
1.2.2.8 The £6 protein 
HPV E6 is encoded by a major oncogene of approximately 150 amino acids. E6 
contains several zinc finger motifs Cys-X-X-Cys and appear to represent duplication 
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of the carboxyl-tenninal region of E7 (Grossman & Laimins, 1989; Barbosa et al., 
1990). The E6 product ofHPV-16 and -18 has been localised to the nucleus and the 
cysteine motifs appear to be important for the nuclear translocation since mutants 
lacking this motif localise predominantly to the cytoplasm (Grossman & Laimins, 
1989; Kanda et al., 1991). 
Similar to proteins encoded by other cancer causing viruses, for example, the EIB 
protein of adenovirus and the large T antigen of SV40, E6 is associated with the 
tumour suppresser gene p53 (Sarnow et ai., 1982; Werness et ai., 1990; Scheffner et 
at., 1990). This association is mediated by certain risk HPV types only and results in 
the degradation of the p53 protein mediated through an interaction with the 100,000 
Da E6-AP cellular protein (Werness et al., 1990; Huibregtse et ai., 1993). HPV -16 
E6 is able to transactivate a series of promoters that activate telomerase in a p53 
independent pathway to overcome p53 mediated G 1 arrest and apoptosis (Sedman et 
al., 1991; Desaintes et at., 1992; Klingelhutz et ai., 1996). 
1.2.2.9 The E7 protein 
The E7 ORF is a second major oncogene that encodes a protein of 100 amino acids. 

E7 has transcriptional activity and can be found localised within nuclear 

compartments and in the cytoplasm (Smotkin & Wettstein, 1987; Sato et al., 1989). 

Like E6, E7 contains zinc binding domains Cys-X-X-Cys which are thought to 

facilitate the dimerisation ofE7 proteins and playa role in protein stability (\Vatanahe 

et af., 1990; McIntyre et ai., 1993). 

E7 has distinct sequence homology with two other proteins from DNA virus proteins, 

namely, adenovirus EIA and SV40 large T-antigen. Like these proteins, E7 is able to 
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bind the tumour suppressor retinoblastoma gene product (PRB) and thus interferes 
with cellular growth and cycling (Phelps et al., 1988; Whyte et at., 1988; DeCaprio et 
at., 1988; Dyson et at., 1989; Imai et at., 1991). The E7 proteins of high-risk HPV 
types have greater affinity for pRB than the low risk types (Dyson et at., 1989; 
Munger et at., 1991; Heck et at., 1992; Sang & Barbosa, 1992). The E7 protein also 
binds some pRB related proteins pl07 and p130 and may modulate the cell cycle in 
other ways for example by binding to cyelin A and cyclin dependent kinase 2 or 
histone HI kinase controlling transition from the G 1 phase to the S phase of the cell 
cycle (Dyson et at., 1992; Davies & Vousden, 1992). 
1.2.3 Classification of papillomaviruses 
PV s are classified according to their host range and the degree of DNA homology 
(Coggin & zur Hausen, 1979). HPV-l and bovine papillomavirus type-l (BPV-l) 
were the first to be sequenced allowing the genetic organisation of PV s to be 
determined (Danos et at., 1982; Chen et at., 1982). 
The episomal and linear forms ofHPV DNA were first characterised in 1963, when it 
was thought that all 'wart like' lesions in humans were caused by a single type of 
HPV and that lesions were determined by the anatomical site (Crawford & Crawford, 
1963). The concept of more than one HPV was first proposed when five different 
types were described (Law et at., 1979). Subsequently, a uniform nomenclature was 
proposed under which a new virus isolate was defined as having less than 50% 
homology with known PV types using DNA:DNA liquid hybridisation techniques 
(Coggins & zur Hausen, 1979). 
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Later, after advances in DNA sequencing, the nomenclature was changed. Under this 
system, for a new type of PV to be classified its entire genome had to be cloned and 
the nucleotide sequences of its E6, E7 and L1 open reading frames (ORPs) had to 
(9thshare less than 90% identity to the homologous sequences of other PV s 
International Conference on Papillomavirus, Seattle, 1991). This classification was 
changed again at the 13th International Papillomavirus meeting in Quebec, 1995, 
where a new type of PV can be classified as long as its complete L1 ORP displays 
less than 90% identity to other L1 sequences. To date over 95 different HPVs have 
been cloned (van Ranst et al., 1996). 
DNA sequencing has also permitted the classification of HPVs into different 
phylogenetic groups in which viruses with similar tropism or malignant potential are 
placed together (Chan et aI., 1992; 1995: van Ranst et aI., 1992; 1996; Figure 1.5). 
DNA sequence analysis has also allowed the designing of specific or consensus 
oligonucleotide primers for the PCR mediated detection of HPV DNA in clinical 
samples and has allowed epidemiological and natural history studies of a range of 
HPV infections (van den Brule et at., 1990; Manos et al., 1992). 
1.2.4 Subtypes, variants and the evolution of human papillomaviruses 
Although genetically stable, some intratypic variation does occur leading to subtypes 
and variants of HPV types. A subtype displays between 90 and 98% L1 sequence 
similarity and not many of these have been found. A variant is defined as having 
more than 98% nucleotide similarity to the reference. 
As the sequence variance of individual HPV types appears clustered in different 
geographical regions of the world it has been possible to study the spread and 
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evolution of these variants in several populations. For example, it is now believed 
that HPVs originated in Africa, where the largest number of different variants and the 
deepest branches are found as well as the closest relatives between HPY -18 and -45 
(Chan et al., 1992; Eschle et al., 1992; Ong et al., 1993; Tomesello et al., 1997). 
FUliher indication that these viruses probably co-evolved with their hosts are the 
presence of European, Asian and Native American phylogenetic trees (Ho et af., 
1993; Ong et al., 1993). 
Studies now indicate that HPY types -16 and -18 have evolved in a slow 
accumulation of mutations and have co-migrated as stable variant lineages with their 
human hosts over several hundred thousand years (Icenogle et al., 1991; Ho et al., 
1991; 1993; Chan et ai., 1992; Schwartzman et al., 1993; Ong et al., 1993). 
Three non-human primate PVs closely related to HPVs have also been identified. 
These are the Rhesus monkey papillomavirus (RhPV -1), related to HPY -11 and -·16: 
the Colobus Guereza monkey papillomavirus-l (CgPV -1), related to HPV -3 and -10 
and the Pygmy Chimpanzee papillomavirus (PcPY), related to HPV -13 (Ostrow et al., 
1991; Chan et ai. 1992; van Ranst et al., 1992), suggesting a common ancestor. 
Of the 95 types ofHPV more than 30 infect the genital tract, HPV-6 and-II are found 
in virtually all benign genital warts (CA) and occasionally in 10\\1 grade SIL (van 
Ranst et al., 1996). In contrast, HPV -16 (and also, but less frequently, HPV tY'Pes-18, 
-31, -33, -35, -51 & -54) is found in up to 90% of cervical cancers and the majority of 
SIL (Resnick et al., 1990; van den Brule et al., 1991 ~ zur Hausen, 1991). 
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Figure 1.5 Phylogenetic tree; constructed from the alignment of 384 nucleotides 
in the E6 gene of 48 HPV types. The phylogenetic tree divides I-IPVs into groups 
that are primarily associated with cutaneous and mucosal lesions but also into high 
and low risk mucosal types. The high risk and low risk classification of HPVs 
correlates well with the in vitro biological activity of the E6 and E7 genes 
Reproduced with kind permission from Professor Marc van Ranst (1996). LR,,-oiow 
risk, HR=high risk. 
HPV32 

HPV42 

42 
Chapter One 
1.3 HUMAN PAPILLOMAVIRUS INFECTIONS 
HPV gains entry through micro-abrasions and enters basal cells by direct binding to 
cell surface ligands which belong to the (x'6-intergrin family (Evander et al., 1997). 
The HPV life cycle is tied to the differentiation of the keratinocyte and can be split 
into two stages, non-productive and productive. In the non-productive stage the viral 
genome is established as a low copy number nuclear plasmid. This occurs in the 
proliferating basal layer of the epithelium where HPV replicates its DNA to keep up 
with the division of basal and parabasal cells and establishes a steady state level of 
viral genomes (Chow & Broker, 1994). As infected cells undergo their normal 
lifecycle a subset of daughter cells become detached from the basement membrane to 
stratify and differentiate. This is where the productive stage of the viral life cycle 
begins in the tem1inally differentiated layers of epithelium. During the productive 
stage, HPV amplifies its genome to a higher copy number, expresses late genes 
encoding the capsid proteins, and produces viral progeny. 
1.3.1 Transmission of human papiUomaviruses 
The sexual habits of each individual are major risk factors for infection as the same 
HPV types are not always found in regular male and female partners (Rotola et a!" 
1995). The prevalence of HPV infection is higher amongst sexually active women 
and very low in virgins (Karlsson et at., 1995). Infection is believed to be transient in 
some women and may be associated with a new sexual partner (Evander et al., 1995). 
Sexual acquisition of f-IPVs is thought to be dependent on a large reservoir of infected 
males; men suffer from transient infections which are not usually apparent and have a 
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low propensity to progress to cancer (Campion et aI., 1988; Obalek et ai., 1986; 
Wickenden et ai., 1988). 
The epidemiology of HPV infection in men has been hampered by the lack of a 
satisfactory counterpart to the cervical scrape, although, it is possible by applying 
urethral swabs to the distal 1 centimetre (cm) of the urethra to obtain mucosal 
epithelial cells (Wikstrom et aI., 1991). CA usually occurs in this region, which is 
thought to be analogous to the transformation zone acting as a reservoir for HPV 
infection (Oriel, 1990; Omar et aI., 1991). The male role in transmission of HPV was 
investigated after it was determined that monogamous women had higher incidences 
of cervical cancer, if their male partner had either penile cancer, a number of sexual 
partners or had previously been married to a woman who had died of cervical cancer 
(Rotkin, 1967). It is thought that, the male distal urethra may be the major reservoir 
of genital HPV infection (Siegel & Mellinger, 1992; Higgins et ai., 1992). 
Studies of HPV infection in children have reported the presence of HPV DNA and 
HPV specific antibodies in children from 0-13 years old (Sedlacek et ai., 1989; Smith 
et ai., 1991; Koch et aI., 1997; af Geijersstam et aI., 1999). Genital HPVs are not 
only acquired by sexual contact, but may also be passed from mother to infant or 
between individuals without physical contact via infected clothing, fomites and urine 
(Ferenczy et aI., 1989; Hillman et aI., 1993; Fredericks et al., 1993; Annbruster­
Moraes et aI., 1994; Kaye et ai., 1994). 
HPV DNA has also been detected in the amniotic fluid, placenta and cervical scrapes 
of pregnant women with BV, rendering vertical transmission of BY associated HPVs 
likely (Favre et ai., 1998). Indeed, pregnant women with latent HPV infections have 
been shown to have a 30% transmission rate of transmitting HPY to the 
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oropharyngeal mucosae of their infants (Tanti et al., 1999). Similarly, another 
member of the papovaviridae family, JC polyomavirus has been shown to be 
transmitted from mother to child, while both vertical and horizontal transmission of 
BPV-2 has been described under experimental conditions in cattle (Kunitake et al., 
1995). PVs are stable to heat and desiccation. HPV-16 DNA has even been isolated 
from surgical instruments and in smoke generated by the laser ablation of lesions 
(Smotkin, 1989; Kashima, 1991). 
1.3.2 HPV infection and the development of malignant lesions 
The biological behaviour of HPV is complex but the process involves regression, 
persistence and progression of the disease (Sytjanen, 1994). HPV detection 
techniques indicate that transient genital infection is common among asymptomatic 
women but is insufficient for cervical cancer development. Factors additional to HPV 
infection are more than likely to be involved in the development of cervical cancer 
and this fits in with the theory of multi-step progression of carcinogenesis (Farber, 
1984). Such additional factors would include: viral integration into the host DNA; 
activation of cellular oncogenes; inactivation of tumour suppresser genes and failure 
of the immune system. It is unlikely that HPV infection alone is sufficient for 
malignant transformation and reasons supporting the multi-step progression of cancer 
include a long latency period between initial HPV infection and the eventual 
development of cervical cancer (zur Hausen, 1986). Further, keratinocytes 
immortalised in vitro with high risk HPV types are initially non-tumourigenic when 
injected into nude mice (Hawley-Nelson et al., 1989; Munger et al., 1989) and 
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malignant tumours are only evident after prolonged culturing (62 passages or more) 
ofthe transformed cells prior to injection (Hurlin et al., 1991). 
1.3.3 Human papillomavirus integration into genomic DNA 
As previously discussed, it is presently postulated that following viral integration into 
the host genome a series of molecular events occur (see section 1.3.2). Integration 
into the host genome occurs when the El and E2 genes are inactivated and the 
production of the E6 and E7 proteins are increased, these events are necessary for 
viral replication but when over-produced result in the development of cancer, after the 
functional inactivation of p53 and/or pRB tumour suppressor genes (Schneider­
Manoury et al., 1987). These tumour suppressor genes may playa critical role in 
programmed cell death, which is crucial to the elimination of cells with oncogenic 
potential (Levine & Momand, 1990). 
The site of HPV -16 integration may be random although specific integration into 
chromosome 8q21-q22, adj acent to c-myc, has been described (Durst et al., 1985; 
1987; Smotkin & Wettstein, 1986). Once integrated HPV 16 is non-replicating and 
non-infectious and results in the linearisation of viral DNA with the Ll and L2 ORFs 
often lying upstream from the viral promoter and unlikely to be transcribed (Gissman 
& Schwartz, 1986). This permits only the E6 and E7 open reading frames to be 
transcribed and in carcinomas the mRNA ofthese ORFs is abundant (Schwartz et ai., 
1985; Durst et al., 1985; zur Hausen, 1991). 
The complex regulation of gene expression in HPVs is controlled by cellular and viral 
transcription factors, different promoter usage, differential splicing differential 
transcription termination and mRNA stability. Various splicing patterns and the 
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activity of different promoters results in a wide range ofHPV-16 mRNAs (Smotkin et 
al., 1989; Rohlfs et al., 1991; Sherman et ai., 1992). These mRNAs contain ORFs 
with translation initiation codons and it is thought that translation of these 
polycistronic messages is influenced by alternative splicing. 
The viral transcription patterns vary considerably in different layers of epithelium; 
there is weak expression of early genes in the basal layers of low grade cervical 
dysplasias induced by HPV-16 or -33 and in some induced by HPV-6 or -11 CA 
(Beyer-Finkler et ai., 1990; Durst et ai., 1992; Stoler et ai., 1992). The majority of 
HPV-6 containing CA display clear E6 signals in the basal layer and E7 signals in the 
lowest layers of the epithelium. It is thought that this may be due to evolution of the 
high risk types in order to prevent neoplastic conversion of the host cells which would 
be counterproductive for the replication of the virus (Fuchs & Pfister, 1994). 
Genes with rare triplet codons are not efficiently translated in undifferentiated 
mammalian cells and this is manipulated by PVs. In terminally differentiated 
epithelial cells, the use of rare triplet codons by PVs can result in the efficient 
expression of late genes as cellular mRNAs are not present in large enough numbers 
in terminally differentiated cells to compete with PV mRNAs. 
HPV integration could also result in the activation of cellular proto-oncogenes which 
may be a major step towards the malignant transformation of a HPV infected cell. 
There is an over-expression of the nuclear proto-oncogene ets-2 in cells derived from 
cervical cancer (Dipaolo et at., 1993). The ras and myc oncogene families have also 
been shown to be altered in some cervical lesions and this could be a requirement in 
the progression of cervical cancer (Ocadiz et at., 1987), for example, the 
amplification of c-myc which occurs in HPV transfonned cell lines affecting the 
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morphological and growth characteristics of such cells (Crook et at., 1990). 
However, the amplification of c-myc appears to be a late rather than an initiating 
event in anogenital malignancy (Crook et at., 1991). Mutations of Ha-ras genes have 
been found in HPV infected cultured keratinocytes and these have been shown to be 
sufficient to induce complete cellular transformation (Balmain, 1985). However, 
inj ection of transformed cells into mice results in the formation of malignant tumours 
after prolonged culturing indicating that additional factors are required in the 
pathogenesis of cervical cancer (zur Hausen, 1991; Hurlin et at., 1991). 
1.3.4 Other human papillomavirus associated lesions 
Genital warts (CA) consist of localised epithelial hyperplasia and unlike cervical 
lesions they do not progress to malignancy but have a defined boundary and an intact 
basement membrane. They vary widely in appearance and location and can be 
divided into genital (mucosal) and non-genital (cutaneous) types, all of which usually 
regress after a period of time. 
Cutaneous EV carcinomas developing m adult life are usually confined to sun 
exposed sites suggesting a co-carcinogenic role for ultra violet radiation. EV is 
characterised by impaired cell mediated immunity (CMI) and the appearance in 
childhood of extensive refractory plane warts mainly over the face and limbs that 
progress to squamous cell carcinoma in 30-59% of patients. At least 20 HPV types 
have been found in EV lesions although only a few types (HPV -5 and HPV -8) have 
consistently been detected in EV malignant tumours (Orth, 1987). It serves as a 
model not only for cutaneous viral oncogenesis but also of local defence mechanisms 
in the progression of HPV associated cancer (Lutzner, 1978). Patients with EV are 
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usually infected with multiple HPV s, which can be classified into two groups based 
on DNA homology. EV specific transfonning HPV s have also been found in warts, 
pre-malignant and malignant skin lesions of renal transplant recipients (de Jong­
Tieben, 1995). The mechanism of BV HPV induced transformation of keratinocytes 
is unknown but the process seems to differ from that involved in HPV associated 
cervical cancer in that no integration of viral sequences into the host genome occurs 
and the effect of BV oncoproteins on tumour suppresser genes is unknown 
(Androphy, 1994). 
HPV s are also known to infect oesophagus, upper and lower respiratory organs, 
vulva, vagina, bladder and skin. Respiratory papillomas are more common in 
children than in adults and are associated with HPV types-6 and -11, these can 
develop into malignant lesions after X-ray irradiation. HPVs may even be involved in 
a minority of prostate cancers (Dillner et ai., 1997). The high risk HPV types -16 and 
-33 can also be found as rare periungual infections (Moy et at., 1994; Ruedlinger et 
aI., 1989). Cancer of the vagina and vulva is mostly observed in women in their 70s 
and 80s and has been found to be linked with pre-existing or co-existing HPV­
associated genital warts and to seropositivity to HSV-2 (Shennan et ai., 1991). 
For HPVs, mucosal types affect the anogenital and aero digestive tract while 
cutaneous types predominantly infect cutaneous epithelium and are rarely found at 
anogenital sites or within the oral mucosa. However, there is at least one exception, 
namely HPV -2, which can cause warts on both the hands and anus (de Villiers et at., 
1986; 1991; Fleming et al., 1987; Snijders et aI., 1992). 

Most animal PVs are associated with the development of squamous epithelial warts, 

which are either cutaneous or mucosal in origin. A subgroup of PVs are also known 
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to cause benign fibropapillomas, these proliferative lesions differ from the more usual 
papillomas in that there is a dermal fibroblastic component associated with squamous 
epithelial proliferation. This subgroup comprises BPV-l, -2 and -5, European elk 
papillomavirus, deer papillomavirus and reindeer papillomavirus (Lancaster & Olson, 
1982). 
Generally PVs are unable to cross speCIes barriers. There are however, two 
exceptions to this, namely BPV -1 and -2 which can also infect horses, donkeys and 
sheep although infection in horses is non productive (Segre et al., 1955; Sundberg, 
1987; Lancaster, 1981; Angelos et al., 1991; Reid et al., 1994; Trenfield et at., 1990). 
To date PVs or their antigens have been detected in humans, primates, cattle, rabbits, 
goats, sheep, horses, dogs, elephants, multimammate rats, wild European harvest 
mice, molluscs and racoons (Davies & Kemper, 1936; Fulton et al., 1970; Gibbs et 
al., 1975; Sundberg et al., 1986; 1987a; 1987b; 1988; Amtmann & Wayss, 1987; 
Kloster et al., 1988; Ramir et ai., 1995). 
1.3.5 Co-factors 
HPVs are not unique amongst PVs with respect to their association with cancers, a 
number of PVs are strongly associated with the development of malignant lesions in 
cattle and cottontail rabbits (Shope & Hurst, 1933; Jarrett et at., 1978). In such cases 
it seems that co-factors are required for malignant transformation, for example, 
exposure to sunlight acts as a co-carcinogen in the case of patients with EV infected 
with RPV -8, bracken ingestion in cattle infected with BPV -4 and the application of 
coal tar in rabbits infected with CRPV (Orth et at., 1978; Jarrett et at., 1978). Indeed, 
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as discussed below, many endogenous and exogenous factors are strongly associated 
with the progression ofSIL to cancer in humans. 
1.3.5.1 Sexual behaviour 
The risk of acquiring HPV in the lower genital tract and developing cervical cancer 
increases with the number of sexual partners independently of other risk factors 
(Rosenfeld & Wentz, 1989; Moscicki et aI., 1990; Fisher et ai., 1991; Ley et aI., 
1991). Indeed, the risk associated with having had sexual intercourse with 10 or more 
partners is nearly 3 times higher than that associated with one or no partners (Peters et 
ai., 1986; Brinton et at., 1987). 
Coitus before the age of 16 years is also an independent risk factor. The odds ratio 
for developing cervical cancer in subj ects who had their first coitus before 16 years of 
age is 4.3 when compared to those who had remained virgins until 24 years of age 
(Brinton et ai., 1987; Cuzick et al., 1990; Herrero et al., 1990; Bosch et al., 1992). 
This enhanced susceptibility of the cervix to carcinogenesis may arise due to the 
development of metaplastic epithelium at the transformation zone that occurs in 
adolescence (Reid & Campion, 1989). It is also possible that the number of sexual 
partners and early coitus may only increase the risk of HPV infection (Schiffman et al 
1993) ifbarrier contraceptives are not used (Kjaer et ai., 1996). 
1.3.5.2 Age 
An age less than or equal to 30 years has also been shown to be a significant risk 
factor for HPV infection (van den Velde & van Beers, 1992; Nindl et al., 1997). The 
group with the highest incidence of HPV infection (13%) is 20-24 years of age and 
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this is reduced to 5% in those of 55 years of age (de Villiers et al., 1987). Similarly, 
the falling incidence of cervical cancer in Bombay over the last two decades has been 
attributed to older age at marriage and a decline in the number of sexual partners 
(Yede et al., 1989). 
1.3.5.3 Diet 
Evidence for deficiencies of vitamins A, C, ~-carotene and folate have been found for 
women with invasive cancer and SIL (Harris et al., 1986; Palan et ai., 1988). 
Retinoic acid treatment of HPV -18 containing HeLa cells (derived from cervical 
cancer) has been found to inhibit E6 and E7 expression suggesting that insufficient 
retinoic acid receptor gene expression could contribute to cervical cancer (Bartsch et 
al., 1992). Similarly, animal and in vitro studies have shown that retinoic acid can 
inhibit cell transformation in BPV containing mouse cells and significantly enhances 
the regression of cottontail rabbit papillomavirus (CRPV)-induced lesions 
(McMichael, 1965; Tsang et al., 1988). 
1.3.5.4 Cigarette smoke 
The constituents of tobacco inhalate such as nicotine and cotinine have been found in 
the cervical mucus of smokers and are thought to have transforming effects on HPV­
infected tissue (Hoffmann et al., 1985; Ho et al., 1998). In addition a decreased 
number of Langherhans' cells is found in the cervical tissues of smokers which may 
reduce the local cellular immune response. Indeed nicotine derivatives have been 
isolated from cervical mucus (Schiffman et al., 1987; Barton et al., 1988). 
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1.3.5.5 Oral contraceptives 
Progesterone and glucocorticoid endocrine steroid honnones in the oral contraceptive 
pill, appear to slightly increase the risk of developing cervical cancer in long term 
users, and a similar trend has been observed for CA (Francheschi et al., 1983; Daling 
et al., 1986; Brinton et al., 1986; Peto & zur Hausen, 1986; von Knebel Doeberitz et 
al., 1990; Pater et al., 1990; Mittal et al., 1993). Treatment with progesterone 
enhances HPV gene expression which may lead to increased viral production and 
proliferation of HPV infected cells (Pater et al., 1990). Indeed, infection with HPV 
has been detected with increasing frequency the longer the oral contraceptives are 
taken, however, this could equally relate to an increasing number of sexual partners 
(Ley et al., 1991). The contributions of these steroid hormones are supported by the 
presence of three hormonal responsive elements in the NCR of genital HPV s (Mittal 
et al., 1993). 
1.3.5.6 Immunosuppression 
Evidence for a role of the immune system arises from the increase in HPV associated 
lesions during immunosuppression. Organ transplant recipients receiving 
immunosuppressive therapy are also known to have an increased incidence of viral 
warts, premalignant and cancerous skin lesions and show some similarities to patients 
with EV. 25-50% of renal transplant recipients develop warts 1 year after 
transplantation, rising to 77-95% after 5 years (Dyall-Smith et al., 1991; Glover et at., 
1994). These tend to be common palmoplantar warts in the early post transplant 
years, followed by numerous plane warts developing predominantly on sun exposed 
skin some years later. 
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Clinical genital HPV infections also occur more frequently during pregnancy, when 
women are immunocompromised, often with regression of lesions after delivery 
(Woodruff & Petersen, 1958; Oriel, 1971; Cook et at., 1973; lablonska et at., 1982; 
Garry & Jones, 1985). An increase in HPV prevalence may predispose to perinatal 
transmission of the virus. (Schneider et at., 1987; Czegledy et at., 1989; Villa & 
Franco, 1989). 
1.3.5.7 Other infectious organisms 
Other infectious organisms may be involved in the development of cervical cancer in 
HPV infected tissue. Transient infection with HSV-2 in the presence of ongoing 
chronic infection with high risk HPVs may contribute to the oncogenic process 
through a 'hit and run' mechanism (Yamakawa et at., 1994; Galloway & McDougall, 
1983). HSV-l infection may also contribute to an increased risk of cancer in the 
presence of HPV as ICPO protein is able to activate HPV -18 gene expression in 
cervical cancer cell lines (Gius & Laimins, 1989). Human herpes virus type 6 has 
also been associated with some SIL and cervical cancers and there is enhanced 
expression of HPV early proteins and an increased tumourigenicity in mice (Chen et 
at., 1994). 
Other infectious agents that have been suggested to act as co-factors in the 
development of SI1 and cervical cancer include Treponema pal/idum, Neisseria 
gonorrhoea, cytomegalovirus and Epstein Barr virus, although no substantive data 
have been described (Lacey, 1992). Several studies have shown that 20% to 32% of 
men attending genitourinary clinics with genital warts have evidence of at least one 
other sexually transmitted disease. For example, the incidence of Neisseria 
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gonorrhoea in these patients can be as high as 9.9% (Kinghorn, 1978; Came & 

Dockerty, 1990; Crawshaw & Haran, 1990). 

HPV infection of the anogenital tract is more common in subjects infected with 

human immunodeficiency virus (HIV) due to the immunosuppression that occurs 

during HIV infection and also as a result of viral interaction and alteration of viral 

pathogenesis (Palefsky, 1995). 

1.3.5.8 Genetic susceptibility 
Many diseases are thought to have a genetic basis. There is a significant link between 
cervical carcinomas containing HPV types-16 or -18 and presence of the human 
leukocyte antigen (HLA) DQBI*0602 allele. The HLA-II antigen Dqw3 (an allele of 
the DQBI) is expressed by 67-88 % ofwomen with cervical cancer while only 50% of 
a control population express this antigen (Wank & Thomssen, 1991; Wank et at., 
1992; Helland et ai., 1992). Individuals with certain tissue types e.g. HLA-B7 tend to 
have more aggressive carcinomas with a poorer prognosis (Ellis et al., 1995). 
Conversely, the absence of HLA-B71B40 has been associated with metastatic spread 
of HPV -16 containing cervical carcinomas. However, at present, it is not completely 
clear whether these genetic associations represent susceptibility to cancer 
development and/or to infection with cancer associated viruses (Wank et at., 1993; 
Honma et al., 1994). 
1.4 LABORATORY INVESTIGATIONS OF HUMAN PAPILLOMA VIRUSES 
Studies of HPVs have been hampered as virions are often only present in low 
amounts in clinical lesions and are notoriously difficult to propagate either in vitro or 
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in vivo. HPV replication occurs in the supra basal layers of squamous epithelium. 
The expression of early proteins is largely restricted to these layers, while virion 
assembly takes place in the upper layers where capsid proteins are expressed. This 
localisation, together with the non-lytic nature ofHPV, may provide the initial barrier 
against the immune system. This may also explain the delay of serum antibody 
responses to virus like particles (VLPs) in women after the first exposure to HPV and 
the late induction of T-Iymphocytes to E7 (Carter et al., 1996). It appears that HPV 
infections are ignored until antigen is released due to physical damage (biopsy) or by 
the over expression of E7 after viral integration (Jeon & Lambert, 1995). This 
'immunological tolerance' theory is supported by studies in E7 transgenic mice, 
although keratinocytes expressed and presented a known E7 epitope cytotoxic T­
lymphocytes (CTLs) were neither primed nor tolerised in vivo. However, CTLs 
against this epitope could be primed in vitro providing that clonal deletion does not 
occur, and that consequently there is no possibility of a hole in the T -lymphocyte 
repertoire of these mice (Herd et al., 1997; Melero et al., 1997). 
HPV-11 has been replicated in vivo using nude mice with infected human xenografts 
inserted under the renal capsule (Kreider et al., 1987). Subsequently, HPV-16 virions 
have also been produced in a single nude-mouse transplanted with the SIL-derived 
cell line W12 but this has not been repeated (Sterling et al., 1990). Infectious HPV­
31 virions were produced via HPV -31 DNA infected human keratinocytes propagated 
using raft cell cultures which permit keratinocyte differentiation at an air/liquid 
interface (Meyers et al., 1992). Unfortunately, the yield of particles in these systems 
is low, hence the main source of HPV proteins used for research purposes are those 
produced by the techniques of recombinant DNA or organic chemistry. 
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The antigens chosen for investigations in this thesis are synthetically constructed 
peptides, that have been used successfully in previous studies for investigating HPV 
proteins (Jocmus-Kudielka et at., 1989; Mann et al., 1990; Mandelson et al., 1992; 
Muller et at., 1992; Hamsikova et at., 1994). Synthetically constructed peptides have 
also been used in viral diagnosis to detect serum antibody levels and include: hepatitis 
delta antigen (Poisson et at., 1993), hepatitis E virus (Coursaget et at., 1994), HPV-16 
E2 protein (Sharma et at., 1996), respiratory syncytial virus (LangedYjk et al., 1996) 
and the Japanese encephalitis virus (Huang et al., 1996). Indeed, in mice immunised 
with synthetic peptides to internal proteins of influenza virus, the peptides are often 
recognised and lysed by CTLs just as well as target cells that had been infected with 
live influenza (Townsend, 1986). 
1.4.1 Animal models 
Animal models used for immunological investigations of natural PV infections may 
provide parallels for HPV infections and are useful in evaluation of potential 
vaccination strategies. One of the most useful ways of modelling HPV infection is to 
examine natural animal infections. For example, there are multiple types of BPV 
which attack the skin in a similar maImer to HPV. Indeed, like 'high risk' HPVs, 
BPV-4 can also progress to cancer, but the genome is lost in the process. Animals 
vaccinated with BPV-2 Ll are protected from challenge with BPV-l or -2 virions but 
are still susceptible to BPV-4 infections indicating that vaccination induces type­
specific immunity (Jarrett et al., 1990). Protection against re-infection via 
neutralising antibodies to BPV-1 & -2 was induced by inoculating cattle with 
bacterial Ll and L2 fusion proteins (Pilacinski et at., 1986; Jarrett et al., 1991). BPV­
.... 
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4 E7 fusion proteins can also induce regression of papillomas, presumably through 
the induction of specific CTLs. Similarly, immunisation of cattle with BPY -2 L2 
fusion protein induces regression of benign tumours in cattle (Jarrett et ai., 1992). 
Similarly, CRPY cause skin papillomas that can spontaneously regress or progress to 
squamous cell carcinoma. Vaccination of cotton tail rabbits parentally (to avoid 
contact with skin) with virus, protects against subsequent infection but does not 
induce regression of established lesions (Shope, 1937). Vaccination of cotton tail 
rabbits using bacterial fusion L1 or L2 constructs, vaccinia virus expressing L1 or, 
virus-like particles results in the production of neutralising antibodies and protection 
to subsequent viral challenge. Vaccination with non-structural proteins E1 and E2 
can induce regression of established papillomas (Christensen et at., 1991; Breitburd et 
ai., 1995; Selvakumaretal., 1995). 
Canine oral papillomaviruses (COPV) also cause lesions on mucosal surfaces but 
these do not usually progress to malignancy unless injected intramuscularly 
(Sundberg et al., 1987). A crude formalin inactivated oral papilloma homogenate was 
used successfully in a large study to prevent oral COPV infections (Bell et al., 1994). 
This led to further trials of COPV L1 VLPs in beagles, resulting in production of 
neutral ising antibodies and animals that were completely resistant to re-challenge 
with COPV. This has now progressed to vaccine trials for high risk HPYs developed 
by Medlmmune (Table 1.1). 
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Company 
Apollon 
Cantab 
Cantab 
Cantab 
Medlmmune 
Medlmmune 
Merck 
Merck 
NCr 
Pangaea 
Pasteur Merieux 
Connaught 
Stressgcn 
\0 
f d IinicaI trial 
Components Type 
Plasmid DNA types unknown Unknown 
Live recombinant vaccinia virus, HPV-16 & -18 E61E7 Therapeutic 
(TA-HPV) 

Recombinant L2 and E7 ofHPV-6 (TA-GW) Therapeutic 

Unknown (TA-CIN) Unknown 

VLP eLl) ofHPV-ll Prophylactic 

Multivalent VLPs high risk types Prophylactic 

VLP (Ll) of various HPV types Prophylactic 

Naked plasmid DNA HPV types unknown Unknown 

HPV-16 E7 + lipid moiety Therapeutic 

Plasmid DNA encoding HPV MHC epitopes Therapeutic 

Vaccinia/molecular tag VLP/E7 chimera Therapeutic 

Recombinant E7 (HspE7) Therapeutic 

Development stage 
Pre-clinical 
Phase IIII 
Phase lIa 
Pre-clinical 
Phase I 
Phase I 
Pre-clinical 
Pre-clinical 
Pre-clinical 
Phase I1IIa 
Pre-clinical 
, 
Pre-clinical 
Reference 
National Cancer 
Institiute, 1999 
Editorial, The 
Scientist, 1997 
i 
Lacey et al., 1999 I 
Editorial, The 
Scientist, 1997 
National Cancer 
Institute, 1999 
National Cancer 
Institute, 1999 
National Cancer 
Institute, 1999 
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Institute, 1999 
National Cancer 
Institute, 1999 
Editorial, The 
Scientist, 1997 
Editorial, The 
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Canadian News 
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RhPV positive neoplastic genital lesions have been reported in sexually-active 
monkeys. These may provide a model for HPV associated cervical oncogenesis as 
RhPV is closely related to HPV -16 and may have similar oncogenic potential (Ostrow 
et al., 1990). RhPV-1 E5, E6 and E7 DNA can transform murine Nlli 3T3 cells in 
vitro (Ostrow et al., 1993; Schneider et al., 1991). 
Transgenic mouse models have proved extremely useful in the study of the 
transforming properties of PVs. The first transgenic model to be described was for 
BPV-1 where mice developed dermal fibrosarcomas involving at least three stages 
mimicking the multi-step development of cancer (Lacey et al., 1986). Transgenic 
models for HPV also exist and HPV -16 transforming genes have been targeted to a 
variety of tissues including the skin, where squamous epithelial hyperplasia and 
dysplasia develop and sometimes progress to cancer (Arbeit et al., 1994). 
1.4.2 Virus like particles 
Using vaccinia virus vectors, HPV-16 Ll and L2 can be assembled into empty virus 
like particles (VLPs) in the nuclei of infected cells (Zhou et al., 1991). In HPV types 
-1, -6, -11, -16, BPV -1 and CRPV, the L 1 protein is sufficient to form VLPs but the 
presence of L2 significantly increases the efficiency of the L1 assembly process 
(Kimbauer et al., 1993; Hagensee et al., 1993; Rose et al., 1993; Zhou et al., 1993; 
Sasawaga et al., 1995; Heino et al., 1995). VLPs display authentic particle 
morphology and are highly immunogenic probably carrying the same conformational 
epitopes as native particles (Hagensee et al., 1993; Rose et al., 1993; Zhou et al., 
1993). Several workers are now investigating the use of VLPs as prophylactic 
vaccines or chimeric (prophylactic/therapeutic) vaccines, and it may even be possible 
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to use VLPs as vectors for delivering HPV DNA vaccines into target cells as with 
polyomavirus (Slilaty et ai., 1982; Slilaty & Aposhian, 1983; Table 1.1). 
1.5 CONTROL OF HUMAN PAPILLOMA VIRUSES BY THE IMMUNE 
SYSTEM 
The importance of an effective immune response in the control of HPV infection can 
be demonstrated by the increase of HPV associated lesions in the immunosuppresed 
(see section 1.3.5.6). This section describes immune responses to HPV infection and 
the methods used to detect them. Also included are protocols for vaccine 
development, some of which are still experimental while others are undergoing 
clinical trials. 
1.5.1 An overview of immune responses to viruses 
Both antigen specific and innate immunity are important in the control of virus 
infections. Indeed, natural killer (NK) cell activity is associated with the regression of 
HPV -induced cervical lesions (Garzetti et aI., 1995). However, it is antigen specific 
immunity that can specifically target responses and immunological memory. 
Mechanisms used to eliminate virus infections include viral neutralisation, where 
antibodies specific for virus surface antigen contain the spread of acute infection and 
protect against re-infection. In the context of HPV infection, secretory 
immunoglobulin class A (IgA) in mucous secretions may play an important role in 
host defence by blocking viral attachment to mucosal epithelial cells. Circulating 
antibody or complement may also agglutinate and oppsonise virus particles 
facilitating Fc or C3b receptor mediated phagocytosis. Once an infection has 
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occurred, antibodies are not usually able to eliminate a virus, particularly if the virus 
is capable of entering a latent state in which its DNA is integrated into host 
chromosomal DNA. The main components of a cell mediated immune (CMI) 
response are clusters of differentiation antigen 8 (CD8+) positive CTLs and CD4+ T 
helper type 1 cells (Th1). Activated Thl cells produce cytokines including interferon 
gamma (IFN-y) and interleukin-2 (IL-2). IFN-y acts directly to eliminate virus by 
inducing an anti-viral state in cells while IL-2 acts indirectly by assisting the 
activation of CTL precursors into an effector population. Both IFN-y and IL-2 
activate natural killer (NK) cells, which are important in the first few days of 
infection until a specific CTL response develops. In most viral infections a CTL 
response develops within 3-4 days. As CTLs destroy infected cells, they eliminate 
potential sources of new infection. 
HPV infections resemble those ofnon-lytic viruses as they do not cause cell death but 
are released from infected cells by desquamation (Stanley, 1994). Therefore, the ideal 
defence against these infections would be a combination of neutralising antibodies 
and CTL mediated cell lysis of infected cells for the prevention of subsequent re­
infection by released virions (Zinkernagel, 1996). The target cell for CTL mediated 
lysis would be the keratinocyte present in the intermediate layers of the squamous 
epithelium where viral transcription and replication takes place and where the early 
proteins (E1, E2, E4, E5, E6 & E7) are abundantly expressed. The late proteins L1 
and L2 would be unsuitable CTL targets as they are expressed in the superficial layers 
where cells are already dying. Neutralising antibodies would have to be directed at 
these proteins (Schiller & Roden, 1995). 
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1.5.2 Antibody responses in human papillomavirus associated lesions 
Seropositivity to HPV-16 may be associated with persistent infection, as 83% of 
women found to be HPV-16 DNA positive on more than one occasion had detectable 
HPV antibodies compared to 22% for those found to be HPV DNA positive only once 
(Wideroff et al., 1995). Generally, 50-60% of women who are positive for HPV -16 
DNA have circulating antibodies to HPV -16 VLPs. When lesions clear, however, 
antibody responses decline rapidly (Heim et al., 1995; Wikstrom et al., 1995; 
Andersson-Ellstrom et al., 1996). Patients infected with genital HPVs often exhibit 
immune responses as antibodies, for example, HPV -16 E4 antibodies occur in sera 
from immunocompromised patients and from patients with H-SIL and these may even 
be predictive of HPV infection (Jochmas-Kudielka et aI., 1992; Muller et al., 1990). 
Moderate reactivity has been detected in the sera of HPV-16 DNA positive SIL 
patients to HPV-16 L1 synthetic peptides and VLPs (Cason et aI., 1992). Naturally 
occurring neutralising antibodies to HPVs are type-specific and recogmse 
conformational epitopes (Steele & Gallimore, 1990; Jarrett et al., 1984; Christensen 
et al., 1990; Jensen et at., 1980; Pfister et al., 1981; Favre et aI., 1975). Responses to 
VLPs are more often detected in subjects with genital warts than those without (Heim 
et ai., 1995). Viral persistence is thought to be a key factor in disease progression as 
increased HPV -16 seropositivity is associated with an increased risk of developing 
cervical cancer (Nonnenmacher et al., 1995; Lehtinen et aI., 1996). 
1.5.3 Cell mediated immunity in human papillomavirus-associated lesions 
It is CM! which is thought to playa major role in containing HPV infections, and 
reasons for this include: 
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(i) Human warts are more prevalent and increase in size during conditions that 
suppress T-lymphocyte functions, these include pregnancy, immunosuppressive 
chemotherapy, organ transplantation and HN infection (see section1.3.5.6). These 
warts tend to disappear when the immunosuppression is reduced or eliminated. The 
regression of papillomas in rabbits and cattle is also thought to occur by CMI 
(Spradbrow, 1987). 
(ii) The histological picture of regression flat skin warts shows infiltration by 
mononuclear cells suggestive of a CMI response (Tagami et ai., 1983). Trauma to 
one wart often results in the regression of warts at other sites, suggesting an 
immunological response triggered by release of antigen from the wart. 
(iii) An altered CD4+/CD8+ ratio has been reported in patients with extensive genital 
HPV infections (Carson et aI., 1986). 
(iv) Genital cancers associated with HPVs occur at increased frequency in organ 
transplant recipients (Penn, 1986). 
CMI, rather than humoral immunity, appears to be of importance against both de novo 
and re-infection with HPVs. Patients with common variable immunodeficiency 
(characterised by the inability to produce specific-antibodies, but intact T -lymphocyte 
responses) are not unduly susceptible to the development of HPV lesions (Benton et 
aI., 1992). Conversely, CMI responses probably explain why most SIL do not 
progress to malignancy since inherited, iatrogenic or acquired immunosuppression 
encourages development of lesions and progression to cancer (Nasiell et aI., 1976). 
In patients with severe H-S1L and cervical cancer HPV-16 and -18 E6/E7 specific 
CTLs are present in the peripheral blood and at sites of disease implying that CM! is 
triggered eventually (Borysiewicz et al., 1997). These findings have led to phase II 
64 
Chapter One 
clinical trials of a live recombinant vaccinia virus expressing the E6 and E7 proteins 
ofHPV-16 and -18 (TA-HPV; [see section 1.6, Table 1.1]). 
Th cells can be divided into two subsets according to cytokine expressIOn and 
immunoregulatory function: Thl cells promote predominantly CMI while Th2 cells 
stimulate humoral immunity (Mosmann & Sad, 1997). The current prevailing dogma 
in viral immunology is that Thl type CMI is vital to the clearance of infection while 
Th2 activity is detrimental and leads to viral persistence. However, there is an 
increasing awareness that successful immunity against pathogens most often does not 
entail polarised ThJ or Th2 responses but usually more subtle combinations of the two 
(Allen & Maizels, 1997). 
CD4+ Th cells are also important, as they are required for the potent anti-viral and 
anti-tumour immune responses and provide long term immunological memory (Chen 
& Ananthaswamy, 1993; Sprent, 1994; Lin et al., 1996). CD4+ Th cells may also 
play an important role in the elimination ofHPV infection. Evidence for this includes 
(i) regressing warts are mainly infiltrated by CD4+ Th cells, reminiscent of a delayed 
type hypersensitivity (DTH) reaction (Rogozinski et af., 1988; Vardy et al., 1990; 
Coleman et al., 1994); (ii) in mice grafts ofE7 transfected keratinocytes on skin led to 
priming of specific CD4+ T -lymphocyte which were detectable after challenge in a 
DTH reaction (McLean et af., 1993); (iii) vaccination of mice with HPV-16 E7­
LAMP-l vaccinia virus construct targeted E7 to lysosomal and endosomal 
compartments in the major histocompatiblity complex class II (MHC-II) pathway led 
to enhanced protection against subsequent challenge (Lin et af., 1996; Wu et at., 
1995); (iv) HLA associations with susceptibility to or protection from HPV infection 
and cervical disease have been found for the MHC-II HLA-DR and HLA-DQ alleles 
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(Wank et al., 1991; 1993; Apple et al., 1994; 1995; Odunsi et al., 1996; Sastre-Garau 
et al., 1996). 
1.5.4 Immunological cells in human papillomavirus infected lesions 
Both cervical cancer and SIL are infiltrated with poorly activated CD8+ T­
lymphocytes that show very little in vitro tumour specific activation of CTLs and only 
a few express IL-2 receptors (Ferguson et aI., 1985; Viac et at., 1990; Glew et al., 
1992; Ghosh & Moore, 1992). A reduction in the number of the professional antigen 
presenting Langherhans' cells is also seen in genital warts and L-SIL (Viac et at., 
1990). This is more pronounced in H-SIL and the histology of Langherhans' cells in 
these lesions is often disturbed showing abnonnal morphology (Hughes et at., 1988; 
Fink-Puches & Smolle, 1993). NK cells are present in cervical lesions but in limited 
numbers and often with a reduction in their natural cytotoxicity (Tay et al., 1987; 
Malejczyk et al., 1989; 1993). 
Macrophages may also play an important role in the control of HPV infection since, 
murine fibroblasts transfected with the early region or the E7 gene of HPV-16 are 
susceptible to being killed by activated macrophages (Denis et aI., 1989; Banks et aI., 
1991). There is evidence of natural immunity to HPV infections from HPV lesions 
that manifest themselves as warts and lesions during immunosuppression. In humans, 
warts are prevalent and more likely to increase in size during conditions that depress 
T-Iymphocyte functions, but these disappear once the immunosuppression is reduced 
or eliminated. 
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1.5.5 Cytokines associated with human papillomavirus infection 
There is evidence that HPV infection may be under some sort of autocrine control of 
locally released cytokines especially in the early stages of infection, when decreased 
expression of anti-HPV cytokines by infected cells may favour HPV replication and 
lesion growth. Cultured keratinocytes are known to produce a variety of cytokines 
including 1L-l, 1L-6, 1L-8, granulocyte-macrophage colony stimulating factor (GM­
CSF) and tumour necrosis factor-a. (TNF-a.) (Kimbauer et ai., 1989; Luger & 
Schwarz, 1990; Barker et ai., 1991). However, cervical keratinocytes immortalised 
by HPV -16 or -18 show a significant reduction of these cytokines when compared to 
normal cells (Woodworth & Simpson, 1993). The epidermal growth factor (EGF) 
family may play an important role in the growth and differentiation of HPV 
associated lesions and cells (Bauknecht et ai., 1989; Goppinger et ai., 1989; Zyzak et 
ai., 1994). Up-regulation of the EGF-receptor (EGF-R) appears to be a common 
feature of different HPV -associated lesions and of HPV immortalised cell lines 
(Gullick et ai., 1986; Viac et ai., 1987;Vambutas et ai., 1993). 
Conversely, cytokines with anti-HPV activities may originate from infiltrating 
leukocytes as well as other non-epithelial skin, mucosal cells or fibroblasts. 
Cytokines involved in anti-viral responses may include TNF-a. and IL-l, both of 
which have been shown to down regulate E6/E7 mRNA expression in HPV -16 and 
HPV-18 transfected cell lines. TNF-a. also inhibits the proliferation of other HPV 
containing cell lines (Malejczyk et at., 1992; Villa et ai., 1992; Kyo et at., 1994; Rosl 
et ai., 1994; Woodworth et ai., 1995). Transforming growth factor-~ (TGF-~) also 
has inhibitory effects on HPV mRNA expression at the transcriptional level leading to 
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the loss of E6 and E7, possibly due to down-regulation of c-myc (Woodworth et al., 

1990; Braun et al., 1990). 

Both TNF-a and TGF-~ have been detected in HPV associated lesions and are 

spontaneously released in culture supernatants of HPV -16 harbouring cell lines, 

although decreased TGF-~ expression has also been reported (Woodworth et al., 

1990; Braun et al., 1990; 1992; Malejczyk et al., 1991; 1992; Ho et aI., 1994; 

Comerci et al., 1996). Although IFN-y may inhibit HPV-18 RNA expression and the 

proliferation of HPV containing cell lines, the functions of IFN-a remains unclear 

(Nawa et al., 1990; Woodworth et al., 1992; Kyo et al., 1994). GM-CSF has been 

shown to aid recruitment of Langerhans' and dendritic cells into HPV transformed 

cervical epithelium and may be useful as a new immunotherapeutic approach for 

cervical cancer and SIL (Hubert et ai., 1999). 

It is possible that HPV s may act to escape the immune system by reducing pro­

inflammatory cytokine signals. 

1.5.6 Mucosal immunity in the female reproductive tract 
The female reproductive tract is largely protected by the mucosal immune system. 
Plasma cells in the lamina propria regions secrete either IgAJ or IgA2 antibodies in 
response to stimulus. The main effector site is the uterus with organised lymphoid 
tissue in the endocervix comparable to Peyers patches of the gastrointestinal tract 
(Hordness et aI., 1996; Jalanti & Isliker, 1977). Cells of the immune system drain 
through the cervical, rectal and gastric lymph nodes, all of which may cover 
reproductive tract immunity (Mi1ler et ai., 1992). 
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Immunity may depend to some degree on the levels of steroid hormones, as IgG and 
IgA levels fluctuate during the menstrual cycle. Both IgG and IgA levels in cervical 
secretions are decreased during midcycle when cervical mucus is the thinnest, 
probably providing better penetration of sperm as well as micro-organisms which may 
contribute to increased sexually transmitted diseases in the second part of the 
menstrual cycle (Tristram & Ogra, 1994). Further evidence for hormonal control is 
the up-regulation in the uterus and down regulation in the vagina of secretory 
component and IgA following treatment with oestradiol, whereas treatment with 
progesterone results in down regulation of both secretory component and IgA (Wira 
et ai., 1995). 
Antigen presentation also varies during the reproductive cycle and is lowest at oestrus 
and highest at proestrus as the expression of MHC antigens varies (Edelstam et ai., 
1992). Glucocorticoid hormones have been shown to reduce the expression ofMHC­
I antigens on human genital squamous cancer cell lines (Von Knebel Doeberitz et al., 
1990). This may relate to the increased risk of cervical cancer during pregnancy. 
1.5.7 Cutaneous immunity 
The skin consists of an epidermis separated from the underlying dermis by the 
basement membrane. Both epidermis and dermis contain cell populations that play 
active roles in immune reactions. In the epidermis keratinocytes produce a number of 
cytokines (see section 1.5.5) that stimulate the chemotaxis and activation of immune 
cells. Keratinocytes are also able to express MHC-II after exposure to IFN-y, which 
is similar to the induction of MHC-ll on macrophages (Abbas et ai., 1994). 
Langerhans' cells function as professional antigen presenting cells, interacting with 
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CD4+ lymphocytes. Intraepidermal lymphocytes constitute only 2% of skin 
associated lymphocytes, the rest reside in the dermis and are predominantly CD8+ 
although the specificity or function of this population is not clear. Similar to other 
connective tissues, the dermis contains T-lymphocytes (CD4+ & CD8+) 
predominantly in a perivascular location and scattered macrophages. The major type 
ofT-lymphocyte mediated immune response in the skin is delayed type hypersensitity 
(DTH). This is a reaction to soluble protein antigens or chemicals that can bind to 
and modify self-proteins, creating new antigenic determinants. Little is known about 
humoral immune responses in the skin, although it is known that secretory IgA is 
present. B-lymphocytes are rarely encountered and it is probable that IgA produced 
by B-lymphocytes in draining lymph nodes is transported back to the skin via the 
circulation. 
1.5.8 Methods used to detect human papillomavirus specific immune responses 
Before the heterogeneity of HPV types was appreciated, early studies employed 
virions derived from pooled plantar warts (Pfister, 1984). Although untyped, these 
virions were used to look for antibodies in patients with genital warts! 
HPV-11 virions obtained from nude mice xenografts have also been used to examine 
HPV specific immune responses from subjects with CA and laryngeal papillomas 
(Bonnez et ai., 1991). However, the yield of HPV-11 virions is extremely low and 
other HPV types have not been readily propagated as discussed previously. 
Antigen derived from viral proteins expressed in bacteria, or synthetically constructed 
peptides, have been useful in determining antibody and cell mediated responses to 
individual proteins (Galloway, 1992; Tindle & Frazer, 1994; Viscidi & Shah, 1992). 
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Although bacterially derived proteins have several advantages, including a 
reproducible supply of antigen from any HPV type, most are insoluble and have to be 
used under denaturing conditions in Western blot assays. 
As it is possible to construct VLPs in recombinant baculovirus and vaccinia virus, 
these have been investigated as a source of L1 and/or L2 antigens (Hagensse et al., 
1993; Kirnbauer et al., 1992; Rose et at., 1993). It is also possible to use chimeric 
VLPs, which include an early protein component (Muller et a!., 1997). 
Antigens to be used in this study were synthetically constructed peptides. Attempts to 
develop functional assays to measure eMI have had limited success, although high 
stimulation indices have been reported for some synthetically constructed HPV 
proteins (Tindle & Frazer, 1994; Viscidi & Shah, 1992; Luxton et al., 1996; Shepherd 
et al., 1997). 
1.6 TREATMENT OF HUMAN PAPILLOMAVIRUS ASSOCIATED 
LESIONS WITH VACCINES 
Due to the viral aetiology of SIL and cervical cancer they may be prevented or treated 
using vaccines, as are other viruses such as poliovirus and rabies virus (Brochier et 
al., 1994). 
Three well documented HPV clinical trials are currently underway: (i) Holland, this 
consists of two high affinity HLA-A0201 binding peptides from HPV-16 E7, together 
with a synthetic helper peptide and the Montamide ISA51 adjuvant. This is being 
tested on patients with HPV-16 associated tumours who have not responded to 
conventional therapy and who have a HLA-A0201 tissue type. (ii) Australia, A phase 
IIII trial has been initiated in patients with advanced cervical carcinoma. (iii) Wales, 
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the most promising trial to date involves vaccination with a recombinant vaccinia 
virus expressing HPV-16 and -18 E6 and E7 proteins. For safety reasons, portions of 
the E7 proteins have been mutated to inactivate the pRB binding site. All patients in 
this study responded with an antibody response to vaccinia virus. In addition, two 
patients who already had antibodies to E6 exhibited an increased titre while two 
others developed new antibody responses to E7. Two of four patients developed 
MHC-I restricted CTL responses but four patients who were HLA-A0201 positive did 
not show a CTL response when tested with target pep tides of the Dutch trial. 
There are two HPV vaccine strategies. Prophylactic vaccination with L1 and L2 to 
prevent viral infection and therapeutic vaccination with El, E2, E4, E5, E6 and E7 to 
treat established lesions. A combination of the two may be valuable in treating HPV 
associated disease. 
1.6.1 Prophylactic human papillomavirus vaccines 
Considering VLPs appear identical to authentic HPV virions, it is feasible that they 
would make ideal antigens for prophylactic vaccination and also delivery vectors for a 
therapeutic component. They have already been investigated as irnrnunogens against 
HIV and foxes have been successfully immunised using vaccinia virus and rabies 
virus recombinants (Barnes, 1987; Brochier et al., 1994). The advantages of using 
VLPs are that: (i) their antigenic conformational structure displays a high degree of 
sequence conservation; (ii) immunisation with PV VLPs has shown protection against 
experimental BPV and CRPV infection by the production of neutralising antibodies 
(Breitburd et at., 1995; Donnelly et at., 1996); (iii) they lack potentially oncogenic 
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viral DNA; (iv) VLPs from different viral strains would provide a multivalent vaccine 
covering common HPV types. 
Exposure of cells to VLPs in vitro leads to binding, uptake and transport of capsid 
proteins which are detected in the Golgi, suggesting that processing occurs through 
the MHC-I pathway (Schiller & Roden, 1995; Zhou et al., 1995). This is also true for 
chimeric VLPs (L1 & E7) which induce neutralising antibodies that may provide both 
prophylactic and therapeutic immunity (Muller et ai., 1997). As investigations of 
VLPs in human volunteers continue, there are potential problems associated with the 
testing and introduction of prophylactic vaccines. Whilst testing their efficiency 
against HPV -16 infection is relatively simple, it may take several years to assess their 
efficacy against SIL and impossible to test their protective effects against cervical 
carcinoma for ethical reasons given the evidence for the oncology of cervical cancer 
associated HPVs. Cells in the genital tract expressing Fc receptors could theoretically 
take up antibody-coated HPV virions and antibodies may act as 'enhancing 
antibodies' and promote, rather than negate infection. HPV -16 variants occur with 
coding changes in the Ll protein (Crawford, 1993) and such variants along with the 
other genital HPV s may escape neutralisation mediated by the induction of antibodies 
to a single HPV -16 isolate. In advanced SIL and cervical cancers, when capsid 
proteins are no longer expressed such vaccines will cease to have any effect. Finally 
methods to develop VLPs need to be revised for large-scale production and 
consistency between batches. 
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1.6.2 Therapeutic vaccines to prevent viral replication 
A complementary approach to prophylactic vaccines is the concept of vaccines able to 
induce the destruction of established HPV -16 containing lesions. Such an approach is 
feasible, as in mice CTLs raised against Adenovirus S viral nuclear oncogene EIA, 
were able to eradicate large established tumours of Adenovirus S transformed tumour 
cells (Kast et ai., 1991). Similarly, recombinant vaccinia virus containing the middle­
and large-tumour (large-T) antigen of polio virus confers immunity to rats against 
tumours containing the full length viral genome (Lathe et ai., 1987). Indeed, much 
effort has been devoted to developing HPV -16 and -18 E6 and E7 based vaccines as 
these probably represent tumour specific antigens for the vast majority of HPV 
associated cancers, and as such, rational targets for the design of therapeutic vaccines. 
However, E6 and E7 are potentially oncogenic and so may not be ideal vaccine 
candidates, unless mutated or modified in some way. Protective CTL epitopes may 
be uncoupled from regions involved in binding to p53 and pRB. Truncated or 
mutated proteins could also be constructed. However, it is not known whether such 
mutations would interfere with the immunogenicity of either protein, but since CTLs 
recognise short peptides, most CTL epitopes are likely to be unaffected. Other early 
protein targets such as E1, E2 or E5 may be of potential benefit. They are expressed 
in low grade SIL, which contain HPV-16 DNA and high levels of E5 mRNA are 
detected in L-SIL (Stoler et al., 1992). HPV-16 E5, although an oncogene, has only a 
weak transforming activity and so may be safer than using HPV-16 E6 or E7. It is 
known to remain expressed until very late stages of malignancy (Matsakura et ai., 
1989; Durst et ai., 1992). The use of HPV -16 E5 may also be more appealing to the 
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phannaceutical companies as it involves a potentially huge market for preventing the 
occurrence of SIL. 
Considering that T -lymphocyte responses are MHC-restricted, a vaccine for use in 
outbred populations such as man would theoretically need to incorporate several HPV 
16 CTL epitopes in order to induce a wide coverage of immunity. In most ethnic 
populations, at least 90% will express one of the six most common MHC alleles of 
that community (Tindle & Frazer, 1994). 
1.6.3 Vaccine vectors 
Vaccines designed to stimulate CTLs may be efficiently delivered via attenuated 
intracellular pathogens such as recombinant Bacille Calmette Guerian (BCG) or 
vaccinia virus incorporating HPV -16 CTL epitopes (Klein, 1990; Tartaglia et ai., 
1992). BCG is a safe, well-tested vaccine that can be utilised as a vector to induce 
both strong humoral and cell-mediated immunity to foreign epitopes (Aldovini & 
Young, 1991; Stover et al., 1991). HPV-16/BCG recombinants may prove to be 
particularly useful vectors, bearing in mind the vertical transmission ofHPV-16 and­
18. Such a vaccine could be given at 6 months of age by an oral route conferring long 
lived immune responses with a single dose. 
Other suggested vectors for delivery of HPV 16 antigens include commensal 
organisms of the female genital tract for example Lactobacillus (Crawford, 1993). 
These could be used to induce HPV -16 specific CTLs, to destroy HPV -16 containing 
lesions. Similarly, recombinant Salmonella typhimurium may also serve as a suitable 
vector to induce mucosal antibodies and HPV -16 E7 has already been expressed in 
this system (Chatfield et ai., 1992). 
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The production of DTH in response to recombinant vaccinia viruslHPV -16 E7 has 
been reported in a mouse model (McLean et aI., 1993) It is thought that HPV may 
evade eradication by dampening the DTH effector response as a result of presenting 
viral antigen in very low concentrations (McLean et ai., 1993). By presenting high 
concentrations of HPV -16 E7 antigen, DTH responses are induced in mice and may 
represent effective mechanisms to combat HPV infections (Chambers et aI., 1994). 
Murine CTL responses to vaccinia virus expressed HPV-16 L1 protein have been 
defined (Zhou et ai., 1991) and immunisation which results in the eradication of 
strong DTH may be a potent mechanism for preventing persistent HPV infection. 
However, care must be taken in the selection of live vaccinia vectors since their use 
resulted in four deaths among (HN) immunosuppressed patients (Culliton, 1992). To 
overcome this shortfall, highly attenuated strains of vaccinia virus such as the 
NYV AC-strain or other pox viruses such as the Canary pox (Lancet editorial, 1992) 
should be used instead. 
Vaccines in live attenuated viral vectors are particularly useful, as protection can be 
spread by infection to individuals who have not attended for vaccination. Such 
attenuated vectors may also include poliovirus, which induces strong mucosal 
immunity characterised by secretory IgA antibodies and CMI at the site of infection. 
Indeed, a B-lymphocyte epitope of a HPV-16 LlIpoliovirus chimera was 
immunogenic in rabbits (Jenkins et ai., 1990). Similarly, the equivalent epitope on 
BPV-2 L1 was also immunogenic but did not induce antibodies with neutralising 
activity for BPV-2 in vitro (Cason et ai., 1993). 
Viral proteins and peptides are usually poor inducers of CTLs but the use of 
immunostimulatory complexes (ISCOMS) may permit the induction of CTLs to 
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administered proteins or synthetic peptides (Randall & Souberbielle, 1990). ISCOMs 
or liposomes are vesicles formed from synthetic lipid bilayer membranes composed 
of saponin and cholesterol. The production of ISCOMs can be modified to induce the 
formation of vesicles containing antigen which may potentiate cellular immune 
responses. Indeed, recombinant HPV -16 proteins within ISCOMs are believed to 
potentiate antigenicity (Jones et ai., 1988). Other delivery systems could also be used 
such as pulsed release of antigens from biodegradable micro spheres (Eldridge et al.• 
1989; Moldoveanu et ai., 1989) and plant virus based chimeras such as cowpea and 
tobacco mosaic virus: the latter has been used to produce potential anti-malarial 
vaccines (Turpen, 1995). 
Other vectors include spleen dendritic cells, an Escherichia coli protein carner 
ISCAR and Hepatitis B core antigen. These have protected against challenge with E6 
or E7 transfected tumour cells and produced IgG and IgG2a antibodies as well as IL­
2 and IL-4 (Tindle et ai., 1995; Ossevoort et ai., 1995). 
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1.7 PRIORI RATIONALE 

Reasons for this investigation arise from the fact that HPV-16 E5, a minor oncogene, 

is largely ignored in the context of HPV immune intervention whilst attention has 

primarily focused on E6 and E7, the major oncogenes ofHPV-16. It was postulated 

that immune responses specific for HPV -16 E5 protein may occur as: 

(i) The HPV-16 E5 gene is expressed soon after infection, with both mRNA and 

protein detectable in low-grade SIL (Stoler et ai., 1992; Kell et at., 1994; Biswas et 

ai., 1997). The prevalence of HPV -16 E5 mRNA increases with advancing severity 

of disease (Biswas et al., 1997), suggesting that the contribution of HPV-16 E5 

protein to tumour development occurs in the early stages of infection when HPV 

DNA is still episomal. There is also evidence to indicate HPV -16 E5 expression 

persists from low grade lesions through to cervical cancer in integrated and episomal 

forms as mRNA transcripts have been demonstrated in cervical cancers (Matsukara et 

ai., 1989; Durst et at., 1992; Cavuslu et at., 1996b). 

(ii) HPV-16 E5 protein is probably expressed at the cell surface as a result of 

endosome recycling of ligands and formation of inter-cellular gap junctions 

(Goldstein et ai., 1985; Oelze et aI., 1995), making it available to cells of the immune 

system. 

(iii) Finally, the amino acid sequences of HPV E5 proteins are poorly conserved 

between different types making them potentially type specific targets and thus any 

data obtained in this study will be specific for HPV -16 only. 

Although, the immunogenicity of HPV -16 E5 has not been extensively studied, 

antibodies to E5 synthetic peptides have been reported in humans (Dillner, 1992). 

Furthem1ore, antibodies to HPV -16 E5 have been successfully raised in New Zealand 
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white rabbits and the resulting anitbodies recognised E5 protein in cervical lesions 
(Kell et ai., 1994). Prior to this thesis, there have been no repOlied studies 
investigating eMI to HPV -16 E5. 
1.8 AIMS AND OUTLINE OF THESIS 
The initial aim of work outlined in this thesis was to characterise HPV -16 E5 specific 
immune responses in women with and without HPV -16 infection. In Chapter Two, it 
was anticipated that cell mediated immunity would be inversely correlated with 
disease severity. To investigate this, peripheral blood mononuclear cells were 
isolated from each subject and stimulated with HPV-16 E5 peptides. Cell mediated 
immune responses were recorded as stimulation indices. As the HPV-16 E5 ORF is 
subject to DNA variation, in Chapter Three, the presence of HPV-16 E5 variants 
from DNA amplified from study subjects was investigated. The current school of 
thought applied to HPV serology implies that the presence of HPV specific antibodies 
may be associated with severity of lesions. To test this hypothesis, reference and 
variant E5 peptides were investigated for serum reactivity. Chapter Four- Immune 
responses specific for HPV -16 E5 peptides were investigated after immunisation of 
Balblc mice. Also covered within this chapter is an investigation of the ability of E5 
peptides used in immunisation for binding to MHC-I antigens. Chapter Five- From 
these studies described above, it was detem1ined that E5 was a poor immunogen, 
therefore, both E5 peptides and DNA were studied for effects on MHC-I expression 
and for effects on intracellular transport. Chapter Six- The data of the whole thesis 
are discussed. 
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2.1 INTRODUCTION 
As there is evidence to suggest that CMl is important in controlling HPV infection, it is 
probable that cervical disease occurs as a result of a defective immune response. For 
example, in L-SIL and H-SIL, there are reduced numbers of the antigen presenting 
Langerhans' cells, those that are present exhibit changes in morphology (Hughes et al., 
1988). There are also reductions in the number of intraepithelial T-Iymphocyte numbers 
in all grades of SIL (Morris et at., 1983). In contrast, increased numbers of MHC-I 
restricted CD8+ T -lymphocytes are present locally in cervical cancer (Ghosh et al., 
1994) but the implication ofthis finding remains unclear. 
Proliferative peripheral blood mononuclear cell (PBMC) responses to HPV-16 E6 and 
HPV-16 E7 Th epitopes have been detected in healthy volunteers (Amtmann et at., 
1992). Indeed, proliferative lymphocyte reponses to an E7 peptide were related to 
ongoing infection with HPV -16 (Kadish et al., 1994). As the E6 and E7 proteins of 
HPV -16 are persistently expressed throughout infection and malignancy, most assays of 
proliferative T -lymphocyte responses to HPV epitopes have focused primarily on these 
(Luxton et al., 1997). However, as previously discussed in section 1.6, E6 and E7 may 
not be the sole targets for immune intervention as other proteins encoded by the early 
ORFs (E1, E2, E4 and ES) may also contain major T -lymphocyte epitopes. 
The aims of this chapter were to investigate CMI to ES in relation to infection with 
HPV -16 and with severity of HPV -16 associated cervical disease. As discussed in 
section 1.7, the protein encoded by the HPV -16 E5 ORF is associated with cellular 
membranes and may be expressed at the cell surface (Figure 2.1) where recognition by 
cells of the immune system may occur. If this is the case, then it is anticipated that 
subjects without cervical disease or those with L-SIL are more likely to exhibit HPV-16 
ES specific proliferation as this is the stage of HPV -16 associated disease when ES 
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transcripts are abundant. 
Figure 2.1 Predicted conformational structure of human papillomavirus type-16 
E5 protein in a cellular membrane. The above figure demonstrates the predicted 
conformational structure of HPV -16 E5 in a cellular membrane. The location of HPV­
16 E5 within the cell membrane implies that it interacts with a completely different set 
of cellular factors to those interacting with the E6 and E7 nuclear oncogenes. A role in 
the disruption of the normal signalling processes from a family of growth factors has 
been suggested (Banks & Matlashewski, 1996). The SOUSI database predicts HPV-16 
E5 amino acid sequence as a membrane protein with three transmembrane helices. The 
DAS transmembrane prediction server also predicted three transmembrane helices with 
no N-terminal signal sequences, mitochondrial or nuclear localisation signals. COOH 
carboxyl terminus, NH3 amino terminus (Nakai & Kanehisa, 1991). 
Subjects were tested for HPV-16 DNA using primers for both the E5 and the E6 ORFs. 
The detection of HPV-16 E6 was included as along with E7, it is a major transcript of 
HPV-16 DNA, providing more opportunity for the detection of HPV-16 DNA, i.e. 
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positive identification of HPV -16 positive patients. 
A reverse transcription-PCR (RT-PCR) assay was performed to detect HPV-16 E5 
messenger RNA (mRNA). This enabled the detection of active HPV-16 infections 
producing HPV -16 E5 protein. 
Peripheral blood mononuclear cells (PBMCs) were isolated and tested for proliferative 
responses to HPV-16 E5 synthetic peptides. Proliferative PBMC responses ,vere 
characterised according to HPV-16 infection and to disease severity. 
The antigens used in this chapter were synthetic peptides constructed by solid phase 
peptide synthesis (SPPS). Antigens constructed using SPPS have been used in many 
investigations ofHPV specific immune responses (Jocmus-Kudielka et at., 1989; Mann et 
al., 1990; Mandelson et al., 1992; Muller et ai., 1992; Hamsikova et ai., 1994; Sun et al., 
1994). Similarly, synthetic peptides have also been used in the viral diagnosis of other 
virus types including hepatitis C VIrus, respiratory syncytial virus and the Japanese 
encephalitis virus (Poisson et al., 1993; Sharma et aI., 1996; LangedYjk et al., 1996; 
Huang et al., 1996). For stimulation of PBMCs 9-mer peptides corresponding to whole 
length HPV -16 E5 when overlapped by 4 amino acids were used (Figure 2.2). This length 
of antigen was constructed for two reasons. Firstly, as HPV -16 E5 is extremely 
hydrophobic it would be difficult to solubilise in cell culture media for stimulation of 
PBMCs. Secondly, this length of peptide will bind to both antigen binding grooves of 
MHC-I and MHC-II molecules whilst allowing for a degree of epitope mapping. 
2.2 METHODS 
2.2.1 Subjects 
Women were recruited from 'well-woman' and outpatient clinics at St Thomas' Hospital 
(London, U.K.). Fifty five women had recently undergone histological diagnosis 	to 
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confirm abnonnal cervical smear results, twenty women with normal cervical smear 
results were also recruited (Table 2.1). Clinical samples were collected by a 
gynaecologist, once ethical permIsSIOn had been granted (The Research Ethics 
Committee of St Thomas' Hospital). 
Table 2.1 Characteristics of study subjects 
Total Normal Cervical L-SIL H-SIL Cervical 
Cytology Disease Cancer 
75 20175 55175 15175 33175 7175 
Mean age 30 35 28 28 28.5 61 
(years) 
Age range 18-83 18-79 19-83 19-53 20-45 24-83 
(years) 
Patients were not selected on an age-matched basis but the age range of asymptomatic 
women and patients with cervical disease was not significantly different. When patients 
were divided into grade of disease, cervical cancer patients were significantly older 
compared to asymptomatic women (ut: p=O.03) but not when compared to patients with 
H-SIL or L-SIL (both p>O.05). Indeed, cellular changes associated with HPV infection 
are thought to occur more frequently in younger women (Kainz et at., 1995). 
2.2.2 Sample collection 
Cervical brush smears were collected with Axibrushes™ (Colgate Medical Ltd.), into 5 
ml of sterile phosphate buffered saline (PBS), consisting of 154 mM sodium chloride; 
8.1 mM mono-potassium phosphate; 1.9 mM disodium hydrogen orthophosphate, pH 7; 
84 
E, 

Chapter Two 
(BDH Ltd., U.K.) in sterile universal containers (Sterilin Ltd., U.K.). Four ml were 
stored in 1 ml aliquots at -70°C in cryovials for DNA PCR (Costar Coming Ltd., u.K.). 
The fifth aliquot was centrifuged at room temperature and the cell pellet re-suspended in 
400 III ofRNAzol B (Biotex Inc.). This was also stored at -70°C until required for RT­
PCR. Four ml of peripheral blood were collected into tubes containing no added 
anticoagulant from which serum was prepared by centrifugation at 500 g for 10 min at 
room temperature and stored at -20°C (see section 3.1.1). Sixteen mi of peripheral blood 
were taken into tubes containing 0.02 g ethylene diamine tetra-acetic acid; disodium salt 
(EDTA; BDH) and PBMCs were isolated by layering whole blood onto 24 mi of Ficoll-
Paque™ (Pharmacia Biotech u.K.) and centrifugation at 300 g for 15 min at 4°C. Cells 
at the interface were harvested, washed three times by re-suspension in, then 
centrifugation through, Roswell Park Memorial Institute medium-1640 (RPMI 1640; 
Sigma-Aldrich Company Ltd., U.K.). RPMI-1640 was supplemented with 10% (volume 
for volume; v/v) foetal bovine serum (FBS; Gibco Ltd., U.K.) 2 mM I-glutamine 
(Sigma), 100,000 units/L benzylpenicillin and 0.1 giL streptomycin sUlphate (Sigma). 
Cells were re-suspended in 10% (v/v) dimethyl sulphoxide (Sigma) in FBS on ice, 
divided into three aliquots and frozen at -loC/min to -70°C in 1.8 ml cryotubes (Costar) 
using a freezing chamber (Nalgene) and transferred to liquid nitrogen. All reagents used 
in this thesis were of Analar grade unless otherwise stated. 
2.2.3 Polymerase chain reaction assays 
When required, a 1 ml aliquot of frozen cervical cells was thawed and transferred into 
microcentrifuge tubes (Sterilin). Samples were vortexed for 10 s to re-suspend cellular 
material and then centrifuged at 10,000 g for 10 min at room temperature to pellet 
cellular material. Erythrocytes, if present (assessed by visual inspection), were lysed by 
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washing cell pellets in 1 ml Tris-EDTA buffer (10 mM Tris-hydrochloride; 1 mM 
EDT A; BDH). Cell pellets were re-suspended in 200 III of Proteinase K reaction buffer 
consisting of 50 mM potassium chloride, 2.5 mM magnesium chloride, 10 mM Tris­
hydrochloride pH 8.3, 0.45% (v/v) NP40™, 0.045% (v/v) Tween 20™ (Sigma) and 0.06 
giL (15 units/mg) Proteinase K; (Boehringer Mannheim u.K.). They were then 
incubated overnight at 55°C followed by an incubation at 95°C for 10 min to inactivate 
the proteinase K. Samples were not subjected to a phenol/chloroform DNA extraction as 
there is a variable loss of target DNA in these samples which can result in false negative 
results (Mant et al., 1997). 
To reduce the non-specific amplification of irrelevant DNA species all PCRs were 
performed using a 'hot start' method, in which the sample is separated from the 
oligonucleotide primers by a wax plug (D'Aqui1a et al., 1991; Chou et al., 1992). In a 
clean 'amplicon free' laboratory, PCR reaction mixtures were prepared as two 'master 
mixes', an upper and a lower phase (Table 2.2). The lower solution was mixed in a 0.6 
ml volume microcentrifuge tube, two wax pellets (Fibrowax: BDH) were placed above 
the mix and heated to 70°C for 2 min allowing the wax to melt and seal in the lower mix. 
The wax was allowed to solidify at room temperature for 2 min after which the upper 
phase was added. 
Tubes were taken to a sample preparation laboratory where 10 /-Ll of sample were added 
to the upper phase and then to a third laboratory where they were placed in a thermal 
cycler utilising a thermocouple to monitor the internal tube temperature (Hybaid 
Thermal Reactor; Hybaid Ltd, UK). Samples were then subjected to the appropriate 
cycles of denaturation, primer annealing and elongation programmed (Table 2.3). To 
control for quality of the samples with respect to non-specific inhibitors of PCR and the 
quantity of DNA obtained, clinical samples were tested for human genomic B-globin 
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DNA in a PCR using primers PC04 and GH20 (Table 2.4). 
Only those samples positive for ~-globin DNA were considered suitable for HPV-16 
DNA PCR analyses. Samples were screened for HPV -16 DNA using primers for HPV­
16 E6 and HPV-16 E5 DNA (see Table 2.4). 
Controls were included for every 10 samples tested; the positive control was the HPV-16 
genome contained within the Patl6 plasmid (Jewers et al., 1992) and the negative 
control contained DNA extracted from the control HPV negative A431 cell line 
(European collection of cell cultures, ECACC.). 
After amplification, 18 III of PCR product were mixed with 2 /-ll of DNA loading buffer 
consisting of 30% Ficoll (weight for volume; w/v); 250 mM EDTA (Sigma) and 0.4% 
Orange-G (w/v; BDH). Samples were visualised after separation by electrophoresis 
through a 2% agarose gel. The gel was prepared by heating agarose (Sigma) in 
Trislborate/EDT A buffer (TBE), consisting of, 0.9 M Tris-hydrochloride, 0.9 M boric 
acid (BDH) and 0.002 M EDT A to 97°C for 2 min. This was allowed to cool to 50°C 
and 0.05 giL of ethidium bromide (Sigma) were added per 100 ml agarose gel which was 
permitted to solidify in a flat bed electrophoresis tank (Hybaid). Samples were loaded 
into wells of an agarose gel and an electrical field of 75 volts, 45 mil1i amps was applied 
for 45 min at room temperature. A 1,000 bp molecular weight ladder (Life Technologies 
Ltd., UK) was separated in parallel with amplified DNA. After electrophoresis, gels 
were trans illuminated with ultraviolet light and photographed using the Appligene 
Imager System (Figure 2.2 a,b). Subjects were considered positive for HPV -16 DNA if 
positive for either E6 or E5 DNA in PCRs as determined by bands of the required length. 
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Table 2.2 Volumes for single PCR reaction mixes 
Reaction Volumes 
Reagents HPV-16E5 Nested HPV-16 E5 Final 
HPV-16E6 ~-Globin Concentration 
Lower Qhase 35 b!,1 
10 x PCRBuffer 5 111 5 111 	 25 mM KC1; 5 mM 
Tris-HC1, pH 9; 
0.05% Triton X-IOO 
(Promega) 
MgC12 10 ~l 10 111 	 2.5mM 
DNTPs 8 111 8 ~ll 	 0.8 mM (0.2 mM 
each) 
Primer U 1 ~ll 1 111 	 0.5 11M 
Primer D 1 ~ll 1 f-ll 	 0.5 11M 
H2O 10 ~l 10 III 	 --
UQQer Qhase 65 b!1 
10 x PCR Buffer 5 ~ll 5 III 	 25 roM KCl; 5 roM 
Tris-HCI, pH 9; 
0.05% Triton X-IOO 
(Promega) 
T.aq 0.5 fll 0.5 fll 	 25 units/rnl 
MH20 49.5 fll 55.5 fll 	 -­
DNA Template 10 ~l 4 fll 	 -­
Volumes in microlitres are quantltIes necessary for one lOO1l1 peR reaction when 
preparing 'master mixes' figures are multiplied by n x 1.1 (where n = the number of 
reactions to be performed) to allow for wetting of plastics. T.aq., Thermus aquaticus 
DNA polymerase; dNTPs., precursor deoxynuc1eoside triphosphates; U., upstream 
primer; D., downstream primer. KCI potassium chloride, HCl hydrochloride, H20 
molecular biology grade distilled water, MgCh magnesium chloride. 
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Table 2.3 peR cycling conditions 
Number of [3-Globill HPV-16 E5 HPV-16 E6 
Cycles 
1 94°e 5 min 94°e 5 min 94°e 5 min 
95°e 30 s 94°e 15 s 94°e 1 min 
40 53°e 30 s 55°e 15 s 55°e 1 min 
noe 1 min noe 5 min noe 1 min 
1 noe 5 min noe 5 min noe 10 min 
These cycling conditions were optimised for the Hybaid thermocycler and designed for 
high sensitivity. The thennocycler was programmed to bring the heating block up to 
temperature within 1 second. 
Table 2.4 Oligonucleotide primers 
Protein/primer name Oligonucleotide Sequence position Size Ref 
(bp) 
~-globin 
Gil 20 5'GAA GAG CCA AGG ACA GGT AC3' 286 I 
PC 04 j'CAA CTT CAT CCA CGT TCA CC" 
Human Keratin 
HK-l s'GAG GCA GCG GCC TOC TGA G3' 220 II 
HK-2 s'GGC CAG ACG GGC ATT GTC AA3' 
HPV-16 E6 
C-16-E6-D sTTG GAT CCG AGA ACT GCA ATG TTT CAG GAC3' 94-113 482 III 
C-J6-E6-U 5'ACA GAT CT A TT A CAG CTG GGT TTC CTA cm' 562-543 
HPV-16 E5 
C-J6-E5-U s'ATT TAG ATC TAT ATG ACA AATCTT GAT ACT GC3' 3837-3868 482 III 
C-16-E5-D 5'TAC AGG A TC CTT ATG TAA TT A AAA AGC GTG CAT" 4110-4078 
HPV-16 E5 RT-PCR 
PI s'TTT TTT TTT TTT TTT TTT TTT TTT TT A AGT3' 4214227-4330 III, 
P2 s'ATT TAG ATC TAT ATG ACA AAT CTT GAT ACT GC3' .. 3837-3868 IV 
4078-4110 &VP3 s'TAC AGC ATC CTT ATG TAA TTA AAA AGC GTG CAT3'. 202 
P4 5'GTO CTT TTG TGT GTC TOC CT A TTA A TA C3' 3910-3936 
bp: base pairs; HPV: human papillomavirus; A: adenine; T: thymine; G: guanine; C: cytosine; 
position relates to the nucleotide position on the HPV-16 reference isolate. Ref: Reference (I) 
Saiki et aI" 1986; (II) Bosma et al., 1995; (III) Cavuslu et al., 1996; (IV) Biswas et al., 1997; 
(V) *Schwartz et aI, 1985. All primers were made by Oswel DNA services Ltd., U.K. 
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2.2.4 Reverse-transcription polymerase chain reaction assays 
The aliquot of pelleted cervical cells stored in RNAzol B was thawed and washed once 
with 70% (v/v) aqueous ethanol (Sigma), air dried and re-suspended in 50 ~l of Tris 
EDTA buffer (2.2.3) in a microcentrifuge tube. 
Samples were incubated overnight at 37°C with 5 U of DNase I (Amersham Life 
Sciences Ltd., U.K.) in 10 ~l of 100 mM magnesium chloride containing 10 mM 
dithiothreitol (Sigma) and 3.3 U of the RNase inhibitor guanidium thiocyanate 
(InhibitAce; 5' ~3 ' Inc). An equal volume of phenol-chloroform-isoamyl alcohol 
(25:24: 1, vlv, Sigma) was added to the RNA pellet, vortexed for 30 seconds then 
centrifuged for 5 min at 13,000 g (Sambrook et at., 1989). The upper phase (100 ~l) was 
transferred to a fresh microcentrifuge tube and an equal volume of ethanol was added to 
precipitate the RNA. 75 ~g of linear polyacrylamide (Life Technologies) was also 
added to the sample as a carrier to facilitate visualisation of the precipitated RNA 
(Gaillard & Strauss, 1990). 
RNA pellets were re-suspended in 20 ~l of RNase free molecular biology grade distilled 
water (H20). One negative control containing H20 was processed along side every 5 
samples. Reverse transcription was primed by 2.5 micro molar (~M) of a 25-30 dT 
oligonucleotide (dT; Pharmacia) with Moloney murine leukaemia virus reverse 
transcriptase (Life Technologies). The final volume of 20 ~l contained 200 U of reverse 
transcriptase, 0.7 U of Inhibit Ace, 1 mM of each deoxynucleoside triphosphate, 5 ~l of 5 
times (x) first-strand buffer (Life Technologies) and 3 ~l of RNA sample. Assays were 
perfom1ed with and without reverse transcriptase to confirm that mRNA and not 
contaminating DNA was detected. Samples were incubated at 37°C for 90 min and then 
at 99°C for 5 min to inactivate the reverse transcriptase. Primers PI and P2 (Table 2.4) 
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were used in first round hot start PCR to produce a 421 bp amplicon (Figure 2.2 c). The 
100 1-11 PCR mixture included the 20 1-11 reverse transcription mixture, 2.5 U of 
Thermophilus aquaticus (T.aq) DNA polymerase (Promega Corporation U.K.) in a final 
concentration of 4 mM magnesium chloride, 0.5 I-1M PI and 0.5 I-1M P2. 
Samples were placed on a thermocycler (Hybaid) and incubated at 94°e for 5 min (1 
cycle) followed by an incubation at 94°e for 5 min 49°e for 15 s, 72°e for 10 s (25 
cycles) and a final incubation of 72°C for 5 min. 
Reactions that produced amplicons of 421 bp after electrophoresis through a 2% agarose 
gel (Figure 2.2 c) were subjected to a further nested PCR employing primers P3 and P4 
(Table 2.4; Biswas et aI., 1997) to produce amplicons of 202 base pairs. The nested 
PCR mix included 10 1-11 of the first round PCR product, 2.5 mM magnesium chloride 
0.5 I-1M of P3, 0.5 ~lM of P4 and 2.5 U of Taq. The PCR mixes were placed on a 
thermocyc1er and incubated 94°C for 5 min (1 cycle), 94°e for 15 s, 500 e for 15 s, 72°C 
for 10 s (25 cycles) followed by a final incubation of72°e for 5 min. A nested RT-PCR 
for human keratin mRNA (Table 2.4; Bosma et ai., 1995) was performed in parallel to 
EmRNA on all samples to ensure that clinical samples were suitable for amplification by 
RT-PCR. 
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a 
b 
c 
Figure 2.2 Photographs representative of PCR products after electrophoresis 
through a 2% agarose gel stained with ethidium bromide 
a. HPV-16 E5, b. HPV-16 E6 c. HPV-16 E5 RT-PCR using P3 and P4 primer pairs 
MW refers to molecular weight marker, pos positive control, neg negative control, + 
addition of reverse transcriptase, - absence of reverse transcriptase. Arrow indicates a 
positive band at a 273 bp, b 482 bp, c 202 bp. 
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2.2.5 Synthetic peptides 
Solid phase peptide synthesis (SPPS) is based on the sequential addition of alpha 
(a) amino and side chain protected amino acid residues to an insoluble polymeric resin 
support (Houghton et ai., 1985). After removal of the protective group, the next 
protected amino acid derivative is added. The resulting peptide is attached to the resin, 
via a linker, through its C-terminus and may be cleaved to yield a peptide amide. Side 
chain protecting groups are designed to be cleaved simultaneously with detachment of 
the peptide from the resin. 
Synthetic peptides were synthesised from the carboxylic terminus stepwise toward the 
amino tenninus and relied upon the base labile Fmoc (9-Fluorenylmethyloxycarbonyl) ­
group for N-a-protection amino acids. Cleavage of this protecting group was achieved 
by piperidine (Sigma) and final cleavage of the peptide resin and side chain deprotection 
by the strong acid trifluoroacetic acid (TF A, Sigma). N,N-dimethylformamide (DMF; 
BDH) was the primary diluent/solvent used for resin deprotection, coupling and 
washing. Peptide synthesis was carried out in a continuous flow manner, where the inert 
4-(a-Fmoc-amino-2',4'-dimethoxybenzyl) phenoxyacetic acid resm (UltraSyn-C; 
Novabiochem, u.K.) was contained in a column through which reagents and solvents 
were pumped continuously under semi-automatic control (Biocycle; Pharmacia, U.K.). 
The UltraSyn-C resin has an acid labile 'handle' specifically designed for the synthesis 
of peptide amides by the Fmoc polyamide method. The use of this synthesis system 
allows easy removal of excess reactants and by-products with continuous solvent flow 
through the column. All reactions were performed in a fume cabinet. 
For each peptide, 0.25 g resin was pre-swollen in DMF in a glass beaker and after 
removal of fine factory dust, were transferred to the peptide synthesis reaction column. 
The column was placed in the Biocycle and resin washed with DMF for 5 min. After 
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washing, resin was deprotected with 20% (v/v) piperidine in DMF (Millipore, U.K.) for 
10 min. Resin was washed again with DMF for 5 min, to remove excess piperidine. 0.5 
mM of the relevant amino acid Pfp ester (Novabiochem) and 0.5 mM (0.067 g) 1­
hydroxybenzotriazole (HOBt; Sigma) were then dissolved in DMF and loaded onto the 
column. HOBt is included in the amino acid addition to prevent racemisation and 
dehydration of amino acids, as well as acting as a catalyst (Konig & Geiger, 1970). This 
mixture was allowed to re-circulate through the column for 45-60 min. The system was 
then flushed out with DMF for 5 min. Subsequent amino acids were added to the 
peptide chain in a series of cycles of deprotection, amino acid addition and DMF 
washing. 
When the peptide of required length was constructed the ammo (N)-terminal Fmoc 
group was removed with 20% (v/v) piperidine in DMF, prior to cleavage from the resin. 
Resin was placed in a glass universal and washed with DMF, acetic acid and then DMF 
again before being allowed to dry overnight. The cleavage cocktail consisting of, 94% 
(v/v) TFA, 5% (v/v) phenol and 1 % (v/v) ethandithiol (BDH) was added to dried resin 
(Atherton & Shepherd, 1989; Fields & Nobel, 1990). Cleavage was performed at room 
temperature for at least 6 hours (h), with occasional swirling. Cleavage cocktail 
containing the cleaved peptide product was decanted off into a clean glass universal. 
Resin was washed twice with clean TFA and all washings were combined with the 
cleaved product. Peptide was precipitated by the addition of 8-10 volumes of cold 
diethyl ether (BDH). Washing by evaporation of ether with a nitrogen stream was 
performed and five ether washes carried out. After the final ether wash peptide was 
dissolved in 10% (v/v) aqueous acetic acid and then lyophilised using a Herto Freeze 
dryer (DK-345, Prior Labs.). 
94 
I 
1 
Chapter Two 
2.2.6 Short term peripheral blood mononuclear cell lines 
One aliquot of frozen PBMCs was thawed, the viability assessed using trypan blue dye 
exclusion (see Appendix 1) and the cell number adjusted to 1 x 105 viable PBMCs/ml in 
stimulation media consisting of, RPMI 1640, 10%FBS (v/v), 2 x 104 units recombinant 
human IL-2 (Sigma), 4 x 103 units recombinant human IL-4 (Sigma) and an equimolar 2 
mM (final concentration) mix ofE5 HPV-16 9-mer peptides (Figure 2.3). 
Whole length HPV-16 E5 
I MTl\LDTASTTCCACFLLCFCVLLCVCLLIRPLLLS VSTYTSU ILVLLLWITAASAFRCFIVYIIFVYIPLFLIHTHATNQ Iy83 
9-mer peptides 
IMTNLDTAS' JORPLLLSVSTJ8 45LVLLLWITA5) 
4DrSLlILVLL48 
Figure 2.3 Synthetic HPV-16 E5 peptides. 9-mer peptides were designed with a 4 
amino acid overlap to ensure that epitopes would not be lost due to the design of 
peptides. Amino acid positions are shown in superscript. 
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To each well of a 96 flat bottom well microtitre plate (Coming) 200 J.ll of PBMCs were 
dispensed and incubated at 37°C in a tissue culture incubator providing a humidified 
atmosphere containing 5% (v/v) carbon dioxide (C02) in air. After 72 h (day 3) the 
medium was changed and cells were incubated for a further 96 h (day 4) after which they 
were washed and re-suspended in fresh stimulation media. 
A second aliquot of PBMCs was thawed and treated with 1 giL mitomycin-C for 3 h at 
37°C, washed twice in Dulbeccos Phoshate Buffered Saline (DPBS; Sigma) and re­
suspended in RPMI 1640 media supplemented with 10% FBS. These cells were 
adjusted to 2 x 104 in a volume of 50 fl.l and added to each conesponding well as 
autologous antigen presenting cells. This method was first assessed in laboratory donors 
(see Appendix 4). 
2.2.6.1 Proliferative responses ofperiphera I blood mononuclear cells to Human 
papillomavirus -16 £5 peptides 
On day 14, cells were washed three times in DPBS (as above) and adjusted to 1 x 105 
viable PBMCs/ml. Fifty J.ll volumes were dispensed into 18 to 21 wells of a 96-well flat­
bottomed tissue culture plate (Coming). To three wells, 0.012 giL (final concentration) 
concanavalin A (Sigma) were added, to ensure that cells were viable and capable of 
proliferation. Another three wells contained just RPMI 1640/FBS and the remaining 
wells contained 2 mM pooled 9-mer peptides (final concentration). 
Forty-eight hours later (day 16), 50 fl.l of a solution containing 2 giL of the tetrazolium 
salt 3-[ 4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma; 
Denizot & Lang, 1986) in RPMI 1640IFBS were added to each well for 4 h at 37°C (1 
giL final concentration). Plates were centrifuged at 400 g for 5 min at room temperature, 
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the supernatant removed by aspiration and 100 )lllwell of dimethyl sulphoxide were 
added aseptically to solubilise the purple precipitate from mitochondria. Colour 
development (absorbance at a wavelength of 570 run; AS70) was assessed after a 10 min 
incubation at room temperature using a Labsystems Multiscan MCC 349 plate reader 
(see Appendix 2). 
Results were expressed as stimulation indices (SI) representing the absorbance at AS70 of 
cells stimulated by peptides divided by the AS70 of cells which were not stimulated with 
HPV -16 E5 peptides. Subjects were considered to have positive responses if at least five 
wells had SI values in excess of 1.5 and at least one greater than 2.499: data are 
expressed as the mean of all wells greater than 2.499. Those cultures with SI values 
below 1.5 were considered negative. 
2.2.6.2 Detection ofinterferon gamma in culture supernatants 
The production of INF-y; TNF-a and 1L-2 is characteristic of Thl cells (Mosmann & 
Sad, 1997) which may play an important role in the regression of genital warts and SIL 
(Coleman et ai., 1994; see 1.5.3). However, as 1L-2 and -4 were exogenous constituents 
of media supplements, the alternative experimental test was to determine INF-y 
concentrations in available culture supernatants of peptide stimulated PBMCs. 
Flat-bottomed 96 well plates (Coming) were coated overnight at 4°C with either 25 ~d of 
human INF-y diluted in carbonate bicarbonate buffer (13 ml 0.2M anhydrous sodium 
bicarbonate; 37 ml 0.2 M sodium hydrogen carbonate, pH 9.8; Sigma) at 8 
concentrations: 10-4, 10-3, 10-2, 10-1 1,101 102 and 103 )lglL, or with 50 ~d of supernatant 
from proliferative cultures diluted 1110 (v/v) in carbonate bicarbonate buffer. Plates 
were then washed three times with 400 fll of 0.01 % Tween™ (Sigma) in PBS (PBST) 
97 
Chapter Two 
and wells blocked for 20 min at room temperature with 400 J.lI of 1 % bovine serum 
albumin (BSA; w/v) in PBST. Plates were washed three times with 400 J.lI ofPBST then 
50 ~LI of a 1 :200 (v/v) dilution of a rabbit anti human INF-y IgG antibody (Genzyrne 
Diagnostics) in PBS were added to each well and incubated for 2 h at room temperature. 
Plates were washed three times with 400 J.lI PBST and 50 J.ll of a 1 :250 (v/v) dilution of 
secondary goat anti rabbit IgG antibody conjugated to horse radish peroxidase (HRP; 
Sigma) in PBST were added to each well and incubated at room temperature for 2 h. 
The plate was washed three times with 400 J.lI PBST and 100 J.ll of orthophenylene 
diamine (OPD) substrate (Sigma Fast™; Sigma) were added to each well and colour was 
allowed to develop for 30 min, after which ~90 values were determined on a plate reader 
(Labsytems). 
2.2.7 Statistical tests. 
Paired and unpaired, students' t-test (pt; ut), Fishers' exact (Fet) and the Mantel­
Haenszel/ (M-H}) tests were used to assist the interpretation of data. 
2.3 RESULTS 
2.3.1 Detection of Human papillomavirus-16 nucleic acid 
Two of the 75 samples, both SIL, were negative for p-globin DNA and hence excluded 
from HPV-16 DNA analyses. HPV-16 DNA was detected in cervical brush samples in 
55 of the remaining 73 samples, 40 of 53 (75.5.4%) patients with cervical disease and in 
15 of 20 (75%) asymptomatic women (Fet p>0.05). Of 21 HPV-16 E5 DNA positive 
samples, 19 were adequate for mRNA analyses (one asymptomatic and one L-SIL 
sample did not produce amplicons after RT-PCR for keratin, Table 2.5). 
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HPV-16 EmRNA was not detected in samples from asymptomatic patients (0 of 19: 0%) 
but was detected in 14 of 52 (26.9%) patients with cervical disease (Fet p=0.073; Table 
2.5). The prevalence of HPV-16 EmRNA increased in parallel with non-malignant 
disease, 0 of 19 (0%) asymptomatic, 3 of 15 (20%) patients with L-SIL, 10 of 31 (32%) 
with H-SIL and 1 of7 (14%) cancer patients were positive (M-H X2 test p<0.0007; Table 
2.5). 
Table 2.5 Detection of human papillomavirus-16 nucleic acid 
Total Normal Cervical L-SIL H-SIL Cervical 
Cytology Disease Cancer 
75 20 55 15 33 7 
HPV DNA 550f73 150f20 40 of 53 13 of 15 230f31 40f7 

status 
 (75%) (75%) (75%) (87%) (74%) (57%) 
EmRNA 140f71 oof 19 14 of 52 3 of 14 100f31 10f7 
(20%) (27%) (21°/c» (32[)Io ) (14%) 
The HPV status is expressed as percentages of all positive samples, percentage of E6 or 
E5 positive samples and those with active infections characterised by EmRNA. 'Normal 
cytology' refers to asymptomatic women. 
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2.3.2 Peripheral blood mononuclear cell proliferation in response to 
stimulation by human papillomavirus type-16 E5 synthetic peptides 
Proliferative PBMC responses to pooled HPV-16 E5 peptides were found for 16 of the 
75 (21%) samples (Table 2.6). Overall, there were no differences between the 
frequencies of proliferation for women with normal cytology (4 of 20: 20%) or those 
with cervical disease (12 of 55, 22%: Fet: p>0.05). PBMC proliferation was most 
common in women with L-SIL (6 of 15,40%) and lower in H-SIL (5 of 33, 15%) or 
cancer (1 of 7, 14%): this trend was significant (M-H X2 test, p=0.027: Table 2.6). 
Proliferative PBMC responses were more common in HPV-16 DNA positive subjects 
(15 of 56,27% compared to 1 of 17, 6%, HPV-16 negative subjects, Fet p>0.05; Table 
2.6). 
However, proliferative responses in women with normal cytology were statistically 
independent ofHPV-16 DNA status (3 of 15,20%, HPV-16 DNA positive women and 1 
of 5, 20%, in the HPV-16 DNA negative group: Fet p>0.05). For those with cervical 
lesions proliferative responses were restricted to HPV-16 DNA positive women (12 of 
41: 29%, cj negative [0 of 12J: Fet p=0.04S). 
The frequency of PBMC proliferation for HPV-16 DNA positive women with cervical 
lesions was highest in L-SIL (6 of 14, 43%), lower in H-SIL (5 of 23, 22%) and cancer 
(1 of 4,25%, M-H X2 test, p>0.05). 
Five of 16 (31 %) patients who exhibited PBMC proliferation were ErnRNA positive and 
nine of 55 (16%) non-responders were EmRNA positive (Fet: p>O.05). There were no 
significant associations between PBMC responsiveness and EmRNA status in any of the 
subject groups (Fet & M-H X2 tests, all p>O.05: Table 2.6). All PBMCs tested responded 
to stimulation with concanavalin A. Equivalent analyses of responses to Concanavalin 
A failed to produce any differences (all p>O.05, Figure 2.4). 
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Table 2.6 Proliferative PBMC responses amongst subjects with/or without cervical 
lesions and with differing HPV-16 nucleic acid status. 
HPV-16 Status 
HPV-16 HPV-16 HPV-16 E5 HPV-16E5 
Total DNA- DNA+ EmRNA- EmRNA+ 
Normal 4/20 115 3115 4/19 0/0 

Cytology (20%) (20%) (20%) (21%) (0%) 

Cervical 12/55 0112 12/41 12/38 5/14 

Disease (22%) (0%) (29%) (32%) (35%) 

Total 16175 1117 15/56 16/57 5/14 

(21%) (6%) (27%) (28%) (35%) 

L-SIL 6115 011 6/14 5/11 1/3 

(40%) (0%) (43%) (45%) (33%) 

H-SIL 5/33 0/8 5/23 5/21 3/10 

(15%) (0%) (22%) (24%) (30%) 

Cervical 117 0/3 114 0/6 1/1 

Cancer (14%) (0%) (25%) (0%) (100%) 

Data recorded as the number of PBMC responding over the total tested and in parentheses 
the percentage positivity in each group. L-SIL: low grade squamous intra-epithelial 
lesion; H-SIL: high grade squamous intra-epithelial lesion; HPV-16: subject positive 
(+) or negative (-) for HPV-16 DNA peR; EmRNA: no of samples with proliferative T­
cell response amongst those positive or negative for HPV-16 EmRNA. For 32 samples 
there were sufficient cells to assess reproducibility in duplicate, which was invariably high 
(e.g. subject 750, r2= 0.82). 
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Figure 2.4 PBMC responses to concanavalin A. Patient PBMCs responding to 
concanavalin A were expressed as stimulation indices (8I). The 81 between 
asymptomatic patients and those with varying degrees of cervical disease were not 
significantly different. The 81 of those patients negative for HPV -16 DNA were not 
significantly different when compared with 81 values from patients positive for HPV-16 
DNA (p>O.05). 
2.3.2.1 Detection ofinterferon gamma 
Cell-culture supernatants were available from 21 samples (8 from proliferative PBMC 
cultures). IFN-y was detected in 4 of 8 (44%) samples from proliferative culture 
supernatants and in 3 of 11 (27%; Fet p=O.34) non-responsive subjects (Figure 2.S; 
Table 2.7). There were no associations between concordant detection of ErnRNA and 
proliferative responses 4 of 22 (18.2%) patients were positive by RT-PCR: whereas 
ErnRNA was only found in 9 of the 53 (17%) patients who did not exhibit proliferation 
(Fet: p>O.OS). 
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Table 2.7 Characteristics of subjects with proliferative PBMC responses 
Patient Lesion HPV-16 HPV-16 IFN-y SI>2.499 Highest 

Number DNA EmRNA SI 

781 Cancer + + Nt 20f26 8.9 

681 H-SIL + + + 20f24 21.4 

724 H-SIL + + Nt 30f80 2.9 

628 H-SIL + + - 70f24 12.5 

790 H-SIL + - Nt 10f80 2.5 

799 H-SIL + - - 13 of 43 3.0 

749 L-SIL + + + 1 of 42 2.5 
812 L-SIL + 
-
- 10f20 2.8 
791 L-SIL + - Nt 10 of 52 4.5 
678 L-SIL + - - 120f24 15.3 
746 L-SIL + - Nt 80f24 25.7 
750 L-SIL + - + 18 of 18 10.5 
823 A + - Nt 10f30 2.8 
673 A + - + 70f24 3.0 
789 A + - Nt 1 of 80 2.5 
820 A - - Nt 1 of25 8.4 
Patient Number: patient identIficatIOn number; A: asymptomatic; L-SIL: low-grade 
squamous intraepithelial neoplasia; H-SIL: high-grade squamous intraepithelial 
neoplasia; HPV DNA: positive (+) or negative (-) by peR for E6 and/or E5 DNA; 
EmRNA: results of an RT-PCR for EmRNA. IFN-y enzyme-immunoassay: +: 
positive; - : not detected; nt: not tested; The number of cell lines with an SI greater 
than 2.499; Highest SI: highest SI value obtained in a single well. 
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Figure 2.5 Detection of interferon gamma in culture supernatants 
a IFN-y dose response curve, b IFN-y in culture supernatants, Culture supernatants 
have been divided into those with stimulation indices greater than 2.5 and those with 
stimulation indices less than 2.5. 
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2.4 DISCUSSION 
The initial hypothesis for this investigation suggested that women infected with HPV-16 
were more likely to exhibit HPV -16 specific CMI which, if protective should be inversely 
correlated with disease severity. The data obtained in this chapter indicate that 
proliferative PBMC responses were inversely correlated with disease severity but not with 
the presence of HPY -16 DNA. 
Testing for the presence of HPV-16 DNA by PCR revealed that 75% of the recruited 
women were positive, when primer pairs for both HPV-16 E6 and E5 ORFs were used. 
Due to the nature of the gynaecological clinics from which subjects were recruited, the 
majority of samples were expected to be positive for HPV-16 DNA. Similarly, previous 
studies performed on subj ects from the same regional health authority had reported HPV­
16 detection rates of 41-62% (Cavuslu et al., 1996; Biswas et al., 1997). However, both 
of these previous studies had included a larger number of asymptomatic women than the 
current study, and more importantly had failed to check for the presence of ORFs other 
than E5, thus explaining the lower HPV-16 DNA positivity. It is possible to miss HPV-16 
infections using primers for E5 alone, considering it may not be expressed in H-SIL or 
cervical cancer where integration of the viral genome has occurred. The E6 and E7 ORFs 
however, are not present in all early region mRNA transcripts but are expressed 
abundantly in H-SIL and cervical cancer (Sherman et al., 1992) and are therefore useful in 
detecting HPV infections in these lesions. 
It was not possible to include a matched control group never exposed to HPV-l6 due to 
reports of vertical transmission, HPV infection in virgins and to transient HPV infections 
where exposure to virus has occurred previously but where viral DNA is no longer 
detectable (see section 1.3.9). 
It was anticipated that CMI may be more common in subjects with transcriptional active 
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HPV-16 infections. Samples were therefore tested for EmRNA, the detection of which 
is indicative of transcriptionally-active infections. There was a significant trend for 
EmRNA positivity with increasing grade of cervical lesion (p<0.0007). This correlates 
with the findings of Biswas et al., (1997) who also reported that EmRNA prevalence 
increased with increasing severity of disease and was more frequently detected in 
samples from subjects with cervical disease than from samples from asymptomatic 
SUbjects. 
The EmRNA assay is also an indirect measure of a high viral load compared to the 
HPV-16 DNA PCRs (E5 & E6) due to its comparative insensitivity, as the assay can 
only detect greater than 1,000 EmRNA copies (Biswas et at., 1997). It is possible 
therefore that most subjects had low HPV-16 copy numbers, explaining the lack of 
association between EmRNA and proliferative PBMCs (p>0.05). 
Patients PBMCs cultured with T-Iymphocyte cytokines proliferated in response to HPV­
16 E5 peptides. Proliferative PBMCs were detected primarily in samples from 
asymptomatic women. Similarly, proliferative T -cells have been detected in 
asymptomatic patients when stimulated with HPV E6 and Ll peptides and are thought to 
represent viral clearance (Strang et at., 1990). This is in broad agreement with other 
studies which report between 18% to 47% of healthy subjects have T-Iymphocyte 
responses to HPV-16 11 and E7 proteins (Luxton et ai., 1996; Shepherd et al., 1996). 
This data suggests that subjects with competent immune systems are able to mount 
effective CMI responses. 
Although the proliferative PBMe responses in these asymptomatic subjects were 
independent of HPV-16 DNA status (both 20%: p>0.05), proliferative PBMCs in cervical 
disease were inversely correlated with severity of SIL (p= 0.03) and with the presence of 
HPV-16 DNA (p>0.05). This allows a comparison of data of Tsukui et al. (1996) who 
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reported an inverse correlation between in vitro CMI responses to HPV -16 E7 protein and 
severity of lesion. Similarly, proliferative T-Iymphocyte responses to HPV-16 E7 were 
reduced in cervical cancer in comparison to SIL and healthy controls suggesting an altered 
functional balance between subsets ofTh cells in HPV-16 infections (Luxton et ai., 1996). 
The same trend was seen for HPV-16 Ll protein where a decrease in Thl responses were 
seen in increasing grade of dysplastic lesion (Luxton et al., 1997). Furthermore, it has 
been suggested that women with SIL are unable to respond to stimulation with HPV 
antigens as well as those women without cervical lesions (Nakagawa et at., 1996). This 
implies that viral escape mechanisms may be used by HPVs to avoid recognition by the 
hosts' immune system. 
A Thl response was also determined after stimulation of PBMCs with E6 arid E7 proteins, 
where IL-2 production was greatest in cytologically normal women and declined with 
increasing severity of disease whilst responses to a recall influenza antigen were not 
significantly different between groups (Tsukui et ai., 1996). 
An investigation ofIFN-y production in culture supernatants based on the same principle 
was performed in this study. IFN-y was detected in supernatants from 4 of 8 patients with 
proliferative PBMC responses, suggesting a Thl response. Ideally, other Thl-associated 
cytokines including TNF-a. and cytokines associated with Th2 type responses should also 
have been measured if larger quantities of culture supernatants had been collected. This 
may have helped to determine the type ofIh response involved in HPV-16 E5 immunity. 
Other investigations have shown a slight decrease in the CD4+/CD8+ ratio in SIL and 
tumours especially when MHC-I arltigens were lost suggesting a role for Th cells (Tay et 
at., 1987; Hilders et al., 1993). Protection in other chronic viral diseases such as HIV has 
also been shown to be mediated by Thl responses (Hilleman, 1994; Clerici et al., 1994). 
It would also have been worthwhile to measure mRNA for IL-6 in the cervical brush 
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samples, as the production of IL-6 has heen shown to he related to severity of cervical 
disease (Tjiong et al., 1999). The detection of IL-6 mRNA may have indicated which 
subjects were likely to exhibit proliferative PBMC responses and would have supported 
the link between IL-6 and disease severity. 
It may be argued that these results reflect in vitro immunisation as PBMCs were cultured 
with E5 peptides, this is unlikely however, due to the inverse correlation between PBMC 
proliferation and disease status and the positive association between proliferation and 
HPV -16 DNA in lesions. It is currently thought that proliferative PBMCs could be the 
result of an effective immune response to HPV infections. 
In conclusion, these studies suggest that patients with moderate to high-grade cervical 
lesions may have impaired proliferative PBMC responses to HPV -16 E5 peptides. In light 
of the HPV -16 E5 specific proliferative PBMC responses, the presence of antibodies to 
HPV -16 E5 should also he investigated. As individual HPV -16 E5 variants may have 
different immunogenic potential, further work should be directed at investigating 
common variants in this population. 
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Chapter Three 
DNA Variation in the Human Papillomavirus Type-16 E5 Open 
Reading Frame and Detection of Reactive Serum Antibodies in Women 
with and without Cervical Disease 
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3.1 INTRODUCTION 
The reference HPV -16 E5 ORF contains over 45 predicted restriction endonuclease cut 
sites. Comparison of these cut sites with established HPV -16 E5 variants revealed that 
three endonuclease cut sites within HPV -16 E5 would be disrupted in each variant DNA 
sequence (Seedorf et al., 1985; Halbert & Galloway, 1988; Chan et al., 1992). For 
example, DNA variation occurring at nucleotide position 3978 would result in the loss of 
a Ssp-1 cut site (3977-3982), variation at positions 3871 and 3873 would interrupt the 
Xcm-1 site (3871-3885) and variation at nucleotide 4076 would disrupt the Nsp-l site 
(4076-4081). These endonuclease cut sites allow the identification of up-to 8 different 
HPV -16 E5 variants as well as the reference sequence (Table 3.1). 
Similarly, the HPV-16 E6 ORF may also be subject to DNA variation, for example, an 
amino acid change at position 131 (characterised by the introduction of a second MspJ 
cut site) has been correlated with severity of lesion or the effectiveness of an immune 
response (Stem et al., 1996). The introduction of an Nsi cut site at position 253 
correlates with a second HPV -16 E6 variant which rna y also have indications for 
prognosis (Table 3.1). 
The HPV-16 E5 and E6 amplicons from Chapter Two (see section 2.2.3) were 
investigated for DNA variation using restriction fragment length polymorphism (RFLP) 
analyses and DNA sequencing (Chan et al., 1992). This was performed in order to 
determine the predominant local variants and to detect differences in serum reactivity to 
them, which may be correlated with disease severity. 
As with investigations of CMI, most serological assays have focused on the HPV -16 E6 
and E7 proteins and far less is known about antibody responses to other early HPV 
proteins. Antibody responses to E7 and E6 are thought to develop as a consequence of 
prolonged exposure to tumour because they are strongly associated with cancer with no 
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elevation of seropositivity in patients with SIL (Jochmus-Kudielka et ai., 1989; Mann et 
al., 1990; Hamsikova et al., 1994; Mandelson et ai., 1992; Muller et ai., 1992; Dillner et 
ai., 1993). 
Table 3.1 Examples of restriction endonuclease cut sites on human papiUomavirus 
type-16 E5 and E6 DNA 
Restriction endonuclease cut sites 
HPV-16 E5 ORF HPV-16 E6 ORF 
Ssp! AAT-i-ATT Nsil ATGCA-I-T 
Position 3989 bp Position 257 bp 
XcmJ CCANNNNNWNNTGG MspJ d'CGG 
Position 3878 bp Position 130 bp 
NspJ (AlG)CATG,l.(T/C) 
Position 4080 bp 
bp=base pairs. For HPV -16 E5, peR amplicons are of 273 base pairs in length, when 
that cut site remains intact two bands are produced after digestion with each particular 
restriction endonuclease. 1. SspI fragments are 152 and 121 bp, 2. XcmI fragments are 
41 and 232 bp and 3. NspI fragments are 243 and 30 bp. 
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The need for a detailed investigation of HPV -16 E5 specific antibodies arises from the 
fact that only one previous study of this antigen has been reported. This previous study 
in humans reported weak IgG and IgA antibodies in HPV -16 positive patients with 
cervical neoplasia but, the same peptides were not tested on controls or asymtomatic 
women. The antigens used were 20-mer synthetic peptides corresponding to HPV -16 E5 
and these might have been too long and folded tightly on themselves due to the 
hydrophobic nature ofES (Figure 3.1). 
For this study shorter 9-mer peptides were used to investigate serum reactivity to HPV­
16 E5. Although still hydrophobic in nature, these peptides are more likely to be 
dispersed in solution than the peptides used by Dillner, (1992). To investigate serum 
reactivity to variant regions of HPV-16 E5, peptides of 13 amino acids were used, this 
length allowed the central (changed according to DNA variance) amino acid to be 
flanked by 6 non-variant amino acids (Figure 3.2). Subject's serum collected in section 
2.2.2 was used for this investigation. 
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-2 
-3 
Figure 3.1 Hopp and Woods hydrophobicity plot of HPV-16 E5 Each point 
represents the mean hydrophobicity of five amino acids overlapped by one amino acid. 
The hydrophobicity values of all peptides used in this thesis are detailed in Appendix 3. 
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Control peptides 
HPV-16 E2:13 
NKVWEVHAGGQVILCPTSUF 
HPV-16 E7:1 
HGDTPTLHEYMLDLQPETTD 
13-mer HPV-16 peptides with and without amino acid changes 
Reference Variants Resulting endonuclease cut site 
Rl 3NLDTASITCCACFl5 VI 3NLDTAS,rTCCACFI5 XernI 
R2 38TYTSLI1LVLLLw50 V2 38TYTSLI!LVLLL W50 SspI 
R3 59CFIVYIYFVYIPL71 V3 59CFIVYl!FVYIPel NspI 
Figure 3.2 Synthetic human papillomavirus type-16 E2, E7 and E5 peptides Whole 
length HPV -16 E5 and the 9-mer peptides used in this study are described in Figure 2.2. The 
amino acid change in the variant 13-mer E5 peptides is compared to the reference peptides 
and the amino acid position is underlined and highlighted in bold. Variant peptides are 
referred to as V1-3 and peptides identical to the reference sequence of HPV-16 E5 are 
referred to as R1-3. The E2 and E7 peptides were included to allow comparisons between 
population and EIA variation. Superscripted numbers refer to amino acid position. 
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3.2 METHODS 
3.2.1 Determination of human papillomavirus type-16 DNA variation in the E5 
and E6 open reading frames 
HPV 16 E6 and E5 PCR amplicons isolated from fourteen patients (see section 2.2.3) 
were analysed for DNA variance using RFLP. Individual variant sequences were 
confirmed by DNA sequencing. 
3.2.1.1 Restriction fragment length polymorphism analysis of human papilloma virus 
type-16 £5 and £6 open readingframes 
HPV -16 E5 positive peR products (Table 2.5) were sUbjected to overnight digestion at 
37°C with the Ssp!, Xcm! or Nsp! endonucleases (Table 3.l). Briefly, 0.5 ml 
microcentifuge tubes were labelled Ssp/, Xcm/ or Nsp/ and placed on ice. Three III of 
non-purified PCR product were placed in each tube to which 2 fll of lOx enzyme buffer 
were added, for tubes labelled Xcm! and Nsp!, 2~ll of BSA were also added. Molecular 
biology grade distilled water (H20) was added to each tube to obtain a final volume of 
19 Ill. Finally 1 III of each enzyme was added to appropriately labelled tubes mixed 
gently and placed in a waterbath set at 37°C and incubated overnight (Table 3.2). 
After incubation, 10 III of 'digested' PCR products were mixed with 2 III loading buffer 
and visualised after separation through a 2% agarose gel (see section 2.2.3; Figure 3.2). 
Similarly HPV-16 E6 amplicons were also subjected to overnight endonuclease 
digestion (Table 3.2). 
115 
Chapter Three 
Table 3.2 HPV-16 E5 and E6 enzyme digests 
HPV-16 E5 HPV-16 E6 
Enzyme Ssp-l Xcm-l Nsp-l Msp-l NSf 
DNA 3 3 3 5 5 
Buffer 2 2 2 2 2 
BSA* 2 2 
Enzyme 1 1 1 1 1 
dHzO 12 14 14 10 12 
Total 20 20 20 20 20 
volume (J..tl) 
Units are expressed as fJJ and volumes of reactions were adjusted to enable overnight 
digestion of DNA. Enzymes were obtained from New England Biolabs and were supplied 
with the appropriate buffers. One III of stock contained 10 units of enzyme. 
a b 
Figure 3.3 Agarose gel showing restriction fragment length polymorphism 
patterns of HPV-16 E5 and E6 after digestion. a. arrow indicates 273 bp band. E5 
lanes 1 & 5=uncut 2 & 6=SspI cut, 3 & 7=XcmI cut, 4 & 8=NspI cut. b.arrow indicates 
482 bp band. E6 lane 1 =uncut, 2=MspI cut, 3= NsI cut. 
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3.2.1.2 Ligation of human papillomavirus type-16 E5 and E6 peR products to the 
pGE~-T vector in preparation ofDNA sequencing 
HPV-16 E5 and E6 amplicons (from section 2.2.3) were ligated to the pGEM® -T 
plasmid vector (see Appendix 7) using the pGEM®-T TA cloning kit (Promega). The 
pGEM®-T plasmid was selected because it has overhanging thymidine at the 3' end 
which combines efficiently with the overhanging adenine at the 5' end of peR 
amplicons (Mezei & Storts, 1994; Robles & Doers, 1994). The pGEM®-T plasmid 
contains T7 RNA and SP6 RNA polymerase promoters flanking a multiple cloning 
region within the a-peptide coding region of the enzyme p-galactosidase allowing 
amplification of inserted DNA after cloning. Insertion of the a-peptide allows 
recombinant clones to be directly identified by colour allowing blue/white screening in 
the presence of the substrate for p-galactosidase. Reactions were prepared in sterile 0.5 
ml microcentrifuge tubes in which 1 fll of 10 x T4 DNA Ligase Buffer consisting of300 
mM Tris hydrochloride (pH 7.5), 10 mM magnesium chloride, 100 rnM dithiothreitol 
and 10 mM adenosine triphosphate was added to 1 fll ofpGEM®-T Vector (0.05 giL), 2 
fll of PCR product, 1 fll T 4 DNA Ligase (3 Weiss units/ fll) and 5 fll H20. (All reagents 
were supplied with the kit). Control tubes contained 2 fll of pGEM®-T Vector Control 
instead of the relevant HPV-16 PCR product. 
Reactions were incubated for 3 h at 15°C and then heated to 70°C for 10 min. The HPV­
16 E5/vector ligation reaction was cooled to room temperature and transformed into 
JMI09 (Escherichia coli, E.coU) cells (Promega). The JMI09 cells were chosen as they 
were already prepared for transformation using the procedure of Hanahan (1983) and 
contained the laclqZilM 15 mutation providing a-complementation of the p-galactosidasc 
gene. This allows blue/white colour selection of recombinant colonies supplemented 
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with 5-bromo-4-chloro 3-indoyl-~-D-galactopyranoside (X-Gal; Alexis Corp) and 
isopropyl ~-D-thiogalactopyranoside (IPTG; Alexis Corporation). The laclq repressor 
produces 10 fold more lac repressor than found in most host strains ensuring repression 
oftoxic fusion proteins (Lacks & Greenberg, 1977; Yanisch-Peron et at., 1985). 
JMI09 cells (1 x 108 colony fomling units per J...lg DNA) were gently thawed by placing 
on ice for 5 min, then a 50 J...lI aliquot was transferred to sterile 1.5 ml microcentlifuge 
tubes containing 2 J...ll of ligation products (from above) on ice. Cells and ligation 
mixture were gently mixed, left on ice for 20 min and heat shocked by placing on a 
heating block at 42°C for 40 sec and back on ice for 2 min. After 2 min, 1 ml of SOC 
media consisting of 0.2% (w/v) tryptone; 0.05% (w/v) yeast extract; 0.01 M sodium 
chloride; 0.0025 M potassium chloride; 0.02% (v/v) magnesium chloride; 0.02 M 
glucose; (Gibco) was added to each reaction tube and incubated at 37°C for 1 h. 
Agar plates were prepared containing 25 ml Lauria Bertoni (LB) agar (1 % (w/v) 
tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) sodium chloride; 1.5% (w/v) agar: Gibco) 
25 fll of 10% ampicillin (Sigma), 20 l-Ll of 12.5 mM X-Gal and 12.5 J...ll of 10mM IPTG. 
Plates were inoculated with 50 J...lI JM 1 09 cells and incubated ovemight at 37°C. Cells 
from single white recombinant colonies containing insert were checked for the correct 
insert by PCR using SP6 and T7 primers. PCR products of 421 bp were examined on a 
1 % (w/v) agarose gel after electrophoresis. Positive colonies were transferred into 3 ml 

LB medium consisting of 1 % (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) 

sodium chloride; (Gibco) and 0.1 % (w/v) ampicillin, then incubated in a shaking mixer 

(Denley) at 37°C for 5 h. 

DNA was extracted from the JMI09 cells and purified using the QIAprep kit (Qiagen). 

This is based on the modified alkaline lysis method (Bimboim & Doly, 1979) and the 

adsorption of DNA onto silica in the presence of a high salt concentration (Chen & 
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Thomas, 1980; Marko et at., 1982; Boom et al., 1990). JM109 cells were centrifuged at 
13,000 g for 5 min, the cell pellet was re-suspended in 250 f.ll of Buffer PI consisting of 
50 mM Tris-hydrochloride, pH 7.5,10 mM EDTA and 100 f.lg/ml RNase in H20 in a l.5 
ml microcentrifuge tube and inverted until no cell clumps were visible. To this, 250 j.ll 
of buffer P2 (cell lysis buffer) consisting of; 0.2 M sodium hydroxide and 1% (w/v) 
sodium dodecyl sulphate were added, and the tube was gently inverted to mix. To this 
350 f.ll of buffer N3 consisting of l.32 M aqueous potassium acetate, pH 4.8 were added 
and reactants were gently mixed by inversion followed by centrifugation at 13,000 g for 
10 min. 

Supernatants were applied to and centrifuged through QIAprep columns placed in 2 ml 

collection tubes (Qiagen). Eluates were discarded and columns were washed in 0.5 ml 
of buffer PB consisting of 4.5 M guanidine-hydrochloride in 40% (v/v) aqueous 
isopropanol. The columns were then placed in collection tubes and centrifuged at 13,000 
g for 1 min. This was followed by a wash in 0.75 ml buffer PE consisting of 112 rnM 
potassium acetate; 11.8 mM Tris-hydrochloride (pH 7.5), 0.6 mM EDT A and 55% (v/v) 
aqueous ethanol and centrifugation at 13,000 g for 1 min. The QIAprep columns were 
placed in 1.5 ml microcentrifuge tubes and 100 j.ll of H20 was dispensed onto the 
QIAprep membrane to elute bound DNA. Columns were allowed to stand for 1 min at 
room temperature and then centrifuged at 13,000 g for 1 min. The DNA pellet was 
collected and rinsed in 70% (v/v) aqueous ethanol. The final solution containing 
purified DNA was centrifuged at 13,000 g for 30 min and the DNA pellet re-suspended 
in 10 f.ll of H20. The A260 was determined using a spectrophotometer (LKB) and DNA 
concentration was calculated using the following formula: 1 AZ60 Unit=50 )lg DNA/ml 
(Freifelder, 1982). Samples were stored at -20°C until required. 
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3. 2.1. 3 Human papillomavirus type-16 E5 and E6 DNA Sequencing. 
Extracted DNA (above) was sequenced using the AutoRead™ Sequencing Kit 
(Pharmacia). DNA concentration was adjusted to 1 giL in H20 and 32 )ll aliquots were 
added to sterile microcentrifuge tubes containing 8 ~l of2 M aqueous sodium hydroxide. 
Tubes were vortexed gently and centrifuged briefly to collect solutions at the bottom of 
the tube then incubated at room temperature for 10 min after which 7 ~l aliquots of 3 M 
aqueous sodium acetate (pH 4.8), 4 ~l H20 and 120 ~l absolute ethanol were added. 
Tubes were gently vortexed and placed on dry ice for 15 min. Precipitated DNA was 
collected by centrifugation at 13,000 g for 15 min, carefully dried under vacuum for 10 
min and then re-suspended in 10 )ll of H20. To this 2 ~l fluorescent primer (5 pmol) and 
2 ~l annealing buffer (1 M Tris-hydrochloride, pH 7.6; 100 mM magnesium chloride) 
were added. Tubes were gently vortexed and centrifuged 13,000 g to collect contents. 
The annealing reaction was pre-heated to 65°C for 5 min and placed immediately at 
37°C and incubated for 10 min. Tubes were allowed to cool to room temperature for 10 
min after which 1 ~l extension buffer consisting of 304 mM citric acid, 324 mM 
dithiothreitol and 40 mM manganese chloride was added as well as 3 ~l of dimethyl 
sulphoxide. 
To the cooled tubes 2 )ll of diluted T7 DNA polymerase were added and mixed 
thoroughly, 4.5 ~l of the purified HPV -16 E5 or E6 DNA were placed into each of the 
sequencing mixes and incubated at 37°C for 5 min. Sequencing mixes were prepared 
while the annealing reactions were cooling, briefly, 2.5 ~l of A mix (5 ~M ddATP; 1 
mM dCTP; 1 mM dTTP; 1 mM dGTP, 50 mM sodium chloride; 40 mM Tris­
hydrochloride, pH 7.6) were dispensed to a fresh microcentrifuge tube labelled A and 
placed on ice immediately. This was repeated for tubes labelled e, G and T where C 
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mix contained ddCTP; G mix contained ddGTP and T mix contained ddTTP instead of 
ddATP. After incubation 5 ~l of stop solution (0.5% Dextran Blue 2000 in deionised 
fOlTIlamide) was added to each tube and mixed gently. The reactions were heated to 
90°C for 3 min and then quenched on ice. To each of four wells of a sequencing gel, 6 
J-Ll were loaded and electrophoresed. Data was analysed using a semi-automated 
sequencer (ALF; Perkin Elmer; Figure 3.3). Results obtained from the DNA sequencing 
were used to construct peptides for use in enzyme immunoassays. 
3.2.2 Enzyme immunoassay to detect varicella zoster antibodies 
A varicella zoster virus enzyme immunoassay (EIA) was include as a positive control for 
HPV-16 E5 ErA procedures. Due to the epidemiology of chicken pox, it was expected 
that most sera would have antibodies to this antigen. Flat bottomed 96 well plates 
(Corning) were coated overnight at room temperature with 50 ~lIwel1 of varicella zoster 
antigen (Boehringer Mannheim u.K.). Varicella zoster antigen was reconstituted and 
diluted in carbonate bicarbonate buffer consisting of l3 ml 0.2 M anhydrous sodium 
bicarbonate; 37 ml 0.2 M sodium hydrogen carbonate, pH 9.5 (Sigma) to give final 
dilutions of; 1:32,1:64,1:128,1:256,1:512,1:1024 and 1:2048. Plates were washed 
three times with PBS containing 0.01 % Tween20 (sigma, PBST) in an automatic plate 
washer (Dynex Ltd.) and non-specific sites were blocked for 30 min at room temperature 
with 400 ~l of PBS containing 1 % (w/v) BSA. Plates were washed as above and 50 
J-LlIwell of20 randomly selected patient's serum diluted 1:100 in PBST containing 0.1% 
(w/v) BSA were incubated in triplicate, overnight at room temperature in a humidified 
chamber. Plates were washed three times with PBST, after which 25 Ill/well of HRP­
labelled goat anti-human immunoglobulin (Sigma, specific for heavy chains) diluted to 
11250 in PBS were incubated in wells for 45 min at room temperature. Plates were 
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washed three times and 50 Ill/well of Sigmafast™ OPD substrate were added for 10 min 
at room temperature in the dark. Reactions were terminated by the addition of 25 J.LVwell 
of 1 M sulphuric acid (Sigma) and ~90 values were determined on a plate reader 
(Labsystems). All EIAs were performed in triplicate at various dilutions of sera to 
obtain optimal conditions. 
3.2.3 Synthetic peptides 
The antigens used in EIAs were synthetic peptides constructed by SPPS (see section 
2.2.5). Serological assays employed full length HPV-16 E5 and a series of 9-mers which 
when overlapped by 4 amino acids correspond to the sequence of the reference isolate 
(Figure 2.3). Two additional positive control peptides were also constructed, these were 
E2:17 and E7:1 (Figure 3.2; Dillner, 1992). Following the identification ofHPV-16 E5 
variants in the study population, three corresponding pairs of I3-mer peptides were also 
constructed. These 13-mers correspond to the central amino acid substitution in the 
variants flanked by 6 amino acids on each side and the control peptides contained the 
reference sequence (Figure 3.2). 
3.2.4 Coupling synthetic HPV-16 E5 to ovalbumin using carbodimide 
To control for the differential binding of peptides to EIA plates, peptides were 
conjugated to ovalbumin. In a volume of2 ml, synthetic HPV-16 E5 peptide was diluted 
0.01 giL in distilled water to which I-ethyl-3(3-dimethylaminopropyl) carbodimide 
hydrochloride (Sigma) was added to give a final concentration of 0.1 giL. The reaction 
was adjusted to pH 5.0 and incubated for 5 min at room temperature. A 2 ml volume of 
1 giL ovalbumin (Sigma) in water was added. This was incubated for a further 4 h at 
room temperature after which the reaction was stopped by the addition of sodium acetate 
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pH 4.2 (Sigma) at a final concentration of 100 mM (Doolittle 1986). 
3.2.5 Enzyme immunoassays to detect reactive antibodies to full length human 
papillomavirus type-16 E5 peptides 
Flat-bottomed 96-well plates were coated overnight at 4°C with 25 Ill/well of a solution 
containing either (i) 1 giL synthetic HPV-16 ES conjugated to 10 giL of ovalbumin, (ii) 
11 giL ovalbumin conjugated to itself or, (iii) 11 giL ovalbumin in carbonate-bicarbonate 
buffer. Plates were washed and blocked as above (section 3.2.2). After the final wash 
50 Ill/well of patient's serum diluted 1:2, 1:10, 1:100 and 1:1000 in PBST containing 
0.1 % (w/v) BSA were incubated in tIiplicate for each antigen, overnight at room 
temperature in a humidified chamber. 
The ovalbumin-ovalbumin conjugate was selected as a negative control for this EIA as 
any novel epitopes created by conjugation of ovalbumin were controlled for. Results 
were expressed as delta absorbance values (8~90) for each sample (i.e. the mean 
absorbance ~90 for the ovalbumin-ovalbumin conjugate subtracted from the mean A490 
for the peptide-ovalbumin conjugate. 
3.2.6 Enzyme immunoassays to detect reactive antibodies to human 
papillomavirus type-16 E5 9-mer peptides 
Using the procedure described above (3.2.2) EIA plates were coated overnight with 1 
giL of individual synthetic 9-mers conjugated to 10 giL ovalbumin. All patients sera 
were diluted 1:1 00 in PBST containing 0.1 % (w/v) BSA were incubated in triplicate, 
overnight at room temperature in a humidified chamber. Antibodies specific for HPV -16 
E5 9-mers were then detected as described above (3.2.2). 
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3.2.7 Statistical tests. 

Paired and unpaired, students' t-test (pt; ut), Fishers' exact (Fet) and the Mantel-

Haenszel } (M -H}) tests were used to assist the interpretation ofdata. 

3.3 RESULTS 

3.3.1 Variance of the HPV-16 E5 and E6 open reading frames 

Among the 14 patients tested for HPV-16 E5 DNA variance by RFLP, 2 (14%) were 
identical to the reference isolate, 8 of 14 (57%) were Ssp-l variants, 1 of 14 (7%) lost 
both Xcm-l and Nsp-l cut sites and one of 14 (7%) lost all three (Xcm-l, Nsp-l & Sspl) 
cut sites (Table 3.3). Of the 16 patients tested for variance by RFLP in the HPV-16 E6 
ORF all were identical to the reference isolate. 
Table 3.3 Detection HPV-16 E5 and E6 variants 
Disrupted Cut Site N umber of Positives 
HPV-16 E5 None 4 of 14 (28%) 
Ssp 1 8 of 14 (56%) 
Xcml+Nspl 1 ofl4 (7%) 
Xcml+Nspl+Sspl 1 ofl4 (7%) 
HPV-16 E6 None 16 of 16 (100%) 
Msp-l oof 16 (0%) 
Nsi oofl6 (0%) 
The above table shows the distribution of variance in the E5 & E6 ORFs in this study 
population. Ten samples were randomly selected and HPV-16 E5 DNA variance was 
confirmed using DNA sequencing (see section 3.3.2). 
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3.3.2 DNA sequencing 
When DNA sequencing traces (Figure 3.3) of individual samples were compared, the 
DNA sequence in one direction invariably matched the DNA sequence in the opposite 
direction. Sequencing traces confirmed the reference DNA sequence showing no nucleic 
acid substitutions and no deletions of stop codons within HPV -16 E5 reference isolates. 
They confirmed nucleic acid substitution in the variant isolates, for example, Sspl-A to 
C at position 3989; XcmJ!NspJ!SspJ A to a C at position 3878, G for a T at position 
4080 and A to C at position 3989; XcmllNspJ A to a C at position 3878 and G for a Tat 
position 4080. When translated, these changes resulted in amino acid changes at amino 
acid position: (SspJ) 44 L for a I; (XcmJ/NspJ/SspJ) 9 T for a P, 65 V for a I 44 L for a I 
and (XcmllNspl) 9 T for a P, 65 V for a 1. 
3.3.3 Serum responses to varicella zoster antigen 
All 20 sera tested reacted strongly with varicella zoster antigen in all dilutions tested. 
The highest absorbance values were obtained at an antigen concentration of 1 :32 (Figure 
3.4). 
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Figure 3.4 Serum reactivity to varicella zoster antigen Twenty randomly selected 
patients sera were tested to provide a positive control for EIA procedures. The assay 
was perfonned in parallel to the HPV -16 E5 whole length, E2 and E7 EIAs. Results are 
expressed as delta absorbance values 
3.3.4 Serum responses to full length HPV-16 E5, E2 and E7 peptides 
None of 75 serum samples recognised full length E5 peptide in EIAs, but 8 of 75 
(10.7%) sera bound to the control E2 peptide and 13 of 75 (17%) bound to the E7 
peptide. Serum from six patients reacted with both E2 and E7 peptides, 4 of these had 
H-SIL, one had nonnal cytology and the other had cervical cancer. The magnitude of 
serum responses were not significantly different for either of the control peptides at a 
serum dilution of l: 100 (p=0.6: pt, Table 3.4). 
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Table 3.4 Serum reactivity to HPV-16 E2, E7 and whole length E5 peptides 
Peptide HPV-16 E5 HPV-16 E2 HPV-16 E7 
(83 amino acids) 
Total 0175 8175 
(11 %) 
13175 
(17%) 
Normal Cytology 0/20 2/20 
(10%) 
1120 
(5%) 
Cervical Disease 0/55 6/55 
(11%) 
12/55 
(22%) 
L-SIL 0/15 1/15 
(7%) 
4/15 
(27%) 
H-SIL 0/33 4/33 
(12%) 
7/33 
(21%) 
Cervical Cancer 017 117 
(14%) 
117 
(14%) 
HPV-16 + 0/55 4/55 
(7%) 
10/55 
(18%) 
HPV-16 ­ 0/18 4/18 
(22%) 
3/18 
(17%) 
3.3.5 Serum reactivity to HPV-16 E5 9-mer peptides 
Sixteen of 75 (21 %) sera reacted with one or more 9-mer peptides corresponding to the 
least hydrophobic regions of HPV-16 E5 (amino acids 1-8; 5-13; 30-38; 45-53 and 55­
63). Prevalence of seropositivity to one or more peptides was greater in samples from 
patients with cervical disease than those who had normal cytology and this difference 
was significant when peptide 45-53 was used (Fet; p=O.Ol; Table 3.5). When data were 
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analysed with respect to severity of disease, seropositivity rates were generally lower in 
the normal cytology group and usually increased in parallel with severity of disease so 
that when H-SIL (but not L-SIL) were compared to normal cytology women differences 
were significant for 3 peptides (1-8 H-SIL 10 of 33 [30%], NC 1 of 20 [5%]: p=0.04; 
45-53 H-SIL 11 of 33 [33%J; NC 0 of 20 [0%]: p=0.004; 55-63 H-SIL 9 of 33 [27%], 
NC 0 of 20 [0%]: p=O.OI). When seropositivity to peptides was compared between 
HPV-16 DNA positive and negative subjects, the differences were not statistically 
significant (p>0.05). 
3.3.6 Reactivity to Human Papillomavirus Type 16 ES variant peptides 
To determine differences in serum cross reactivity between variant and reference regions 
of HPV-16 E5 all sera were re-tested 13-mer peptides corresponding to each of the 
variant regions of HPV-16 E5 peptide VI, Rl, V2, R2, V3 and R3 (Table 3.6). Only 8 
sera reacted to any peptide, VI 1 sera (L-SIL), V3 2 sera (H-SIL), Rl 2 sera (NC+H­
SIL) and R3 3 sera (NC+H-SIL). Reactivity to all three peptides containing the amino 
acid substitution were significantly greater (p=O.05;ut) than reactivity to 'reference 
peptides' using a total immunoglobulin antibody. 
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Table 3.5 Serum antibodies to HPV-16 E5 9-mer peptides 
Peptide IMTNLDTASs 5DTASTTCCA]3 3ORPLLLSVST38 45LVLLLWITA53 55SAFRCFIVy63 
Total 16175 12/75 9/75 13175 10/75 

(21 %) (16%) (12%) (17%) (13%) 

Normal 1120 3/20 0/20 0/20 0/20 

Cytology (5%) (15%) (0%) (0%) (0%) 

Cervical 15/55 9155 9/55 13/55 10/55 

Disease (27%) (16%) (16%) (24%) (18%) 

L-SIL 3/15 1115 2115 1115 1115 

(20%) (7%) (13%) (7%) (7%) 

H-SIL 10/33 7/33 6/33 11133 9/33 

(30%) (21%) (18%) (33%) (27%) 

Cervical 217 117 117 117 017 

Cancer (29%) (14%) (l4%) (14%) (0%) 

HPV-16+ 8/55 7/55 5/55 8/55 7/55 

(14%) (13%) (9%) (15%) (13%) 

HPV-16- 8/18 5/18 4/18 5/18 3118 

(44%) (26%) (22%) (28%) (17%) 

ErA assays using peptides 1 to 8, 5 to 13, 30 to 38,45 to 53 and 55 to 63 were highly reproducible 
for 10 sera (5 ErA positive and 5 negative) were tested three times in triplicates against these 
peptides (median r2= 0.86). Responses to these peptides were predominant in women with 
cervical disease at a serum dilution of 1: 1 00. Superscripted numbers refer to amino acid position 
of peptide sequences compared to whole length HPV-16 E5. 
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Table 3.6 Serum reactivity to variant HPV-16 E5 13-mer peptides 
Peptide VI PI V2 P2 V3 P3 
Total 37175 6175 13175 5175 5175 15175 
(49%) (8%) (17%) (7%) (7%) (20%) 
Normal 9/20 0/20 1120 4/20 1/30 4/20 
Cytology (45%) (0%) (5%) (20%) (3%) (20%) 
Cervical 28/55 6155 12/55 1120 4/55 11/20 
disease (51%) (11%) (22%) (5%) (7%) (55%) 
L-SIL 10115 1115 4115 0115 0/15 1115 
(67%) (7%) (27%) (0%) (0%) (7%) 
H-SIL 15/33 4/33 7/33 0/33 3/33 8/33 
(46%) (12%) (21%) (0%) (9%) (24%) 
Cervical 317 117 117 117 117 217 
cancer (43%) (14%) (14%) (14%) (14%) (29%) 
HPV-16 + 31155 5/55 8/55 1155 3/55 7/55 
(56%) (9%) (15%) (2%) (5%) (13%) 
HPV-16 ­ 6118 1118 5118 4/18 2/18 8118 
(33%) (6%) (28%) (22%) (11%) (44%) 
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3.4 Discussion 
HPV-16 E5 and E6 isolates were investigated for DNA sequence variation and 
correlated with disease status or the effectiveness of an immune response. Certain E6 
variants have been associated with increased severity of lesions but these were not 
detected in this cohort (Stem et al., 1996). It is likely that these E6 variants are not 
representative of this study population or may not have been detected due to the small 
number of women with H-SIL or cervical cancer. However, 3 E5 variants were detected 
and analysed for significant differences in proliferative PBMC responses, serology or 
disease status but none were found. Synthetic 13-mer peptides accommodating these 
amino acid variants were designed with the variant amino acid located in the centre of 
the peptides for use in EIA. Re-testing of the sera against these peptides did result in 
significant changes when total immunoglobulin was detected. Overall, the ~90 values 
for all 13-mer peptides were much higher than ~90 values to 9-mer peptides, which may 
be a reflection of the length of antigen used. Although the number of variants was 
limited in this investigation, other studies in the department have indicated that 
nucleotide variation ofthe E5 ORF is common and that coding changes occur as a result. 
Whole length HPV-16 E5 was not recognised by any sera in EIAs. This effect may be 
due to the hydrophobicity of HPV-16 E5 which may compromise its antigenicity. 
There was serum reactivity to two control peptides, E2 and E7 which were included to 
allow compansons to previously published data (Dillner, 1992). Although serum 
reactivity for the E2 peptide were eight times lower than in the prevIOUS study, 
reactivity to the E7 peptide was similar in this study responses. These differences may 
reflect variations in methodology used, as all peptides in this study were conjugated to 
ovalbumin and results were expressed as delta absorbance values. 
To overcome the problem of hydrophobicity, five ovalbumin conjugated 9-mer peptides 
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corresponding to the least hydrophobic regions of E5 were selected for use in subsequent 
EIAs. EIA positivity to these 9-mer peptides were more common in patients who were 
negative for HPV-16 DNA. 
It is possible therefore, that seropositivity for HPV-16 E5 may be a marker of an 
effective immune response that results in cell lysis causing release of E5 and the 
production of antibodies. The presence of HPV-16 E5 specific antibodies may be 
protective against the development of cervical cancer. 
Serum reactivity to variant sequences did differ significantly from reference sequences 
suggesting that amino acid change does alter serum reactivity to HPV-16 E5. It could 
also be that patients may have been infected with more than one HPV -16 virus and have 
already seen both variant and reference sequences of E5. Alternatively, as cross 
presentation of antigen is dose dependant the low level of HPV antigen may not have 
been sufficient for cross presentation (Carbone et ai., 1998). 
When serological data were compared with PBMC responses from the previous chapter, 
only two patients were positive in both assays. Only two proliferative PBMC patients 
were concordantly EIA positive (cases 746; L-SIL & 820; asymptomatic). When 
subjects were subdivided according to the correlation of proliferative PBMCs and 
antibody positivity (T+B+: putative Th2 responses) or proliferative PBMCs and antibody 
negative (T+B-: Thl responses), a trend towards greater ThJ responses in patients with 
more severe cervical disease was seen. This is in agreement with Coleman et al., (1994) 
who suggested that ThJ responses are important in the regression of cervical disease. 
These results generally support the observations of decreased ThJ-like responses to 
HPV -16 antigens with increasing grade of neoplasia (Tsukui et ai., 1996; Coleman et ai., 
1994; Luxton et al., 1996). 
Infection with common skin and genital HPVs is generally chronic even in late childhood 
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when the immune system is at its peak (Frazer & Tindle, 1992). This chronic nature 
suggests that there is a problem with papillomavirus antigen presentation to the immune 
system. As with rhinoviruses to which the immune system produces very little immune 
response during natural infection because they are not presented at the right place or in the 
right way or with HIV and herpes which are immunogenic but have host evasion 
mechanisms. The next step towards the characterisation of immune responses would be 
to investigate the in vivo responses to immunisation with HPV-16 E5. This could provide 
data regarding antigenic processing and presentation by a competent immune system. 
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Chapter Four 
Immune Responses to Human Papillomavirus Type-16 E5 
in Mice 
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4.1 INTRODUCTION 
The HPV -16 E5 specific immune responses detected in Chapters Two and Three appear to 
be correlated with disease severity. For 'example, proliferative PBMC responses were 
detected primarily in subjects with normal cytology and in Chapter Three, serum 
antibodies were detected in those subjects who were negative for HPV-16 DNA It may 
be possible therefore, that HPV -16 E5 is effectively presented to cells of the immune 
system and is immunogenic in some subjects. 
In order to investigate the immunogenic propeIiies ofHPV-16 E5, mice were immunised 
with synthetic peptides using three different immunisation procedures (Table 4.1), devised 
to investigate whether both cell mediated and humoral immune responses to HPV -16 E5 
were inducible. The presence of HPV-16 E5 reactive antibodies were investigated as 
evidence of humoral immunity. HPV -16 E5 specific spleen cell proliferation and CTL 
responses were measured as evidence of CMI. 
As CTL responses were detected after immunisation procedure three, peptide-binding 
assays were performed to map the HPV-16 E5 epitopes which bind to MHC-I molecules. 
4.2 METHODS 
Synthetic peptides were used as immunogens and were constructed using SPPS (see 
section 2.2.5). Full length HPV-16 E5, 9-mers (Figure 2.2) and 6-mers which when 
overlapped by two amino acids corresponded to full length HPV -16 E5 (Figure 4.1) were 
used. Peptides of this length were chosen as fragments of 5-15 amino acids are generated 
after in vitro digestion of whole proteins by proteosome units and may represent MHC-I 
epitopes (Wenzel et aZ., 1994; Boes et at., 1994; Dick et at., 1994; Kuckelkorn et al., 
1995; Groettrup et al., 1995). Studies have shown that 9-mers bind to MHC-I 100 to 
1000 fold higher than shorter or longer peptides (Kubie, 1997). Indeed, a 9-mer peptide 
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was also found to have a ten fold higher affinity to pooled antisera from subjects who had 
recovered from Hepatitis B (Kuby, 1997). 
The systematic testing of short overlapping synthetic peptides for MHC-I binding may 
identify peptides that are recognised by MHC restricted CTL responses. MHC-I binding 
epitopes contain amino acids whose residues fit into pockets of a peptide-binding cleft. 
The 6-mer peptides allow determination of anchor residues which are usually hydrophobic 
leucines or isoleucines (Kubie, 1997). Conserved anchor residues exist in peptides to 
various MHC-I molecules and permit the prediction of peptide binding to a particular 
MHC molecule and this may help in designing effective synthetic peptide vaccines. 
Using an epitope mapping kit, SPPS reactions were used to prepare peptides onto high­
density acrylic grafted polyethylene rods (Geysen et ai., 1987). These rods were designed 
in the format of a 96 w~ll microtitre plate and were used in EIAs. Reactions to remove 
Fmoc groups present on the tips of the rods and subsequent reactions involving addition 
of amino acids were carried out in wells of a Teflon block. Peptides were not cleaved 
from the rods and were used in situ during EIAs. Peptides present on Pepscan™pegs 
were 5-mers overlapping by 2 amino acids (Figure 4.2), their short length enables epitope 
mapping of reactive sera. 
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Table 4.1 Immunisation procedures used in this chapter 
Procedure Number Antigen Number of Tests 
Mice 
Procedure 1 full length HPV-16 E5 9 Serum antibody & 
DPBS 4 
Spleen cell 
proliferation 
Procedure 2 full length HPV -16 E5 3 Serum antibody 
ful1length HPV-16 E5 mixed with 3 " 
ovalbumin 
full length HPV-16 E5 conjugated to 3 " 
ovalbumin 
DPBS 3 " 
Procedure 3 full length HPV-16 E5 3 CTL& 
Mucosal antibod1 
full length HPV -16 E5 conjugated to 3 " 
Antigens entrapped ovalbumin 
within ISCOMs 
complexes full length HPV-16 E5 mixed with 3 " 
ovalbumin 
9-mer peptides 3 " 
9-mer peptides conjugated to ovalbumin 3 " 
9-mer peptides mixed with ovalbumin 
3 " 
Ovalbumin 
3 
DPBS " 
3 " 
Various immunological investigations of HPV proteins have used murine models and 
some have even led to clinical trials of vaccines. Such models have shown partial 
protection against BPV -1 E5, E6 and E7 and protection against HPV -16 E6 and E7 
proteins using recombinant vaccinia virus (Meneguzzi et ai., 1991), transfected cells 
(McLean et ai., 1993; Chambers et aI., 1994) or synthetic peptides (Chen et aI., 1992; 
Feltkamp et aI., 1993; Tindle et aI., 1991). HPV-16 E5 specific CTL were investigated 
after immunisation procedure 3 to determine whether HPV -16 E5 pep tides are processed 
by MHC-I molecules. All antigen preparations were emulsified in equal volumes of 
Freunds incomplete adjuvant. DPBS= Dulbeccos phosphate buffered saline, ISCOMs= 
immunostimulatory complexes, CTL= cytotoxic T-lymphocytes 
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6-mer peptides 
30RPLLLS35 
IMTNLDTA7 
Pepscan™ 
8) 
LAFL T -control sequence 
Figure 4.1 Synthetic human papillomavirus type-16 E5 peptides Amino acid 
sequences of the peptides used in this study, 6-mers were constructed with a two amino 
acid overlap. Superscripted numbers refer to amino acid sequences. The Pepscan ™ is made 
up of 5-mer peptides, superscripted numbers in bold refer to rod number, whilst sUbscripted 
numbers refer to amino acid sequences which make up each epitope. The LAFLT sequence 
was constructed as a negative control and was prepared on rod 28 .. 
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4.2.1 HPV-16 E5 containing immunostimulatory complexes (ISCOMs) 
To prepare ISCOMs, 0.5 mg of the required HPV-16 E5 peptide was added a solution of 1 
ml of carbonate buffer pH 9.0, containing 5% (w/v) sodium deoxycholate (Sigma) and 10 
% (v/v) dimethyl sulphoxide. To this, 100 f.ll of chloroform (Sigma) containing 1 giL of 
cholesterol (Sigma) and 1 giL of phosphatidyl choline (Sigma) was added. The 
chloroform was removed under vacuum with constant agitation at 37°C, then 1 giL of 
Quil A (Sigma) was added to the solution. This was dialysed for three days at room 
temperature against 50 roM Tris-hydrochloride buffer at pH 8.0 containing 0.001 % (w/v) 
of the anti bacterial agent thimerosal (Sigma) to allow formation of the ISCOMs. 
After fonnation of ISCOMS the preparation was centrifuged at 30,000 g through a layer 
of 10% (w/v) sucrose in water onto a 40% (w/v) sucrose in water cushion for 18 h at 
20°e. The sucrose solutions were prepared in 50 mM Tris-hydrochloride buffer at pH 8. 
ISCOMS (seen as a red opaque band at the interface) were harvested and then dialysed 
against PBS pH 7 at 4°C overnight. The presence of ISCOMs was determined by 
transmission electron microscopy (Figure 4.2). 
4.2.2 Preparation of injections 
In a class II laminar flow hood, 1 °f.lg of antigen (Table 4.1) were added to 1 ml of filter 
sterilised 10% (v/v) glacial acetic acid in Dulbeccos phosphate buffered saline (DPBS, 
Sigma) and emulsified with 1 ml of Freunds incomplete adjuvant (Sigma). Where 
ISCOMs were used as antigen mice were injected with ISCOM preparation emulsified 
with Freunds incomplete adjuvant. 
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Figure 4.2 Electron micrograph of ISCOMs A transmission electron microscope 
HU12A (Hitachi) was used to prepare these images. 25 /-!l of the ISCOM preparation was 
allowed to dry on copper grids. The excess was removed and 25 /-!l of a negative uranium 
salt dye was used to stain the preparation. Arrows indicate the presence of formed 
ISCOMs. The above figure is magnified 125,000 times. 
4.2.3 Immunisation of mice 
Six-week-old female Balblc mice (Harlan Olac Ltd., u.K.) were anaesthetised in an 
inhalation chamber (Jencons Scientific Ltd., u.K.) containing cottonwool saturated with 
Enflurane™ (Abbott laboratories, Ltd.). Mice were immunised subcutaneously with a 
total of 50 /-!l ofthe appropriate injection suspension at two sites near the nape of the neck. 
Control mice were kept in neighbouring cages and immunised with equal volumes of 
DPBS and Freunds incomplete adjuvant emulsion. Immunisations were repeated at weeks 
two and four. At six weeks mice were anaesthetised as above and exsanguinated from the 
heart using a 21 gauge needle attached to aIm! syringe (Sterilin) and killed by stwU1ing 
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and cervical dislocation. In all three immunisation procedures DPBS was used as a 
negative control, in procedures 2 and 3, ovalbumin provided a positive control. 
4.2.4 Collection of samples 
Whole blood was permitted to clot and then centrifuged at 500 g for 5 min to collect 
serum. Peritoneal cells were harvested under sterile conditions for use as autologous 
feeder cells as follows. Using a sterile needle and syringe, 8 ml of RPMI-1640 
supplemented with 10% FBS, 0.04 giL gentamycin (Sigma) and 0.12 giL benzylpenicillin 
(Sigma) was injected into the peritoneal cavity. The abdomen was then gently massaged, 
to bring cells into suspension, peritoneal fluid was collected by aspiration of the media. 
Cell suspensions were centrifuged at 150 g for 10 min and cell number was adjusted to 1 
x 10sIml in FBS containing 10% dimethyl sulphoxide (v/v). Cells were then frozen to ­
700 e at a rate of -1°C per min in 1.8 ml cryotubes (Coming) using a freezing chamber and 
stored in liquid nitrogen until required. 
Once peritoneal cells had been harvested, spleens from each mouse were removed and 
placed into sterile universals half-filled with wash media consisting of, Hanks balanced 
salt solution; 1% (v/v), 1 M Hepes buffer, 0.04 giL gentamycin and 0.12 giL 
benzylpenicillin. Spleens were removed from wash media in a class II laminar flow hood 
(MDH) and teased through a sterile wetted wire mesh using the plunger of a 10 ml 
syringe. Resulting cell suspensions were washed through the mesh using 5 ml of culture 
media consisting of Dulbeccos modified Eagles media, (DMEM), 10% FBS, 2 mM 1­
glutamine, 100,000 U/L benzylpenicillin and 0.1 giL streptomycin sulphate. 
Cellular aggregates were allowed to settle and the single cell suspension was transferred 
to a 15 ml centrifuge tube (Coming) and centrifuged at 150 g for 10 min. Pelleted cells 
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were re-suspended in 10 ml culture media, centrifuged for a further 10 min at 150 g and 
then placed in 25 cm3 tissue culture flasks (Coming). 
When mice had been killed after immunisation procedure 3, additional samples were 
collected for investigations of HPV -16 E5 specific mucosal (IgA) responses. These 
included faecal pellets expelled after death. These were weighed and re-suspended in 
DPBS at a concentration of 5 giL (w/v). Cotton tipped swabs (Johnson & Johnson, U.K.) 
were used to collect mucous from oral and vaginal cavities and were suspended in 1 ml 
DPBS. 
4.2.5 EIA for detection of antibodies to human papillomavirus type-16 E5 peptides 
Sera collected from mice were diluted in PBS to dilutions of: 1 :50; 1: 1 00, 1 :200, 1 :400, 
1: 800, 1: 1600 and 1:3200. Aliquots of 100 ) ..d were added to each well of a 96 well plate 
previously coated with whole length HPV-16 E5 (see section 3.2.8). After 1 h at room 
temperature plates were washed three times in PBST and 50 III of HRP labelled 
polyvalent goat anti-mouse antibody (Sigma) were added at a dilution of 1 :250. The 
plates were then incubated for 1 h at room temperature. The rest of the EIA procedure 
was previously described in section 3.2.2. 
4.2.6 Pepscan™ immunoassays 
To inactivate non specific binding sites, rods were immersed in 250 III of 1% BSA (w/v) 
in PBST in 96 U-well polycarbonate microtitre plates (Coming) for 1 h at room 
temperature on a rocking platform (Denley A600). After washing in running tap water, 
rods were placed in wells of a fresh 96 U-well microtitre plate containing 50 III of 
immunised or control mouse serum, diluted 1:100, and left to incubate overnight at 4°C in 
a humidified chamber. 
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Rods were washed again under running tap water and placed in a fresh 96 well plate 
containing 50 j.ll per well of goat anti-mouse antibody conjugated to HRP (Sigma) diluted 
to 1 :250 in PBS (v/v) and incubated for 1 h at room temperature. Rods were washed 
thoroughly in tap water and placed in a fresh plate containing 100 /-Ll/well of 2,2 azino­
bis(3-ethylbenzthia-zoline)-6-sulphonic acid (Sigma). They were then left to incubate for 
1 h at room temperature on a rocking platform, to allow colour development. Rods were 
removed and the ~05 of each well were determined using an automatic plate reader 
(Labsystems). The ~05 value obtained for the control peptide (LAFLT, Figure 4.2) was 
subtracted from those obtained for HPV-16 E5 peptides. 
To re-use Pepscans™ bound antibody was removed by placing the rods in a hot (55°C) 
aqueous solution containing 10% (w/v) sodium dodecyl sulphate (Sigma) and 2% (v/v) 2­
mercapto-ethanol (BDH). They were then sonicated for 30 min in a water bath (Grant, 
UK) and washed three times in hot water at 56°C and a final rinse in methanol (Sigma). 
4.2.7 Generation of antigen specific splenic T-lymphocyte lines by continuous 
stimulation 
Cells isolated from spleens were adjusted to 2 x lOs/ml viable cells in 5 ml of RPM I 1640 
containing 1 mM pooled 6-mer peptides, 10,000 U/L IL-2 and 20 giL of concanavalin A. 
Cells were cultured using the method of Good et al., 1987 and were placed in 25 em3 
flasks in a humidified 37°C incubator with 5% CO2 in air (v/v) for three days. On the 
fourth day cultured spleen cells were collected by centrifugation as above and washed 
twice in culture media. Cells were counted and cell number was adjusted to 1 x 105 
viable cells/ml. Aliquots of 225 j.ll were placed in 96 round well tissue culture plates 
(Coming) with. 1 0,000 U/L IL-2, 20 giL concanavalin A and 1 mM pools of four 6-mer 
peptides. Cells were incubated at 37°C in a humidified incubator with 5% CO2 (v/v) in air 
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for 7 days (Good et al., 1987). In three fresh plates 100 ).tl volumes of 1 x 105 mitomycin 
C treated autologous feeder cells (see section 4.2.5) were pipetted into each well of three 
96 round well mierotitre plates into which 75 fll aliquots of stimulated cells were added. 
Two of these plates were stimulated with 25 fll of 1 mM pools of four 6-mer peptides and 
the third received 25 ).tl of culture medium only (negative control). Plates were incubated 
for 5 days in a humidified incubator at 37°C with 5% CO2 in air (v/v), after which cells 
were collected by aspiration. Cells were then washed twice in culture media and re­
suspended as before with stimulation media and incubated for a further 7 days. Cells 
were tested for HPV -16 E5 specific proliferation using the MTT assay and results were 
expressed as SI (see section 2.2.6.1). 
4.2.8 Cytotoxic T -lymphocyte assay 
The murine thyoma cell line p81S (ECACC) shares the same H2d haplotype as Balb/c 
mice and were used as target cells in CTL assays. After immunisation, Balb/e mice have 
been shown to generate CTLs capable oflysing p815 cells indicating that the method used 
in this chapter is an effective one (Zhou et al., 1991). 
pSI5 cells were pulsed with HPV -16 E5 9-mers to induce macropinocytosis (see 
Appendix 4). Briefly, 1 x 10s/ml p81S cells were suspended in 2 ml RPMI 1640 medium, 
containing 0.5 M sucrose, 20 gil polyethylene glycol 1000™ and 2 mM HPV-16 E5 9­
mers. After incubation at 37°C for 10 min in a humidified atmosphere containing 5% 
CO2 (v/v) in air, cells were washed once in a solution of3 parts Hams' F12 media (Sigma) 
and 2 parts tissue eulture grade water (Sigma). Cells were then counted and re-suspended 
at 2 x lOs/ml in RPMIIFBS. 
Aliquots of 50 ).tl were then dispensed into wells of a 96 U-well micro titre plate. To each 
well an equal volume of effector cells (spleen cell populations from each of the nine 
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groups of mice) were added in triplicate wells to give final target effector ratios of 10:1, 
5:1,2.5:1, 1.25:1, 0.62:1 and 0.31:1. A non-radioisotopic colourimetric assay employing 
lactate dehydrogenase (LDH) release to measure CTL activity was used (CytoTox 96® 
Assay, Promega). This required additional control wells also prepared in triplicate 
containing: (a) effector cells corresponding to each cell concentration; (b) target cells 
adjusted to 1 x 10s/ml in 100 III of media; (c) 1 x lOs/ml target cells with 10 III of lysis 
solution (0.8% v/v Triton-X 100™ in water); (d) 100 j..ll media with 10 j..lllysis solution 
and (e) 100 j..ll ofmedia alone. A positive LDH control was also included with the kit. 
Plates were centrifuged at 250 g for 4 min to allow effector and target cell contact and 
incubated for 4 h at 37°C in a humidified atmosphere containing 5% C02 in air (v/v). 
After incubation 10 j.ll of lysis solution was added to each experimental well and to 
control wells (b) and incubated for a further 45 min at 37°C in a humidified 5% CO2 in air 
atmosphere. After incubation 50 III volumes were transferred from each well, placed into 
corresponding wells of a flat bottomed 96 well microtitre plate to which a further 50 III of 
substrate mix were added and incubated in the dark at room temperature for 30 min. After 
incubation 50 III of stop solution were added to each well and the ~90 of each well was 
I 
f 
determined using an automatic plate reader (Lab systems). The percentage cytotoxity was 
B determined as below, using the formula supplied with the CytoTox ® kit. 
I 
A490 Experimental-At9o effector (a) -At90 target cells (b) 
% Cytotoxicity -'______________________ xlOO 
A490L ysed target cell control (c)-At90Media containing lysis solution (d) 
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4.2.9 Measurement of MHC binding by HPV-16 E5 6-mer peptides 
The RMA cell line is a subline of the Rauscher virus induced T -cell lymphoma RBL-5 of 
C57B 1/6 mice (H_2b; [Kb & Db]), its mutant sub-line RMA-s has a reduced MHC-I cell 
surface expression (Ljunggren et aI., 1985; 1989; Karre et al., 1986; Townsend et al., 
1989). RMA-s express approximately 5% of H_2b cell surface molecules compared to 
RMA cells. Furthennore, these molecules are unstable at 37°C due to the lack of pep tides 
in the antigen-binding groove. However, they can be stabilised by supplementing culture 
media with exogenous peptides capable of binding to either of these alleles (Ljunggren et 
al., 1990; Schuhmacher et a!., 1990). The MHC-I binding of a peptide can therefore be 
quantified indirectly by measuring the expression of cell surface MHC-I (H_2b) molecules 
(Townsend et at., 1989; Reinholdsson-Ljunggren et al., 1993; Dillner, 1994). Previous 
studies have screened synthetic HPV-16 E6 and E7 peptides for the ability to stabilise 
MHC-I expression on RMA-s cells using this method (Stauss et al., 1992; Feltkamp et al., 
1993; Dillner, 1994). 
It was not possible to measure peptide binding specific for H_2d molecules, the Balb/c 
haplotype, but considering that MHC-I molecules have a broad specificity for antigen this 
data should provide a general analysis. 
RMA and RMA-s cell lines were maintained in RPMIIFBS 111 a humidified 37°C 
incubator with 5% C02 in air (v/v). Cells were subcultured every 3 days and were grown 
in 75cm3 flasks (Coming). When required, 4 x 104 viable RMA-s cells were dispensed 
into wells of a 96 U-well plate in 40 j.LI of RPMIIFBS. Individual HPV-16 E5 6-mer 
peptides were adjusted to 300 j.LM in 20 j.LI of culture media and added to each well to give 
a final concentration of 100 ).lM per well. Plates were incubated for· 16 hours in a 
humidified 5% CO2 in air incubator at 37°C and each peptide was assayed in 
quadruplicates. The assay plate also contained twelve wells of 4 x 104 RMA cells (100% 
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MHC-I expression) and twelve wells of 4 x 104 RMA-s cells (5% MHC-I expression) to 

which no peptide was added. 

After incubation, plates were washed by adding 180 III of ice cold DPBS to each well, 

vortexing for 10 sec followed by centrifugation at 400 g for 2 min (Denley) after which 

the supernatants were aspirated. The 96 well plate was placed on ice and 25 III of goat 
anti mouse B-2 specific antibody (Pharmingen Ltd.), at a dilution of 1:250 (v/v) in PBS, 
added to each well. The plates were then agitated, incubated on ice for 1 h and washed 3 
times in DPBS. Aliquots of30 III of rabbit anti-mouse HRP conjugate were added to each 
well and the plate was incubated for a further 1 h. Wells were washed six times in ice 
cold DPBS (above) and fixed to prevent cytolysis and release of endogenous cellular 
peroxidase by adding 50 III of formaldehyde (diluted 1:100 in DPBS) and incubating on 
ice for a further 30 min. Wells were washed twice more with 400 III ofDPBS. After this, 
an aliquot of 50 III of Sigma Fast™ OPD substrate was added to each well and incubated 
at room temperature for 30 min after which the ~90 was determined using an automated 
micro-titre plate reader (Labsystems). The mean ~90 of RMA-s cells without peptide 
was subtracted from the mean absorbance value ofRMA cells. The mean ~90 ofRMA-s 
cells with HPV -16 E5 peptide was expressed as a percentage of the control RMA cells 
after subtraction of the mean value ofRMA-s cells (without peptide). 
4.2.10 Statisical Tests 
Paired and unpaired students' t-test (ut) and Fishers' exact test (Fet) were used to analyse 
data. 
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4.3 RESULTS 
4.3.1. Procedure one 
Immunisation of mice with non-conjugated E5 (amino acids 1-83) peptide resulted in the 
production of antisera with low ~90 values using plates coated with full length E5 peptide 
(Figure 4.3). Mean ~90 values of titrated sera from all immunised mice were 
significantly greater than those of control wells in serum dilutions 1 :50 (ut: p=0.046) and 
1:200 (ut: p=0.0003). Maximum ~90 values for HPV-16 E5 peptides were detected at a 
serum dilution of 1 in 200. 
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Figure 4.3 Procedure 1: Antisera to whole length HPV-16 E5 in immunised mice. 
Results are expressed as the mean of nine mice, each tested in triplicate. Error bars 
represent the standard error of the mean (SEM). Sera diluted in PBS to 1 :200 gave the 
greatest absorbance values, indicating a prozone effect which results when when antigen 
concentration is low but antibody is relatively abundant (Hyde, 1976). 
Pepscan™ analyses showed that immunised sera bound to rods 12 (ut: p=0.005), 1 (ut: 
p=O.04) 11 (ut: p=O.048) 25 (ut: p=0.049) and 26 (ut: p=0.05) and were significantly 
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higher in sera from all . . d .Immulllse mICe compared to that from non-immunised mice 
(Figure 4.4). Although the peptides on rods 1 and 26 had the lowest hydrophobicity 
values, immune responses appeared to be independent of hydrophobicity values. 
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Figure 4.4 Procedure 1: Antisera to HPV-16 ES S-mers in immunised mice as 
detected by Pepscans™. Rods numbered 1-27 represent HPV-16 E5 in 5 amino acid 
sequences, the sequence on each rod is overlapped by 2 amino acids. Results are expressed 
as serum absorbance values from immunised mice minus serum absorbance values from 
non-immunised mice. Rod number 28 is the control sequence, made up of randomly 
selected amino acids (Figure 4.1). Each point represents the mean of nine sera each tested 
in triplicate. Error bars represent SEM. 
Spleens from immunised mIce were tested for HPV-16 E5 specific spleen cell 
proliferation in response to stimulation with HPV-16 E5 6-mers. Five pools of four 9-mer 
peptides were tested for HPV-16 E5 specific stimulation. For one mouse (mouse 2), there 
were positive responses to all five pools of peptide, the highest SI was 50.9 and the lowest 
was 15.5 (Table 4.2). SI from other mice were lower in a second mouse (mouse 7) the 
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highest value was 2.6, in a third (mouse 8) 2.3 and a fourth mouse (mouse 9) gave a SI of 
12.1. Results shown for 5 of 9 mice the remaining mouse spleen populations did not show 
HPV -16 E5 specific proliferation. 
Table 4.2 Procedure 1: Proliferative spleen T-Iymphocyte responses in immunised 
mice to pools of four HPV-16 E5 6-mers compared with EIA data 
HPV-16 E5 Specific Stimulation Indices EIA 
Amino acids Amino acids Amino acids Amino acids Amino acids A490 values Mouse 1-19 18-35 34-51 50-67 66-83 
2 15.5 16.6 50.9 37.3 23.3 0.7 
3 1.2 1.3 1.5 0.8 1.5 0.8 
7 1.2 0.6 1.7 2.6 1.0 0.5 
8 1.1 1.2 2.3 0.2 1.3 0.4 
9 1.0 0.8 0.9 0.8 12.1 0.4 
Mouse 1 had the greatest EIA absorbance values at a dilution of 1 :200 (1.067) but 
proliferative spleen cell responses were not detected. The detection of serum antibodies 
to HPV -16 E5 did not correlate with proliferative spleen cell responses. Non-immunised 
mice were not tested for HPV-16 ES specific stimulation. 
4.3.2 Procedure two 
Sera from all mice used in this procedure were tested against the full length HPV-16 E5 
peptide and against ovalbumin which was used as a positive control. Sera were also 
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tested against PBS and bovine serum albumin which were both negative controls. As 
only weak HPV-16 E5 specific antibodies were detected in procedure 1, the peptides used 
in this procedure were conjugated to ovalbumin in order to enhance immunogenicity. 
Immunisation of mice with ovalbumin conjugated to whole length HPV-16 E5 resulted in 
the production of antisera that produced low ~90 values when tested against the full 
length HPV -16 E5 peptide in EIAs (Figure 4.5). Maximum ~90 values were detected at a 
sera dilution of 1 in 200, but reactivity to HPV-16 E5 was not significantly greater when 
compared with ovalbumin, bsa or PBS. Serum antibody titres to ovalbumin was 
significantly higher than antibody titres to HPV-16 E5 (pt: p==O.0003), bsa (pt: p=0.0004) 
and PBS (pt: p=O.OOO 1; Figure 4.5) in two groups of mice immunised with HPV-16 E5 
conjugated or mixed with ovalbumin. 
Antisera from the same groups, when tested against plates coated with PBS and bsa gave 
low ~90 and mean values of titrated sera were not significantly different. Sera from mice 
immunised with ovalbumin mixed with HPV-16 E5 gave similar ~90 values in all EIAs 
(E5, ovalbumin, bsa and PBS coated plates). Serum reactivity to ovalbumin was 
significantly higher when compared to HPV-16 E5 (pt: p=0.0002), bsa (pt: p=0.004) and 
PBS (pt: 0.0003). Serum reactivity to HPV-16 E5/0valburnin conjugates when compared 
HPV -16 E5/0valbumin mixtures were not statistically different (pt: all p>0.05). 
Sera from all four groups of mice were also tested using Pepscans™ as in procedure one. 
In mice immunised with HPV-16 E5 conjugated to ovalbumin mean serum reactivity was 
significantly higher for the amino acid sequence PLLLS (amino acids 31-35) than for any 
other 5-mer sequence (p=0.04). Otherwise antisera from all four groups gave low A.05 
responses and were not significantly different from each other (pt: all >0.05, data not 
shown). 
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Figure 4.5 Procedure 2: Antiserum to HPV-16 E5, ovalbumin (OVA), phosphate 
buffered saline (PBS) and bovine serum albumin (BSA) from mice immunised with 
HPV-16 E5 conjugated to ovalbumin (HPV-16 ES). Greatest absorbance values for 
antibodies to HPV-16 E5 were detected at serum dilutions of 1: 1 00 & 1 :200. Error bars 
represent SEM. 
These data demonstrate the effectiveness of the immunisation procedure in delivering 
antigen to cells of the immune system as strong ovalbumin specific antibodies were 
detected. However, antibodies to the HPV -16 E5/0valbumin conjugate only produced low 
~90 values and it appears that HPV-16 E5 requires further modification in order to 
improve its immunogenicity. Therefore, in procedure three, HPV-16 E5 alone or 
conjugated to ovalbumin was incorporated into ISCOMs. 
152 
--
Chapter Four 
4.3.3 Procedure 3 
Serum reactivity to full length HPV-16 E5 was not significantly different between the 
groups of mice (p>0.05). Similarly, when total immunoglobulin was measured in mucous 
(oral, vaginal of faecal) against full length HPV -16 E5 none was detected in any group or 
sample (ut=all p>O.05). 
Mice were irnmunised with ISCOM preparations to determine whether HPV-16 E5 
specific CTL responses could be induced. CTL responses were seen with the highest 
effector to target ratio of 10 to 1 (Figure 4.6). Cells from mice immunised with whole 
HPV-16 E5 conjugated to ovalbumin, whole HPV-16 E5 mixed with ovalbumin or just 
whole HPV-16 E5 had 5.4%, 4.8% and 4.9% cytotoxicity respectively. Mice immunised 
with 9-mer peptides conjugated to ovalbumin had the greatest cytotoxic activity of 9.8%, 
9-mer peptides mixed with ovalbumin had 8.4% cytotoxicity and 9-mers alone also 
showed cytotoxcity 5.5%. Conjugation of the pooled 9-mer peptides to ovalbumin did 
significantly enhance CTL responses by almost 2 fold (pt =P<0.05). 
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Figure 4.6 Procedure 3: Percentage cytotoxicity to HPV-16 E5 immunogens. 1= 
E5 conjugated to ovalbumin; II = E5 mixed with ovalbumin; III =E5 alone; IV = E5 9­
mers conjugated to ovalbumin; V = 9-mers mixed with ovalbumin; VI = HPV-16 E5 9­
mers only. Error bars represent SEM. 
4.3.4 Peptide binding Assays 
Peptides are presented to CTLs on the cell surface by MHC-I molecules and as CTL 
responses were detected, it was decided to investigate the HPV -16 E5 binding to MHC-I 
molecules. Of the twenty 6-mer peptides tested, 13 were found to bind H_2b MHC-I 
molecules and maintain their cell surface expression on RMA-s cells. Peptides that 
resulted in the highest MHC expression were peptides; 70-75 (162%),34-39 (153%), 38­
43 (147%), 62-67 (98.7%), 54-59 (87%), 74-79 (85.7%), 78-83 (70%),30-35 (65%), 10­
15 (36.4%), 66-71 (32.5%),6-11 (22%), 14-19 (16%),50-55 (14.3%); (Figure 4.7). 
Of those peptides with the highest MHC-I binding only one, 54-59 did not contain leucine 
or isoleucine anchor residues but contained a phenylalanine instead. 
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Figure 4.7 Peptide binding assay. This figure shows the percentage H_2b 
expression on RMA-s cells after stimulation with HPV-16 E5 6-mers. Error bars 
represent SEM. Certain regions including the most hydrophobic parts of HPV -16 
E5 contain MHC-I binding epitopes. 
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4.4 Discussion 
Data from procedure one show that immunisation with full length. HPV -16 E5 alone 
resulted in the production of low titre serum antibodies. These were mapped to specific 
HPV -16 E5 epitopes, three of which were highly hydrophobic in nature but two 
represented the least hydrophobic regions. This suggests that hydrophobicity may not be 
the only requisite in the selection of immunogenic epitopes. 
When HPV -16 E5 was conjugated to ovalbumin in procedure 2, high-titre antibodies 
specific for HPV-16 E5 were not detected even though high-titre antibodies specific for 
ovalbumin were. The ovalbumin specific antibodies confirm that the immunisation 
procedure itself was effective in delivering antigen to the host and suggests that 
ovalbumin may not be the most suitable carrier for HPV -16 E5. It could be an indication 
of the poor immunogenicity of HPV-16 E5. The detection of ovalbumin specific 
antibodies provided a positive control for subsequent immunisations and ovalbumin was 
included in procedure 3. 
Serum and mucosal antibodies reactive with HPV -16 E5 peptides were investigated after 
procedure 3 but were not detected. The absence of mucosal antibody responses after 
ISCOM immunisation may be due to the significant dilution involved during the 
collection of samples. On hindsight absorbant wicks designed to collect mucosal 
secretions from small animals should have been used and these may have been re­
suspended in smaller volumes. 

Immunisation with full length HPV -16 E5 alone, resulted in spleen cell proliferation in 

response to stimulation with pooled peptides. Such a response may be an indication of T­

lymphocyte memory, where immunisation with HPV-16 E5 has primed a population of 

spleen cells which recognise the antigen on a subsequent exposure. Generally, the results 

in mice, correlate with the general [mdings in human subjects in Chapters Two and Three, 
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where strong T -lymphocyte like proliferative PBMC responses were detected in study 
subjects with the detection of low-titre antibodies. Only two subjects with proliferative 
PBMCs (Chapter Two) also had concordant antibody responses (Chapter Three). The 
presence of cellular immunity in the absence of humoral immunity is suggestive of a 
delayed-type hypersensitivity response, mediated by Th] cells. 
Peptides incorporated into ISCOMs usually prime MHC-I and induce strong CTL activity 
(McMowat et al., 1991) and the inclusion of HPV-16 E5 into ISCOMs did result in the 
generation of CTLs. Although highly toxic, it is possible to immunise with very small 
quantities of Quil A (the major component of ISCOMs) mixed with antigen. Mice 
immunised this way were shown to elicit DTH responses and a strong induction of CTLs 
(McMowat et aI., 1991). This approach was tried in what would have been Procedure 4, 
but mice immunised this way developed lesions (1 cm diameter) at the site of 
immunisation and had to be sacrificed. 
Of the 13 peptides that bound H_2b molecules, 9 contained leucine and/or isoleucine 
residues the remaining peptides contained other hydrophobic residues. This indicates that 
the hydrophobicity of HPV -16 E5 is not responsible for the poor immune responses seen 
especially as the most hydrophobic regions of HPV-16 E5 have been shown to bind 
MHC-I molecules. 
It is also possible that HPV-16 E5 is available to the immune system but is poorly 
antigenic, this may be explained by holes in the T-lyrnphocyte repertoire (Niederrnann et 
al., 1995). Indeed, the prediction of T -lymphocyte epitopes is difficult as only a few 
peptides that satisfy binding requirements of MHC class-I molecules are found to be 
immunodominant epitopes (Sijts et al., 1994). 
In conclusion immunisation with HPV-16 E5 peptides induces CMI and low-titre 
antibodies in mice. There is evidence suggesting that HPV -16 E5 is processed and 
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presented by the MHC-I pathway but may not be efficient. It is evid.ent from the high­
titre ovalbumin-specific antibodies detected after Procedure 2 that an alternative route or 
method of immunisation is required for HPV -16 E5. Previous studies of in vivo 
immunisation with synthetic peptides emulsified in incomplete Freunds adjuvant report 
strong CTL responses to HPV-16 E6 and E7 proteins (Aichele et aZ., 1990; Kast et aZ., 
1991). It may therefore, be worth considering alternative adjuvants for HPV-16 E5. A 
more effective immunisation procedure may result in an effective immune response and a 
range of adjuvants and delivery systems need to be investigated. 
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5.1 INTRODUCTION 
Data from Chapters Two, Three and Four indicate that immune responses to HPV-16 E5 
occur. These are predominantly cell-mediated responses accompanied by low-titre 
antibodies. Peptide binding assays in Chapter Four confirm that certain HPV-16 E5 
epitopes do bind murine MHC-I molecules and may therefore be presented to cells of the 
immune system. 
Both MHC-I and MHC-II are cmcial for the production of an immune response. MHC-I 
molecules generally present intracellular proteins, these include host self-proteins and 
proteins produced by intracellular pathogens such as vimses. MHC-ll molecules present 
extracellular proteins that have been phagocyctosed from the extracellular environment. 
The lack, or the low-level expression, of MHC-I can result in cells that are not recognised 
by CTLs as infected or neoplastic and may provide a means for cells to escape immune 
surveillance. Indeed, alterations in MHC-I and MHC-ll cell surface expression have 
previously been described in several human cancers including: malignant melanoma 
(Ruiter et at., 1986), hepatocellular (Patterson et ai., 1988), gastric (Sakai et at., 1987), 
colorectal (Van den Ingh et al., 1987) and laryngeal (Esteban et at., 1990) cancers. The 
importance of MHC-II in HPV associated cervical lesions requires investigation but due to 
shortage of time, it was not possible to investigate MHC-ll molecules in this study but 
MHC-I was investigated. Cell surface expression ofMHC-I molecules is often reduced on 
, 
virally infected cells and in several cases, this effect has been shown to be due to active 
I 
,I 
r. 
interference of the MHC-I pathway by the infecting virus (Table 5.1). This obstruction of 
I the normal functions of the MHC-I pathway may be as a result of viral evolution, where 
? 
, evasion of the immune response results. HPV -16, like other viruses may also interfere 
I with the MHC-I pathway, as reduction in MHC-I expression occurs in cervical cancers 
I 
f 
(Connor & Stem, 1990; Cromme et at., 1993; Hilders et at., 1994). 
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Table 5.1 Examples of viral escape mechanisms affecting MHC molecules 
Virus Function Reference 
Ad 12 EIA Down regulation of Schouten et at., 1995 
MHC-I transcription 
Ad E3 gp19k Retains MHC-I in ER Paabo et at., 1983; 
Burget & Kvist, 1985; 
Hermiston et aZ., 1993 
Murine CMV m152 Blocks MHC transport Thale et at., 1995; 
Ziegler et at., 1997 
Murine CMV early gene Down regulation of Campbell & Slater, 1994 
MHC-I transcription 
Human CMV US3 Retains MHC-I in ER Ahn et at., 1996 
Human CMV US2, US11 Dislocates MHC-I from ER Wiertz et ai., 1996; 
to cytosol Jones & Sun, 1997 
Human CMV US6 Inhibits TAP mediated Ahn et at., 1997; 
peptide transport Hengel et at., 1997 
HSVICP47 Inhibits production and York et at., 1994 
transport of antigenic peptides 
HIVNef Induces endocytic degradation Schwartz et at., 1996 
ofMHC-I 
Poliovirus Blocks transport ofMHC-I Doedens & Kirkegaard, 1995 
fromER 
The loss of MHC-I expression has been observed frequently in malignant cells and in 
virally infected cells (Maudsley & Pound, 1991; Ruiz-Cabello et al., 1991). Such a loss 
would allow these cells to escape from CTL mediated killing and increase their oncogenic 
potential. In virally infected cells additional post transcriptional mechanisms may result 
in the retention of MHC-I complexes in the ER, such as binding of heavy chains by the 
Adenovirus E3 glycoprotein or binding of heavy and or light chains by Cytomegalovirus 
H301 or indeed other proteins (Andersson et at., 1985; Browne et al., 1991; Del Val et ai., 
1992; Paabo et al., 1989). The loss of peptide could also result in a reduced MHC-I 
expression. ER endoplasmic reticulum, HSV herpes simplex VIruS, CMV 
cytomegalovirus, HIV human immunodeficiency virus, Ad adenovirus. 
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It has been suggested that the expression of HPV -16 proteins may result in reduced cell 
surface expression of MBC-I leading to abnormal presentation of viral and tumour 
antigens (Cromme et al., 1993). The loss ofMHC-I (and MHC-II) expression is thought 
to occur at the post-transcriptional level and may be related to the loss of peptide transport 
due to a reduced expression of transporter associated with transport (TAP-) protein 
(Connor & Stern, 1990; Glew et al., 1992; Cromme et al., 1994). In addition to cell 
surface expression, the MHC-I light chain ~rmicroglobulin has also been shown to be 
altered in invasive cervical cancer (Connor & Stern, 1990). It is of interest to determine 
whether HPV gene expression directly or indirectly accounts for the down-regulation of 
MHC-I in cervical cancer. 
It is possible that specific HPV encoded proteins could be involved, which are expressed 
at various levels in different lesions. The HPV -16 E5 protein has been shown to alter the 
acidification of endosomes which may explain the disruption of MHC I and II restricted 
antigen presentation, cellular transport and cellular communication in infected cells 
(Straight et at., 1995), this makes it a prime target for investigation ofMHC-I functional 
alteration. 
The aims of this Chapter were to investigate the presentation of HPV -15 E5 peptides by 
MHC-I molecules by cells positive for HPV-16 DNA and to compare this in cells 
negative for HPV -16 DNA. The cervical cancer derived cell-lines included in this study 
were the XH1 b cell-line, which has been estimated to contain 1 HPV -16 genome copy per 
cell. The SiHa cell-line, which are estimated to contain 40 copies ofHPV-16 per cell and 
the BeLa cell-line which are estimated to contain 100 copies of the BPV-18 genome per 
cell. These cell-lines were included to allow comparisons of HPV viral load on antigen 
presentation. The SiHa and HeLa cell lines will also allow a comparison between HPV­
16 and -18 infected cell lines. The spontaneously transfornled HaCat cell line and nornlal 
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human keratinocytes (NHKC) were included to provide a baseline of 'normal' antigen 
presentation. 
The effect of HPV -16 E5 DNA on intracellular protein expression was also monitored 
using the ovalbumin gene tagged to a green fluorescent protein (GFP). The Pat-16 
(contains the entire HPV-16 genome, Jewers et at., 1992) and Pat-16X (contains the 
HPV -16 genome with a stop codon in the E5 ORF) plasmids (Dr B. Kell) were used to 
determine whether HPV -16 E5 DNA had any direct effects on the intracellular expression 
of ovalbumin. Ovalbumin was chosen as it is known to be highly immunogenic and 
efficiently expressed and processed through the MHC-I pathway (Moore et at., 1988). 
5.2 METHODS 
5.2.1 Keratinocyte cell lines 
The HPV DNA negative cell lines used were primary normal human keratinocytes 
(NHKC) isolated from neonatal human foreskins (see below) and the HaCat cell line 
(provided by Kermani, F.). The HPV DNA positive cells used were; HeLa (HPV-18+; 
ECACC) SiHa (HPV-16+; ECACC) and XHib (HPV-16+). The HPV DNA status of the 
negative cell lines was established using PCR as described in section 2.2.3. NHKC (see 
section 5.2.1.1) were maintained in KMK-2, whilst the HaCat, XH-l, SiHa, Caski and 
Hela cell lines were all maintained in DMEM media supplemented with 10 % (v/v) FBS, 
t 2 mM I-glutamine, 100,000 U/L benzylpenicillin and 0.1 giL streptomycin sulphate 
I (DMEMIFBS). All cells were kept at 37°C in a humidified incubator with 5% (v/v) CO2 
m aIr.I 
( 
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5.2.1.1 Isolation ofkeratinocytes from newborn human foreskins 
Neonatal foreskin from routine circumcision operations (St Thomas' Day Care) was 
collected into 10 ml of collection media consisting of DMEM, supplemented with 5% 
(v/v) FBS, containing 100,000 U/L benzylpenicillin, 0.1 giL streptomycin sulphate and 
0.5 giL amphotericin (Sigma). Tissue was incubated overnight at 4°C then transferred to 
fresh collection media and dissected with a scalpel into 4 mm strips removing excess 
adipose tissue and blood. Strips were rinsed with DPBS without antibiotics, placed into 
10 ml of dispase II (neutral protease, Boehringer Mannheim) and incubated at 37°C for 3 
h. After incubation strips were placed into a sterile petri-dish (Coming) and the dispase II 
discarded. Using fine sterile forceps the epidermis was pulled away from the dermis. 
Both portions were placed into a universal containing 5 ml of trypsin EDT A (Sigma), pre­
warmed to 37°C and shaken vigorously before being incubated at 37°C for 5 min. 
After incubation the universal was shaken once again and the contents passed through a 
sterile wire mesh to collect a single cell suspension free from dennal and epidermal debri. 
The resulting cell suspension was washed and re-suspended in DMEM, supplemented 
with 10% (v/v) FBS, 2 mM 1 glutamine, 100,000 U/L benzylpenicillin, 0.1 giL 
streptomycin SUlphate and 0.02 giL EGF (Sigma, DMEM/FBS). The number of cells 
were adjusted to 1 x 105Iml and 1 ml aliquots placed in 6 well tissue culture plates 
(Coming) which were then incubated overnight at 37°C. After incubation the non 
adherent cells and the serum containing media were removed by aspiration and the 
remaining adherent cells cultured in 2 ml of keratinocyte serum free media (KMK-2, 
Sigma). 
, 
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5.2.2 Interferon-gamma dose response assay 
Cytokines secreted by T -lymphocytes, for example, IFN-y, up-regulate cell surface MHC­
I expression. An IFN-y dose response assay was therefore developed to detemline 
whether cell surface MHC-I expression could be up regulated on the chosen keratinocyte 
cel1lines, thus assessing their suitability for this assay. All cell lines were adjusted to 1 x 
105 cells/ml in DMEMIFBS, dispensed as 100 III volumes into wells of a 96 flat well 
microtitre plate (Coming) and incubated overnight at 37°C in a humidified incubator with 
5% CO2 in air. The media was then aspirated and replaced by DMEM/FBS supplemented 
with increasing concentrations ofIFN-y, 0.75, 1.5,3.1,6.25, 12.5,25,50 & 100 mg/L per 
well in triplicate. The microtitre plate was then incubated at 37°C in a humidified 
incubator with 5% CO2 (v/v) in air for 6 h. The IFN-y containing media was aspirated 
and the plate washed six times in ice cold DPBS. The cells were fixed, to prevent 
cytolysis and subsequent release of endogenous cellular peroxidase, by adding 50 III of 
formaldehyde, diluted 1:100 (v/v) in DPBS and incubating on ice for 30 min. Cells were 
then washed three times in DPBS and 30 III aliquots of goat anti-human HLA-A,B,C HRP 
conjugate (Pharmingen), diluted 1 :300 in PBS, were added to appropriate wells and the 
plates incubated at room temperature for 1 h. Plates were washed three times with 400 ~L1 
of DPBS then 30 III of mouse anti goat antibody (Sigma) were added to each well and 
incubated at room temperature for 1 h. The wells were washed three times with 400 III of 
DPBS/well and 100 III aliquots of Sigma fast OPD substrate were added to each well. 
The micro titre plate was then incubated in the dark at room temperature for 1 h. The 
reaction was terminated by the addition of 25 III of 1 M sulphuric acid and the ~90 of 
each well determined using an automated plate reader (Labsystems). 
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5.2.3 The effects of human papillomavirus type-16 E5 peptides on MHC-I cell 
surface expression 
Pooled HPV -16 E5 9-mer peptides (Figure 2.2) were introduced into the cytoplasm of 
each cell line (Okada & Rechsteiner, 1982). Briefly, the number of ce11s were adjusted to 
1 x 104/ml and 100 III aliquots were added to wells of a 96 flat well microtitre plate which 
was then incubated overnight at 37°C in a humidified CO2 incubator. The plate was 
washed once with 200 ].11 of DPBS. Cells were then re-suspended in 100 III of a pre­
wanned (37°C) hypertonic solution consisting of, 2 mM HPV-16 E5 peptides in 0.5 M 
sucrose (Sigma), 10% (w/v) polyethylene glycol 1000 (PEG 1000, Sigma), in Hams F12 
media (Sigma). Cells were incubated for 10 min at 37°C in a humidified incubator with 
an atmosphere of 5% (v/v) CO2 in air. This solution was gently aspirated and replaced 
with 200 III of 1 part Hams F12 media to 2 parts (v/v) tissue culture grade water pre­
wanned to 37°C and incubated for a further 5 min (see appendix A.5 for 
macropinocytosis). The plate was incubated overnight at 37°C in a humidified incubator 
with 5% CO2 in air after which the cells were stained for cell surface MHC-I expression. 
5.2.4 The effect of human papillomavirus type-16 E5 DNA on the cellular 
expression of ovalbumin 
The pEGFP-NI plasmid (Clonetics, Figure 5.1) encodes green fluorescent protein (GFP) 
and an SV 40 promoter ensuring a strong green fluorescent signal in transfected cells. The 
pEGFP-N 1 plasmid also encodes a multiple cloning site (MCS) directly before the GFP 
sequence allowing the insertion of DNA, this permits the protein product of the inserted 
DNA sequence to be expressed with a GFP tag. The migration of inserted gene products 
has been visualised using this technique and was shown not to affect transport of the 
modi fied protein (Scales et ai., 1997). 
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The gene encoding ovalbumin has been cloned into the pAc-neG-ova gene (Figure 5.2, 
Moore et al., 1988). The ovalbumin gene was excised from pAc-neo-ova and inserted 
into the pEGFP-N1 plasmid to allow its expression to be monitored in cells using a 
fluorescent microscope. 
Ase IIB1 
Apall 
143621 MCS 
Eco0109 I 
138561 
pEGFP-Nl· 
4.7 kb BsrG 1113991 
Not( (14021 
Xba 1* (1~121 
AflIIIIG401 
Dra 11111874) 
(25791 
5'A"'AG CTTCGA ATICTG CAGTCG ACG GTACCGCGG GCC CGG'" GAT CCA CCG GTCGCC ACCATOGT03' 
~ ~ 
HindIII BamHI 
cut site cut site 
I 
! Figure 5.1 The pEGFP-Nl plasmid and multiple cloning site. Upstream -In order to 
ensure that the ovalbumin insert remains in frame the HindIII cut site is engineered into 
the ovalbumin insert which leaves an overhanging A. This releases an overhanging AGi 
which can be ligated to form a new codon and changes nucleotide 20 of ovalbumin from aI G to a T. Downstream -The downstream primer incorporates a BamHl cut site ensuring 
I 
, 
that the ovalbumin insert is kept in frame. The BamBI cuts after a codon triplet resulting 
in three changes; bp 1214 from T to G, bp 1216 from T to A & bp 1218 from T to c. 
I Figure reproduced after kind permission from Clontech Laboratories Inc. 
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pAc-Neo-OVA (i2kb) 
84(& Aeti" 
Promottr 
IVSl Poly A SM t-i 
11<b 
oinl-ctlon 0 I tnlll$cOp tIo n 
SS3 - Human aeta Actin Promoter 
[2Zl - InteNening Se<l,uence 1 
o . S\AO late reQion polyadenylation signal 
_ .. Chicken Ovalbumin eDNA 
~ • Neomycin Resistance Gene 
• p8R322 
Figure 5.2 The linearisedpAc-Neo-OVA plasmid. The complete ovalbumin DNA was 
subcloned into the mammalian pH~Apr-l-neo at the BamHI and HindIII sites under 
control of the human ~-actin promoter. pAc-neo-OVA also contains the neomycin 
resistance gene under control of the SV40 promoter. The restriction sites shown on the 
map are B=BamHI; E=Eco RI, H=HindIII, X=XbaI. Reproduced after kind permission 
from Moore et ai., 1988. 
The published ovalbumin DNA sequence was analysed for enzyme cut sites using a 
computer program (DNASIS, Hitachi Corporation). Enzyme cut sites not present 
included HindUI and BamHI. These cut sites were present within the MCS of the 
pEGFP-Nl plasmid and were considered when designing upstream and downstream 
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oligonucleotide primers for ovalbumin using a computer program (Oligo, Hitachi). The 
ovalbumin DNA sequence was removed from the pAc-neo ova plasmid by an ovemight 
digestion with 1 unit/f.!l of the enzyme EcoRl (New England Biolabs), the digested 
plasmid was electrophoresed through a 1% agarose gel and was purified using a 
commercial gel extraction kit (Qiagen). The purified ovalbumin DNA sequence was 
amplified by peR using oligonucleotide primers that introduced ends complementary for 
the pEGFP plasmid after digestion with HindIII and BamHI (New England Biolabs, Table 
5.1). 
Table 5.2 Ovalbumin oligonucleotide primers 
l Ovalbumin DNA sequence position 11-40 base pairs 
Upstream Primer J 
i 
Ovalbumin DNA sequence i 
f position 1196-1225 base pairs 
I 
I 
Downstream Primer 
Ovalbumin primers 
ATC ITT CGA £.A T AAC GGA AAT CGT GAG TTC 
TAG AAA GCT ITA TTG CCT ITA GCA CTC AAG 
AOA OAA GAA ACC OTC TAC ACAAAG GGG AA1 
TCT CTT CIT TOG CAG ATG GGA T£.C CCC TTA 
The bp shown in bold and underlined are those changed from the original ovalbumin 
primer sequences. 
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In a 1.5 ml microcentrifuge tube, 200 [11 of the ovalbumin PCR product, 100 fll of H20 
and 300 fll of phenol:chloroform:isoamyl alcohol (25:24:1, vlv, Sigma) were added 
together, mixed by vortexing for 10 seconds and then centrifuged for 5 min at 13,000 g. 
The upper aqueous phase was transferred to a fresh 1.5 ml microcentrifuge tube to which 
an equal volume (300 [11) of chloroform:isoamyl alcohol (24:1, v/v) was added. The tubes 
were vortexed briefly and centrifuged for 2 min at 13,000 g. The upper aqueous phase 
was transferred to a fresh tube and the DNA was precipitated in 1 ml absolute alcohol at ­
20°C overnight. Tubes containing the precipitated DNA were centrifuged for 30 min at 
13,000 g. The pellet of precipitated DNA was then washed with 70% (v/v) aqueous 
ethanol, dried under vacuum for 10 min and then re-suspended in 20 III of H20. 
Both the ovalbumin peR product and the pEGFP plasmid were digested with HindIII and 
BamHI to obtain the correct sequences for ligation as follows. Ovalbumin DNA was 
ligated to vector using DNA ligase. Briefly, three volumes of ovalbumin DNA were 
added to one volume of pEGFP plasmid contained in a 1.5 ml microcentrifuge tube, to 
this, 300 fll of absolute ethanol were added. The tube was vortexed for 10 sec and 
centrifuged for 30 min at 13,000 g. The DNA pellet was washed once with 70% (v/v) 
aqueous ethanol and dried under vacuum. Once dry, the pellet was re-suspended in the 
ligation mixture which consisted of, 10 III of ligation buffer (100 mM Tris-hydrochloride 
pH7.6; 5 mM magnesium chloride), 40 fll of solution A and 10 [11 of solution B. The 
ligation reaction was then incubated at room temperature for 3 h. 
The pEGFP plasmid was transformed into electrocompetent E. coli (Top 10 cells, 
Invitrogen) cells to select for inserts containing ovalbumin, as follows. The pEGFP 
plasmid containing the ovalbumin insert was adjusted to 10 Ilg/fll and 1.5 fll placed into a 
sterile 1.5 ml microcentrifuge tube which was then left on ice for 5 min. The 
electro competent E.coli. were removed from storage at -70°C and allowed to thaw slowly 
l 
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on Ice. Once thawed, an aliquot of 30 fll was added to the pEGFP/ovalbumin plasmid, 
mixed by pipetting once and left on ice for 1 min. The E.colilplasmid mixture was 
transferred to a chilled electroporation cuvette (BioRad) and gently shaken to the bottom. 
Condensation was removed along with any air bubbles and the cuvette placed in the 
chamber of an electroporater (Gene Pulser, BioRad) and pulsed with 2.5kV (current 25flF, 
Resistance 2000). The cuvette was removed immediately and a 480 fl} aliquot of SOC 
media, consisting of 0.2% tryptone, 0.05% yeast extract, 0.01 ~ sodium chloride, 0.0025 
M potassium chloride, 0.02% magnesium chloride and 0.02 M glucose (Gibco), added 
and mixed gently by pipetting once. The contents of the cuvette were transferred to a 15 
m} centrifuge tube and incubated at 37°C for 1 h in a shaking incubator (Denley). 
After incubation, Top 10 cells were centrifuged for 30 sec at 13,000 g to col1ect cells at 
the bottom of the tube. An aliquot of 300 fll of SOC media were removed and cells re­
suspended in the remaining volume. A 30 fll aliquot of cells was plated on a pre-prepared 
LB agar plate consisting of, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) 
sodium chloride, 1.5% (w/v) agar (Difco) and 100 giL ampicillin (Sigma), which was 
then incubated overnight at 37°C. The DNA was extracted and precipitated as above and 
the plasmid was transfected into NHKC. 
5.2.4.1 Transfection of the Pat-16, Pat-16X and pEGFP/ovalbumin plasm ids into 
normal human keratinocytes 
For transfection of Pat-16 and Pat-16X DNA into NHKC two solutions were prepared as 
follows. Solution A, contained 1.5 !-lg of plasmid DNA in 100 fll serum free RPMI 1640 
media (SFM) and solution B contained 12 !-ll of lipofectin reagent (Gibco) in 1 00 ~ll of 
SFM. Before use both solutions were allowed to stand at room temperature for 45 min. 
After incubation both solutions were combined, mixed gently and incubated for a further 
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15 min at room temperature. Cells grown to 60-80% confluency in 25 cm2 tissue culture 
flasks were washed twice in SFM which was then replaced with 3 ml of DMEM/FBS 
without antibiotics. To each flask, an aliquot of 800 /-ll of the transfectiniDNA mix was 
added and the solution was mixed by gentle shaking. Cells were incubated for 18 h at 
37°C in a humidified incubator with 5% (v/v) CO2 in air, after which the media was 
replaced with 3 ml of complete DMEM/FBS and the cells were incubated for a further 72 
h. The cells were then washed three times in DPBS and an aliquot of cells were collected 
using a cell scraper (Coming) and pelleted in a microcentrifuge by centrifugation at 
10,000 g for 10 min at room temperature. The cell pellet was subjected to a Proteinase K 
digestion to obtain DNA, which was assayed for the presence of HPV -16 E5 and E6 DNA 
(see section 2.2.3 for details of method). 
An aliquot of cells was also transfected with the pEGFP/ovalbumin plasmid as described 
above. After the final 72 h incubation an aliquot of cells taken by scraping was assayed 
for ovalbumin DNA as follows. A hot start PCR was employed using Tlitoralis (Th) 
polymerase (Promega), which allows proof-reading and thennostability for the long PCR 
reaction required for ovalbumin (Perbal, 1988). A 10 I-Ll aliquot of the extracted DNA 
(from above) was added to the upper mix, which contained 18 /-ll buffer (50 mM 
potassium chloride; 10mM TRIS-hydrochloride, pH 9.0; 0.1 % Triton®X-100), 30 /-ll H20 
and 2 /-ll of Th. The lower mix contained 12 /-ll buffer, 6 ~Ll magnesium chloride 
(concentration obtained after magnesium titration), 8 }ll dNTPs (final concentration 200 
/-lM),4 /-ll of each primer (final concentration 0.5 }lM) and 6 ~Ll H20. Reaction tubes were 
I placed on a thennocycler programmed for 1 cycle of 94°C for 5 min, 37 cycles of 94°CI 
I 
f for 1 min, 58°C for 1 min and 68°C for 1.5 min and 1 cycle of 68°C for 10 min. PCR 
products were electrophoresed through a 1 % agarose gel and photographed (Figure 5.3, asI 
described in section 2.2.3). 
j 
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Figure 5.3 Photograph of gel showing ovalbumin peR product Arrow indicates the 
630 bp PCR product. Lanes l,4=non-transfected HaCat cells, lanes 2,5 non-transfected 
NHKC, lanes 3,6 transfected NHKCs. 
Cells positive for ovalbumin DNA were fixed in a solution of methanol and acetone (1: 1, 
v/v) for 20 min at room temperature then counter stained with 1 % Evans blue (Shandon) 
in PBS (v/v). Once dry the prepared cells were assessed for fluorescence using a 
fluorescent microscope (Ziess) and the number of fluorescent cells per confluent field 
were counted using a haemocytometer (Figure 5.4). 
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Figure 5.5 Effects of increasing concentrations of interferon-gamma on MHC-I 
expression. Error bars represent SEM. 
When cells were stimulated with pooled HPV -16 E5 9-mers the cell surface expression of 
MHC-I on NHKC were significantly higher than with lNF-y alone (p=O.05) and also 
significantly higher than MHC-l cell surface expression on HaCat (p=O.04), XH1b 
(p=O.Ol) and SiHa (p=O.013) and HeLa cells (p=O.023); Figure 5.6). MHC-I expression 
in HaC~t and HeLa cells after stimulation with peptide and IFN-y compared to IFN-y 
alone was not significantly different (p=O.26 & p=O.14 respectively). For XHlb and SiHa 
cell lines the expression of MHC-l was significantly higher on cells that were not 
stimulated with peptide (p=O.002 & p=O.02 respectively). 
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Figure 5.6 Cell surface MHC-J expression on cell lines stimulated with HPV-16 E5 
peptides. The mean cell surface MHC-I expression (~90). Error bars represent SEM. 
5.3.2 The effects of human papillomavirus type-16 E5 DNA on expression of 
ovalbumin 
All cells transfected with GFP/OVA were positive for ovalbumin DNA after PCR. The 
mean number of fluorescent cells per confluent 10 fields were counted (Figure 5.7). 
When analysed, cells that received the GFP-OVA construct had significantly more 
fluorescent cells per field than cells that received both GFP-OVA with the Pat-16X 
construct, but not when compared to cells that received the OFP-OVA construct with the 
Pat-16. When cells that received both the OFP-OVA construct and a Pat construct were 
analysed, those cells that received the entire Pat-16 sequence had significantly lower 
I 
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numbers of fluorescent cells per field that those cells that received Pat-16X (Figure S.7). 
It was noted however, that the GFP product was not present in the nuclei of cells but was 
located in the cytoplasm in all cell preparations (Figure S.4). 
100 ) 
-I 

I 

80 ) 
"0 
I II III 
Plasmid 
Q;j 
t.::: 60 )-.. ~ 
Q;j 
(j 
..... 
Q 
<U 
'"' 
'" <U 10. 
40 ) 0 
= I: 
'­0 
10. 
c:.l 
..Q 
e 
20 )= z 
o ) 
Figure 5.7 Number of fluorescent NHKCs per field A total of 10 fields were 
examined for fluorescence, the number of fluorescent cells were counted using a tally 
counter. All fluorescent cells per x20 field were counted, a total of three fields were 
counted for each cell preparation. I GFP/OVA; II PAT-16X HPV-16 DNA without E5 
ORF; III PAT-16 whole HPV-16 genome. Error bars represent SEM. 
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5.4 DISCUSSION 
The low cell surface MHC-l expression that is sometimes seen in cervical lesions may be 
due to the cells inability to respond to external stimuli. Evidence for this exists in the 
IFN-y dose response assay, which showed that NHKC had a higher cell surface MHC-I 
expression than any other cell line even at low doses of lPN-yo The HPV DNA negative 
cell line, HaCat had much lower expression of MHC-I but this expression was equal to 
that ofNHKC at higher doses ofIFN-y. The HPV-18 containing cell line, HeLa had the 
lowest cell surface MHC-I expression, this cell line also has the highest viral copy number 
estimated to be 100 viral genomes per cell. The HPV -16 containing XHI b cell line has 
only one copy of the HPV -16 genome per cell and after stimulation with IFN-y the cell 
surface expression ofMHC-I was tripled. The cell surface expression ofMHC-l on SiHa 
cells, which have been estimated to contain 40 copies of HPV-16 per cell, doubled after 
stimulation. It appears therefore, independent of HPV type, either, -16 or -18 that the 
inability to up-regulate MHC-I expression after stimulation with IFN-y may result as a 
consequence of viral load. All cell lines showed elevation of cell surface MHC-I 
expression after stimulation with lPN-yo 
After stimulation with HPV -16 E5 peptides, those cell lines containing HPV DNA 
showed no significant changes in MHC-I expression even in the presence of lPN-yo 
Indeed, an unusual finding was the significant decrease in MHC-I expression after the 
addition of pep tides in the XHlb and SiHa cell lines. These data suggest that HPV-16 E5 
peptides are presented on the cell surface in association with MHC-l molecules in human 
cell lines and that this expression may be inhibited by the presence of HPV -16 E5 DNA 
as seen in XHlb, SiHa and HeLa cell lines. It may well be that E5 or indeed, any other 
HPV-16 or 18 gene product acts to decrease the cell surface expression of MHC-I 
molecules by interaction with proteins associated with antigen processing (Table 5.l). 
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The inability to stimulate an increased expressIOn of MHC-I is not limited to cells 
containing HPV -16 DNA as the HPV -18 containing HeLa cell line also failed to show an 
increase in MHC-I expression after stimulation. When the effects of HPV-16 E5 DNA 
were examined in NHKC a significant decrease in intracellular ovalbuminlGFP 
expression was noted. This may be a result of impaired intracellular communication in 
E5 infected cells but the mechanisms involved have yet to be determined. 
In conclusion, these preliminary results suggest that HPV -16 E5 peptides are presented on 
MHC-I molecules. However, this presentation may be inhibited by the presence of HPV­
16 DNA or protein. It also appears that the expression of HPV-16 E5 DNA disrupts the 
expression of GFP tagged ovalbumin. If sufficient time had permitted, this would have 
been investigated further. 
I 
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The major aim of this thesis was to characterise HPV -16 E5 specific immune responses in 
women with and without HPV -16 associated cervical disease. The immune system is 
thought to play an important role in the control of infection as HPV positive lesions are 
known to regress spontaneously. Indeed, individuals who are immunologically 
compromised may be up-to 10 times higher at risk for developing HPV associated cervical 
lesions (Schneider et al., 1983; Rudlinger et al., 1986; Sillman & Sedlis, 1987). 
As hypothesised, in Chapter Two, HPV-16 E5 specific CM! was inversely correlated with 
disease severity and was more frequently detected in women with L-SIL. This suggests that 
subjects with impaired CMI are more likely to develop cervical disease and less likely to 
exhibit HPV-16 E5-specific immunity. Those subjects with a fully functional CMl would 
be less likely to progress to H-SIL or cervical cancer. 
HPV-16 E5 DNA sequence variants were investigated as HPV-16 E6 variants are known 
to alter the conformation of an HLA-B7 binding epitope (Ellis et al., 1995) which may 
have implications in HPV immunity. Similarly, HPV -16 E5 DNA sequence variants may 
evade recognition by the immune system as a result of altering possible T or B-
lymphocyte epitopes. Three HPV -16 E5 variants were detected in this study population 
but were not associated with disease severity, or with HPV -16 infection. 
It was thought that during the course of natural infection, an effective CMl would result in 
cell lysis, leading to the production of HPV -16 E5 specific antibodies. However, in 
Chapter Three, antibodies to full length HPV-16 E5 were not detected and only low-titre 
antibodies to shorter regions of HPV -16 E5 were seen. It is possible therefore, that only 
very small amounts ofHPV -16 E5 are released from an infected cell after cytolysis, or that 
HPV -16 E5 remains associated with cellular membranes and is not seen independently of 
cellular debris. This may result in insufficient amounts of HPV -16 E5 antigen required for 
{ 
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an effective antibody response. Similarly, antibody production may be short lived and 
become undetectable after antigen is no longer available. 
In Chapter Four, when mice were immunised with HPV-16 E5, it was anticipated that HPV­
16 E5 specific CMI and antibody responses would result. Strong spleen cell proliferation 
and a moderate amount of CTL activity was seen but antibody responses were very weak 
and often only barely significantly higher than controls. This phenomenon may be 
attributed to the hydrophobic nature of HPV -16 E5 and with its associations with cellular 
membranes. These data in mice support the data from Chapters Two and Three, where CMI 
was detected in subjects but antibody titres were low. The peptides used to immunise mice 
were tested for their ability to bind MHC-I molecules and several HPV-16 E5 9-mer 
peptides were found to bind and stabilise MHC-I molecules. This indicates that HPV-16 E5 
may be presented to CD8+ cells in vivo and may result in CMI. Unfortunately, neither 
proliferative or CTL associated epitopes were mapped in this study. It would also have 
been interesting to investigate HPV -16 E5 binding to MHC-II molecules had such a model 
been available. MHC-II restricted CD4+ helper lymphocytes stimulate B-lymphocytes to 
produce antibody. 
In Chapter Five, cells infected with HPV -16 E5 DNA all had reduced expression of cell 
surface MHC-I molecules when compared to non-HPV infected cells. Similarly cells 
transfected with the entire HPV -16 genome had a lower level of GFP-tagged ovalbumin 
expression than cells transfected with GFP-tagged ovalbumin alone or those transfected 
with the HPV-16 genome minus the E5 ORF. Together, these data indicate that HPV 
infected cells do not function nonnally in the context of antigen presentation or protein 
expression and that virus escape mechanism may be at play. 
The development of malignant tumours can be regarded as an example of cells escaping 
immune surveillance. One possible mechanism is down regulation of MHC-l expression 
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affecting recognition and clearance by tumour specific CTLs. The decreased levels of 
MHC-I are reported in HPV-irnmortalised cervical cancer cell-lines, this seems to occur at 
the post transcriptional level as MHC-I mRNAs are often present (Woodworth & Simpson, 
1993; Cromme et al., 1993). Similarly, cervical cancers, SIL, cutaneous warts, 
condylomas and laryngeal papillomas can show down-regulation of MHC-I expression 
(Connor & Stem, 1990; Cromme et al., 1993; Viac et al., 1990; 1993). The absence of 
TAP-l in cervical lesions strongly correlates with the loss ofMHC-I expression indicating 
inhibition of peptide transport by down regulation of TAP-1 as a means of malignant cells 
to evade immune surveillance (Cromme et al., 1994). Keratinocytes express low levels of 
MHC-II molecules which may induce tolerance rather than immunity (Chen & Mounts, 
1989; Bal et al., 1990). 
The interference of MHC-I and TAP has been described for other viruses and it is 
possible that HPV somehow interferes with TAP expression and transport of antigenic 
peptides over the ER (Table 5.1). This is supported by the down regulation ofMHC-I in 
HPV positive cell lines under the influence of glucocorticoid hormones which nonnally in 
HPV negative cell lines up regulate MHC-I expression (Bartholomew et al., 1997). In 
addition insertions deletions and point mutations of MHC-I genes are detected in cervical 
cell lines and their corresponding solid tumour tissue. Tumour phenotypes can be 
observed that resulted from two or more independent mechanisms that interfere with 
MHC-I expression (Garrido et ai., 1997; Cabello et ai., 1998). 
It is highly likely considering that as HPVs co-evolved with their hosts that viral escape 
mechanisms exist. It appears that HPV -16 (and other types) has developed mechanisms, 
which enables the virus to hide from the immune system. These mechanisms may 
include: perinatal transmission; absence of cell surface viral proteins; infection of the 
outem10st cells of the host; no viraemic phase; genetic susceptibility to infection/cancer; 
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the reduced number of Langerhans' cells; immune tolerance or the down regulation of 
MHC-I via TAP-I. However, to survive all this time in the face of immune selective 
pressure the HPV s needed to develop mechanisms to successfully evade the host immune 
system. The prevalence of CMI responses against HPV found in the presence of 
persisting HPV infections and H-SIL suggests that such evasive strategies are at work. 
Other possible immune evasion mechanisms that may be used by genital HPVs are 
summarised in Table 6.1. 
Conclusions drawn from this study are that women infected with HPV-16 E5 DNA show 
specific PBMC proliferation which is inversely correlated with disease severity. Humoral 
immunity exists in asyptomatic women and those with L-SIL indicating that immunity 
may be impaired in women with H-SIL and cervical cancer. 
This thesis also supports the hypothesis that women with intact immune responses are 
able to combat HPV infection as those who were HPV negative had reactive serum 
antibodies to HPV -16 E5 9-mers. 
It can also be concluded that full length HPV-16 E5 and 9-mers are poor immunogens 
even after conjugation to immunogenic carTiers and incorporation into ISCOMs. 
However, as some CTL activity was seen 111 immunised mice, the method of 
immunisation may need revisions. HPV -16 E5 peptides do show binding to and 
presentation by MHC-I molecules. It appears that HPV-16 E5 DNA may impair cellular 
function in some way. 
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Table 6.1 Possible viral escape mechanisms used by HPVs 
Mechanism 
Avoidance of host 
immune system 
Altering susceptibility to 
immune response 
Disarming of T -cells 
Tolerance, induction and 
Suppression of cell mediated 
immune response 
Factors 
Supra-basal expression 
Depletion of Langerhan cells 
Sequence variation 
MHC-I and Tap down regulation 
Apoptosis resistance (bcl-, 
serpins) 
Induction of apoptosis in CTL by 
interaction with Fas ligand on 
keratinocytes 
Induction ofKIR expression on 
infiltrated CTL by IL-10 & TGF­
G 
T-cell receptor CD-3~ down 
regulation 
MHC-II expression on 
keratinocytes without co­
stimulatory molecules results in 
un-professional antigen 
presentation: 
-Th 1 ITh2 balance shift 
-Tolerance induction 
-Immunosuppresive cytokines IL 
10 & TGF-f} 
Adapted from Bontkes et al., 1999. 
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Future work 
Considering that CMI to HPV -16 E5 was inversely correlated with disease severity, it 
would be of value to investigate the effects of treatment on immunity in longitudinal 
studies. Treatment of cervical lesions could be correlated with HPV-16 infection and 
immunity over a number of years. Similarly, immune responses to other HPV-16 early 
proteins (El, E1-E4 and E2) may also be investigated. 
The long-tenn variation of HPV -16 E5 within individuals or populations over time 
remains undetermined and the investigation of HPV -16 E5 variants is required. It is 
possible that HPV -16 establishes a persistent infection in which a single variant 
predominates and co-infections with additional HPV -16 variants may result in minor 
populations ofHPV-16 genomes. This as with HPV-16 E6 may affect the nature of any 
immune response or the severity of cervical disease. It is also necessary to correlate 
HPV -16 E5 variation with severity of disease, ethnicity and other co-factors. 
It will also be of interest to investigate the effects of an alternative immunisation 
procedure in an animal model. Such procedures may include 'DNA vaccination' or use of 
an LlIE5 chimera. 
It is thought that HPV -16 E5 may impair normal cellular function affecting antigen 
processing and presentation by MHC-I. The HPV-16 E5 protein is an ideal candidate for 
the investigation of viral escape mechanisms and its site of action could occur at the ER, 
Golgi or at the plasma membrane. It is also possible that E5 or other HPV early proteins 
bind to cellular proteins associated with antigen processing located in the ER where there is 
opportunity for HPV -16 E5 to interfere with their normal functions. The ER is also central 
to the antigen recognition capacity of lymphocytes because it controls the folding and 
assembly of antigen receptors and may be the cellular organelle, where HPV -16 E5 exerts 
186 
Chapter Six 
its affect on nonnal MHC pathways. The work from Chapter Five remains incomplete and 
requires additional studies in order to clarify the effect of HPV-16 E5 on cellular function 
and antigen presentation. 
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Appendix 1 Trypan blue dye exclusion test 
The trypan blue method of cell viability is based on the principle that live cells do not 
take up certain dyes but dead cells do. A 4% solution of trypan blue was prepared in 
PBS (w/v) and 2001-1-1 were added to a 1 x lOs/m1 cell suspension in a volume of200 J.ll. 
The cells were allowed to stand for 5 min and then transferred to the chambers of a 
Neubauer haemocytometer. All the cells in the 1 mrn centre square and four 1 mm 
comer squares were counted, a separate count of viable and non- viable cells was 
recorded. The percentage of cells excluding dye was determined by brightfield 
illumination using a Nikon microscope (x 10 objective lens). 
Appendix 2 The MTT assay 
A water soluble yellow terazolium salt MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5­
diphenyltetrazo1ium bromide; Thiazolyl blue) is converted to an insoluble purple 
formazan by cleavage of the tetrazolium ring by dehydrogenase enzymes (Slater et ai., 
1963). The formazan can be solubilised using dimethyl sulphoxide and measured 
spectrophotometric ally allowing the measurement of concentration of converted dye. 
The MTT assay was used to detect cell proliferation as it produces results equivalent to 
conventional 3H-thymidine incorporation tests but is simpler to use and does not require 
I 
i 
I the use of radioisotopes. This assay has been published for use in several studies 
, 
I including those of interleukin-2 production (Mossman, 1983; Denizot & Lang, 1986). 
I, 
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Appendix 3 Hydrophobicity values of HPV-16 E5 peptides used in this thesis 
Amino acids 
Full length 
5-mer 
1-5 

4-8 

7-11 

10-14 

13-17 

16-20 

19-23 

22-26 

25-29 

28-32 

31-35 

34-38 

37-41 

40-44 

43-47 

46-50 

49-53 

52-56 

55-59 

58-62 

61-65 

64-68 

67-71 

70-74 

73-77 

76-80 

79-83 

! 
II' 
t 
Hydrophobicity 
-l.13 
-0.06 
0.12 
-004 
-0.78 
-1.52 
-1.62 
-1.72 
-1.42 
-1.58 
-0.48 
-1.02 
-0.62 
-0.5 
-1.1 
-1.74 

-2.06 

-1.58 

-0.34 

-0.14 

-0.7 

-1.84 

-1.98 

-1.48 

-1.58 

-1 
-0.32 

-0.82 

Amino acids 
6-mer 
1-7 

6-11 

10-15 

14-19 

18-23 

22-27 

26-31 

30-35 

34-39 

38-43 

42-47 

46-51 

50-55 

54-59 

58-63 

62-67 

66-71 

70-75 

74-79 

78-83 

9-mer 
1-8 

5-13 

10-18 

15-23 

20-28 

25-33 

30-38 

35-43 

40-48 

45-53 

50-58 

55-63 

60-68 

65-73 

70-78 

75-83 

Hydrophobicity 
-0.17 
-004 
-0.62 
-1.77 
-l.6 
-1048 
-0.57 
-0.35 
-0.9 
-1.07 
-1.75 
-2.02 
-l.05 
-0.2 
-1.02 
-1.9 
-1.65 
-1.4 
-0.68 
-0.77 
-0.11 

-0.1 

-1.2 

-1.74 

-1.47 

-0.94 

-OA1 
-0.81 

-1.38 

-1.56 

-0.7 

-0.98 

-1.96 

-1.78 

-1.09 

-0.67 
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Appendix 4 Measurement of HPV-16 E5 specific PBMC proliferation in 
Laboratory donors 
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Figure A.I PBMC proliferation to HPV-16 E5 9-mer peptides in anonymous 
laboratory volunteers. When tested for HPV-16 E5 specific proliferation only one 
donor showed SI values in excess of 1.5. 
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Appendix 5 Macropinocytosis 
Sucrose, 

PEG 1000 

c+ Antibody t>. '. 
H20 
. . 
. 
~ 
. 
<=======:JHypotonic •• 
. . 
Culture 
Medium 
Fluid 

Phase 

Pinocytosis 

.. f!! 
. . 
Figure A.2 The principle of macropinocytosis Adapted from Morgan & Roth, 1988. 
A peptide is included into the MHC-I processing pathway if it is present in the cytosol, 
e.g. proteins (i.e. influenza nucleoprotein or ovalbumin) added to the culture media of 
cells expressing both MHC-I & MHC-II are internalised and processed in association 
with MHC-II but, when the genes encoding protein are transfected into the san1e cells so 
that protein is synthesised endogenously then MHC-I association is seen. Similarly, if 
these proteins are introduced into the cytoplasm by transiently permeablising the cell 
membrane using osmotic shock (macropinocytosis) they are also processed associated 
with MHC-I (Okada & Rechsteiner, 1982). 
Macropinocytosis involves two consecutive incubations at 37°C, the first 10 min in 
hypertonic solution containing HPV -16 E5 peptides and the second 5 min in mildly 
hypotonic culture medium. The black symbols. represent HPV-16 E5 peptides. This 
method has little effect on cell viability (Morgan & Roth, 1988). 
192 
Appendix 
Appendix 6 MTT assay to evaluate the effect of macropinocytosis on cell viability 
R 0.5 ~ 
o 
I II III IV 
Treatment 
Figure A.3 I hypertonic solution only; II hypotonic solution only, III 
macro pinocytosis, both solutions; IV cell culture media only. The above figure shows 
that macropinocytosis or treatment with hyper or hypotonic solutions does not affect cell 
viability. Error bars represent SEM. 
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Appendix 7 pGEM® -T Plasmid 
pGEM®-T. 
Vector Not I 
Sac II 
feoRI 
r SP6 
T7 L 
1 start 
Apal 14 
Aatll 20 
Sphl 26 
Nco I 37 
BstZI 43 
43 
49 
52 
64 
70 
77 
77 
88 
90 
97 
109 
118 
127 
141 
Figure AA pGEM®-T Vector. Reproduced with kind permission from Promega. 
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